{"title":"Biotechnology","description":"\u003cp\u003eHardmanwell.com stands as a premier hub for comprehensive biotechnology market research, recognizing its status as a swiftly evolving industry ripe with potential for growth and innovation across various product applications and global markets. Our platform hosts a diverse array of biotechnology market research reports, offering invaluable insights and data on key market segments worldwide.\u003c\/p\u003e\n\u003cp\u003eBiotech Market Research to Propel Business Expansion Our reports address pivotal inquiries concerning the biotechnology market, serving as indispensable guides for shaping your business strategies. Our research encompasses:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEvaluation of current market performance, industry outlooks, and industry lifecycles\u003c\/li\u003e\n\u003cli\u003eExpert analyses of supply chains, products and services, market drivers and challenges, and noteworthy markets to monitor\u003c\/li\u003e\n\u003cli\u003eProvision of market share information, profiles of established and emerging players, discussions on key success factors, and financial benchmarking\u003c\/li\u003e\n\u003cli\u003eInsights into new technologies and patents, pipeline analyses, data on revenue fluctuations, and reviews of regulations and policies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eStay Ahead with our Biotechnology Industry Analysis The biotechnology market evolves rapidly, with new technologies and products continually surfacing. Our reports empower businesses to stay abreast of these developments and identify novel growth opportunities. With our esteemed reputation and unwavering commitment to quality, Hardmanwell.com stands as the quintessential source for biotechnology market research reports crafted by seasoned analysts boasting extensive industry expertise. Having been a trusted purveyor of business intelligence for over two decades, our esteemed clientele includes numerous leading companies in the life sciences sector. Should you require assistance, our team of knowledgeable research specialists remains readily available to expedite the process and address any inquiries you may have.\u003c\/p\u003e","products":[{"product_id":"2023-global-forecast-for-blood-bank-and-immunology-laboratory-instrumentation-used-to-process-blood-and-specimens-for-testing-2024-2029-outlook-manufacturing-markets-report","title":"2023 Global Forecast for Blood bank and immunology laboratory instrumentation, used to process blood and specimens for testing (2024-2029 Outlook)-Manufacturing \u0026 Markets Report","description":"\u003cp\u003eThe 2023 Global Forecast for Blood bank and immunology laboratory instrumentation, used to process blood and specimens for testing (2024-2029 Outlook)-Manufacturing \u0026amp; Markets Report, published by Barnes Reports, contains timely and accurate market statistics and forecasts on the market for over 40 countries.\u003c\/p\u003e\n\n\u003cp\u003eEstimates on equipment or material sales (product shipments value) are published historically for 2019 to 2020, projections for 2021 to 2023 and forecasts for 2024 to 2029. Product shipments include the total value of all products produced and shipped by all producers. For selected products, this can represent value of receipts, value of production, or value of work done. More than 140 countries are featured in this report as well as global and regional summaries. Product shipments value are presented in US Dollars and local currency units for historical and forecast years.\u003c\/p\u003e\n\n\u003cp\u003ePublished annually, this report provides a unique and accurate estimate on market sizing for this equipment\/material using a proprietary economic model that integrates historical trends (horizontal analysis) and longitudinal analysis of incorporated industries (vertical analysis).\u003c\/p\u003e\n\n\u003cp\u003eRegional summaries include North America, Europe, Asia-Pacific, Latin America, Africa, and Middle East. Percent shares are presented for each region as a share of the global market.\u003c\/p\u003e\n\n\u003cp\u003eProduct shipments values are also broken down by related costs, such as cost of materials, cost of fuels\/electricity, contract work and value added, as well as capital expenditures, such as expenditures on buildings, machinery, vehicles and computers.\u003c\/p\u003e\n\n\u003cp\u003eThese estimates product shipment values are also considered \"\"market potentials\"\" because the calculations assume efficient, free markets. Estimates can vary in countries with inefficient, closed markets with such issues as oppressive regulations and tariffs, black markets, and political problems impacted a regular business cycle.\u003c\/p\u003e\n\n\u003cp\u003eThis report does not list key players\/companies in the market but focuses on a top-down and outlook view of the market despite the existing and entering of market companies.\u003c\/p\u003e\n\n\u003cp\u003eBarnes Reports' Manufacturing \u0026amp; Markets reports are an essential part of any GAP analysis, benchmarking project, SWOT analysis, business plan, risk analysis, or growth-share matrix.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 132 Pages \/ MCW16225177","offer_id":47639643357490,"sku":null,"price":1140.0,"currency_code":"USD","in_stock":true}]},{"product_id":"2023-global-forecast-for-chromatographic-instruments-2024-2029-outlook-manufacturing-markets-report","title":"2023 Global Forecast for Chromatographic instruments (2024-2029 Outlook)-Manufacturing \u0026 Markets Report","description":"\u003cp\u003eThe 2023 Global Forecast for Chromatographic instruments (2024-2029 Outlook)-Manufacturing \u0026amp; Markets Report, published by Barnes Reports, contains timely and accurate market statistics and forecasts on the market for over 40 countries.\u003c\/p\u003e\n\n\u003cp\u003eEstimates on equipment or material sales (product shipments value) are published historically for 2019 to 2020, projections for 2021 to 2023 and forecasts for 2024 to 2029. Product shipments include the total value of all products produced and shipped by all producers. For selected products, this can represent value of receipts, value of production, or value of work done. More than 140 countries are featured in this report as well as global and regional summaries. Product shipments value are presented in US Dollars and local currency units for historical and forecast years.\u003c\/p\u003e\n\n\u003cp\u003ePublished annually, this report provides a unique and accurate estimate on market sizing for this equipment\/material using a proprietary economic model that integrates historical trends (horizontal analysis) and longitudinal analysis of incorporated industries (vertical analysis).\u003c\/p\u003e\n\n\u003cp\u003eRegional summaries include North America, Europe, Asia-Pacific, Latin America, Africa, and Middle East. Percent shares are presented for each region as a share of the global market.\u003c\/p\u003e\n\n\u003cp\u003eProduct shipments values are also broken down by related costs, such as cost of materials, cost of fuels\/electricity, contract work and value added, as well as capital expenditures, such as expenditures on buildings, machinery, vehicles and computers.\u003c\/p\u003e\n\n\u003cp\u003eThese estimates product shipment values are also considered \"\"market potentials\"\" because the calculations assume efficient, free markets. Estimates can vary in countries with inefficient, closed markets with such issues as oppressive regulations and tariffs, black markets, and political problems impacted a regular business cycle.\u003c\/p\u003e\n\n\u003cp\u003eThis report does not list key players\/companies in the market but focuses on a top-down and outlook view of the market despite the existing and entering of market companies.\u003c\/p\u003e\n\n\u003cp\u003eBarnes Reports' Manufacturing \u0026amp; Markets reports are an essential part of any GAP analysis, benchmarking project, SWOT analysis, business plan, risk analysis, or growth-share matrix.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 132 Pages \/ MCW16225178","offer_id":47639643390258,"sku":null,"price":1140.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-contract-development-and-manufacturing-organization-cdmo-outsourcing-market-2023-2027","title":"Global Contract Development and Manufacturing Organization (CDMO) Outsourcing Market 2023-2027","description":"\u003cp\u003eGlobal Contract Development And Manufacturing Organization (CDMO) Outsourcing Market 2023-2027\u003c\/p\u003e\n\n\u003cp\u003eTechnavio has been monitoring the contract development and manufacturing organization (CDMO) outsourcing market and it is poised to grow by $84.14 bn during 2023-2027, accelerating at a CAGR of 12.76% during the forecast period. Our report on the contract development and manufacturing organization (CDMO) outsourcing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.\u003c\/p\u003e\n\n\u003cp\u003eThe report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the growing pharmaceutical industry, increasing demand for one-stop-shop CDMOs, and support of CDMO in reducing operational and capital expenses.\u003c\/p\u003e\n\n\u003cp\u003eThe contract development and manufacturing organization (CDMO) outsourcing market analysis include Product, Service, and Geography\u003c\/p\u003e\n\n\u003cp\u003eTechnavio's contract development and manufacturing organization (CDMO) outsourcing market is segmented as below:\u003c\/p\u003e\n\n\u003cp\u003eBy ProductSmall moleculesBiologicsBy ServiceAPI\/bulk drugsDrug product manufacturingPackagingBy Geographical LandscapeNorth AmericaEuropeAPACSouth AmericaMiddle East and AfricaThis study identifies the growing use of analytics by CDMOs as one of the prime reasons driving the contract development and manufacturing organization (CDMO) outsourcing market growth during the next few years. Also, growing demand for CDMOs for cell and gene therapies and increasing market consolidation will lead to sizable demand in the market.\u003c\/p\u003e\n\n\u003cp\u003eTechnavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the contract development and manufacturing organization (CDMO) outsourcing market covers the following areas:Contract development and manufacturing organization (CDMO) outsourcing market sizingContract development and manufacturing organization (CDMO) outsourcing market forecastContract development and manufacturing organization (CDMO) outsourcing market industry analysisTechnavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading contract development and manufacturing organization (CDMO) outsourcing market vendors that include Alcami Corp., Almac Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., Celonic AG, Corden Pharma International GmbH, Eurofins Scientific SE, FAMAR Health Care Services, FUJIFILM Holdings Corp, Lonza Group Ltd., Piramal Enterprises Ltd., Recipharm AB, Siegfried Holding AG, The Lubrizol Corp., Thermo Fisher Scientific Inc., Aenova Holding GmbH, Curia Inc., Laboratory Corp. of America Holdings, NextPharma GmbH, and Vetter Pharma-Fertigung GmbH \u0026amp; Co. KG. Also, the contract development and manufacturing organization (CDMO) outsourcing market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.\u003c\/p\u003e\n\n\u003cp\u003eThe study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.\u003c\/p\u003e \n\n\u003cp\u003eTechnavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 120 Pages \/ MCW16225179","offer_id":47639643488562,"sku":null,"price":3000.0,"currency_code":"USD","in_stock":true}]},{"product_id":"2023-global-forecast-for-biological-products-excluding-diagnostic-for-veterinary-industrial-and-all-other-misc-uses-biological-products-2023-2028-outlook-manufacturing-markets-report","title":"2023 Global Forecast for Biological products, excluding diagnostic, for veterinary, industrial, and all other misc uses, biological products (2023-2028 Outlook)-Manufacturing \u0026 Markets Report","description":"\u003cp\u003eThe 2023 Global Forecast for Biological products, excluding diagnostic, for veterinary, industrial, and all other misc uses, biological products (2023-2028 Outlook)-Manufacturing \u0026amp; Markets Report, published by Barnes Reports, contains timely and accurate market statistics and forecasts on the market for over 40 countries.\u003c\/p\u003e\n\n\u003cp\u003eEstimates on equipment or material sales (product shipments value) are published historically for 2016 to 2020, projections for 2021 to 2023 and forecasts for 2024 to 2028. Product shipments include the total value of all products produced and shipped by all producers. For selected products, this can represent value of receipts, value of production, or value of work done. More than 140 countries are featured in this report as well as global and regional summaries. Product shipments value are presented in US Dollars and local currency units for historical and forecast years.\u003c\/p\u003e\n\n\u003cp\u003ePublished annually, this report provides a unique and accurate estimate on market sizing for this equipment\/material using a proprietary economic model that integrates historical trends (horizontal analysis) and longitudinal analysis of incorporated industries (vertical analysis).\u003c\/p\u003e\n\n\u003cp\u003eRegional summaries include North America, Europe, Asia-Pacific, Latin America, Africa, and Middle East. Percent shares are presented for each region as a share of the global market.\u003c\/p\u003e\n\n\u003cp\u003eProduct shipments values are also broken down by related costs, such as cost of materials, cost of fuels\/electricity, contract work and value added, as well as capital expenditures, such as expenditures on buildings, machinery, vehicles and computers.\u003c\/p\u003e\n\n\u003cp\u003eThese estimates product shipment values are also considered \"\"market potentials\"\" because the calculations assume efficient, free markets. Estimates can vary in countries with inefficient, closed markets with such issues as oppressive regulations and tariffs, black markets, and political problems impacted a regular business cycle.\u003c\/p\u003e\n\n\u003cp\u003eThis report does not list key players\/companies in the market but focuses on a top-down and outlook view of the market despite the existing and entering of market companies.\u003c\/p\u003e\n\n\u003cp\u003eBarnes Reports' Manufacturing \u0026amp; Markets reports are an essential part of any GAP analysis, benchmarking project, SWOT analysis, business plan, risk analysis, or growth-share matrix.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 132 Pages \/ MCW16225180","offer_id":47639643554098,"sku":null,"price":1140.0,"currency_code":"USD","in_stock":true}]},{"product_id":"2023-global-forecast-for-hematology-laboratory-instrumentation-used-to-measure-and-identify-substances-or-cells-contained-in-blood-2024-2029-outlook-manufacturing-markets-report","title":"2023 Global Forecast for Hematology laboratory instrumentation, used to measure and identify substances or cells contained in blood  (2024-2029 Outlook)-Manufacturing \u0026 Markets Report","description":"\u003cp\u003eThe 2023 Global Forecast for Hematology laboratory instrumentation, used to measure and identify substances or cells contained in blood  (2024-2029 Outlook)-Manufacturing \u0026amp; Markets Report, published by Barnes Reports, contains timely and accurate market statistics and forecasts on the market for over 40 countries.\u003c\/p\u003e\n\n\u003cp\u003eEstimates on equipment or material sales (product shipments value) are published historically for 2019 to 2020, projections for 2021 to 2023 and forecasts for 2024 to 2029. Product shipments include the total value of all products produced and shipped by all producers. For selected products, this can represent value of receipts, value of production, or value of work done. More than 140 countries are featured in this report as well as global and regional summaries. Product shipments value are presented in US Dollars and local currency units for historical and forecast years.\u003c\/p\u003e\n\n\u003cp\u003ePublished annually, this report provides a unique and accurate estimate on market sizing for this equipment\/material using a proprietary economic model that integrates historical trends (horizontal analysis) and longitudinal analysis of incorporated industries (vertical analysis).\u003c\/p\u003e\n\n\u003cp\u003eRegional summaries include North America, Europe, Asia-Pacific, Latin America, Africa, and Middle East. Percent shares are presented for each region as a share of the global market.\u003c\/p\u003e\n\n\u003cp\u003eProduct shipments values are also broken down by related costs, such as cost of materials, cost of fuels\/electricity, contract work and value added, as well as capital expenditures, such as expenditures on buildings, machinery, vehicles and computers.\u003c\/p\u003e\n\n\u003cp\u003eThese estimates product shipment values are also considered \"\"market potentials\"\" because the calculations assume efficient, free markets. Estimates can vary in countries with inefficient, closed markets with such issues as oppressive regulations and tariffs, black markets, and political problems impacted a regular business cycle.\u003c\/p\u003e\n\n\u003cp\u003eThis report does not list key players\/companies in the market but focuses on a top-down and outlook view of the market despite the existing and entering of market companies.\u003c\/p\u003e\n\n\u003cp\u003eBarnes Reports' Manufacturing \u0026amp; Markets reports are an essential part of any GAP analysis, benchmarking project, SWOT analysis, business plan, risk analysis, or growth-share matrix.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 132 Pages \/ MCW16225181","offer_id":47639643586866,"sku":null,"price":1140.0,"currency_code":"USD","in_stock":true}]},{"product_id":"2023-global-forecast-for-biological-products-excl-diagnostic-other-blood-etc-2023-2028-outlook-manufacturing-markets-report","title":"2023 Global Forecast for Biological products, excl. diagnostic, other blood\/etc. (2023-2028 Outlook)-Manufacturing \u0026 Markets Report","description":"\u003cp\u003eThe 2023 Global Forecast for Biological products, excl. diagnostic, other blood\/etc. (2023-2028 Outlook)-Manufacturing \u0026amp; Markets Report, published by Barnes Reports, contains timely and accurate market statistics and forecasts on the market for over 40 countries.\u003c\/p\u003e\n\n\u003cp\u003eEstimates on equipment or material sales (product shipments value) are published historically for 2016 to 2020, projections for 2021 to 2023 and forecasts for 2024 to 2028. Product shipments include the total value of all products produced and shipped by all producers. For selected products, this can represent value of receipts, value of production, or value of work done. More than 140 countries are featured in this report as well as global and regional summaries. Product shipments value are presented in US Dollars and local currency units for historical and forecast years.\u003c\/p\u003e\n\n\u003cp\u003ePublished annually, this report provides a unique and accurate estimate on market sizing for this equipment\/material using a proprietary economic model that integrates historical trends (horizontal analysis) and longitudinal analysis of incorporated industries (vertical analysis).\u003c\/p\u003e\n\n\u003cp\u003eRegional summaries include North America, Europe, Asia-Pacific, Latin America, Africa, and Middle East. Percent shares are presented for each region as a share of the global market.\u003c\/p\u003e\n\n\u003cp\u003eProduct shipments values are also broken down by related costs, such as cost of materials, cost of fuels\/electricity, contract work and value added, as well as capital expenditures, such as expenditures on buildings, machinery, vehicles and computers.\u003c\/p\u003e\n\n\u003cp\u003eThese estimates product shipment values are also considered \"\"market potentials\"\" because the calculations assume efficient, free markets. Estimates can vary in countries with inefficient, closed markets with such issues as oppressive regulations and tariffs, black markets, and political problems impacted a regular business cycle.\u003c\/p\u003e\n\n\u003cp\u003eThis report does not list key players\/companies in the market but focuses on a top-down and outlook view of the market despite the existing and entering of market companies.\u003c\/p\u003e\n\n\u003cp\u003eBarnes Reports' Manufacturing \u0026amp; Markets reports are an essential part of any GAP analysis, benchmarking project, SWOT analysis, business plan, risk analysis, or growth-share matrix.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 132 Pages \/ MCW16225182","offer_id":47639643619634,"sku":null,"price":1140.0,"currency_code":"USD","in_stock":true}]},{"product_id":"2023-global-forecast-for-other-biologics-allergenic-extracts-and-other-biologics-2023-2028-outlook-manufacturing-markets-report","title":"2023 Global Forecast for Other biologics, allergenic extracts and other biologics (2023-2028 Outlook)-Manufacturing \u0026 Markets Report","description":"\u003cp\u003eThe 2023 Global Forecast for Other biologics, allergenic extracts and other biologics (2023-2028 Outlook)-Manufacturing \u0026amp; Markets Report, published by Barnes Reports, contains timely and accurate market statistics and forecasts on the market for over 40 countries.\u003c\/p\u003e\n\n\u003cp\u003eEstimates on equipment or material sales (product shipments value) are published historically for 2016 to 2020, projections for 2021 to 2023 and forecasts for 2024 to 2028. Product shipments include the total value of all products produced and shipped by all producers. For selected products, this can represent value of receipts, value of production, or value of work done. More than 140 countries are featured in this report as well as global and regional summaries. Product shipments value are presented in US Dollars and local currency units for historical and forecast years.\u003c\/p\u003e\n\n\u003cp\u003ePublished annually, this report provides a unique and accurate estimate on market sizing for this equipment\/material using a proprietary economic model that integrates historical trends (horizontal analysis) and longitudinal analysis of incorporated industries (vertical analysis).\u003c\/p\u003e\n\n\u003cp\u003eRegional summaries include North America, Europe, Asia-Pacific, Latin America, Africa, and Middle East. Percent shares are presented for each region as a share of the global market.\u003c\/p\u003e\n\n\u003cp\u003eProduct shipments values are also broken down by related costs, such as cost of materials, cost of fuels\/electricity, contract work and value added, as well as capital expenditures, such as expenditures on buildings, machinery, vehicles and computers.\u003c\/p\u003e\n\n\u003cp\u003eThese estimates product shipment values are also considered \"\"market potentials\"\" because the calculations assume efficient, free markets. Estimates can vary in countries with inefficient, closed markets with such issues as oppressive regulations and tariffs, black markets, and political problems impacted a regular business cycle.\u003c\/p\u003e\n\n\u003cp\u003eThis report does not list key players\/companies in the market but focuses on a top-down and outlook view of the market despite the existing and entering of market companies.\u003c\/p\u003e\n\n\u003cp\u003eBarnes Reports' Manufacturing \u0026amp; Markets reports are an essential part of any GAP analysis, benchmarking project, SWOT analysis, business plan, risk analysis, or growth-share matrix.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 132 Pages \/ MCW16225183","offer_id":47639643652402,"sku":null,"price":1140.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-automatic-cell-imaging-system-market-2022-2029","title":"Global Automatic Cell Imaging System Market - 2022-2029","description":"\u003cp\u003eGlobal Automatic Cell Imaging System Market - 2022-2029\u003c\/p\u003e\n\n\u003cp\u003eMarket Overview\u003c\/p\u003e\n\n\u003cp\u003eThe global automatic cell imaging system market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 9.1% during the forecast period (2022-2029).\u003c\/p\u003e\n\n\u003cp\u003eAutomated image analysis employs software to isolate data from digital images. Algorithms identify specific shapes and patterns in the images and compile quantitative information that is then utilized in cell imaging studies of cellular structure and function in cells. It enables the visualization and quantitation of dynamic cellular processes in real-time.\u003c\/p\u003e\n\n\u003cp\u003eMarket Dynamics\u003c\/p\u003e\n\n\u003cp\u003eThe increasing research activities and related funding from various entities will boost the global automatic cell imaging system market growth during the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eThe increased research initiatives and findings fuel its demand in the global market.\u003c\/p\u003e\n\n\u003cp\u003eAs life sciences and biomedicine studies advance, they become more sophisticated and require automated technology to maintain the data throughput necessary for scientific advancement. Microscopic imaging of biological processes is a fundamental data acquisition and analysis technique used in biomedical research. Therefore, the growing research initiatives and funding in biomedicine boost the global automatic cell imaging system market. For instance, the independent ISREC Foundation focused on supporting innovative cancer research in Lausanne and Western Switzerland, particularly translational oncology that is guaranteed to positively impact the future treatment of cancer patients. Moreover, in 2020 the estimated funding budget for research according to the NCI for various chronic diseases was $6,440.4 million, and the Professional Judgement Budget Proposal for the fiscal year 2024 is $9988 million. Similarly, in July 2021, the Cancer Research Institute (CRI), a U.S. nonprofit organization dedicated to saving more lives through the discovery and development of potent immunotherapies for all cancers, reported that it had awarded more than $28.5 million in research grants and fellowships during the 2021 fiscal year ending June 30, 2021. Thus, the increased research initiatives and findings for biomedicines are boosting the growth of the global automatic cell imaging system during the forecasted period.\u003c\/p\u003e\n\n\u003cp\u003eThe high cost of the automatic cell imaging system will hamper the global automatic cell imaging system market growth.\u003c\/p\u003e\n\n\u003cp\u003eHowever, the high cost of the automatic cell imaging system is expected to hamper the global market growth. For instance, according to Avantor, the ImageXpress Pico Automated Cell Imaging System costs from $69,727.58 to $81,637.99 based on the specifications.\u003c\/p\u003e\n\n\u003cp\u003eCOVID-19 Impact Analysis\u003c\/p\u003e\n\n\u003cp\u003eCOVID-19 has positively impacted the global automatic cell imaging system market since post-COVID, and increased investments in biomedical research have been made. For instance, according to Research America, a non-profit medical and health research advocacy association, the United States (U.S.) medical and health research and development (R\u0026amp;D) investment reached $245.1 billion in 2020, an 11.1% increase from 2019. The 2020 estimates suggest changes in growth rates across the public-private sector R\u0026amp;D ecosystem, but it is likely these changes predominantly reflect the reaction to, and effect of, the COVID-19 pandemic.\u003c\/p\u003e\n\n\u003cp\u003eSegment Analysis\u003c\/p\u003e\n\n\u003cp\u003eLive cell and in vivo imaging are predicted to dominate the forecast period (2022-2029).\u003c\/p\u003e\n\n\u003cp\u003eLive cell and in vivo imaging are estimated to hold most of the global automatic cell imaging system market throughout the forecast period (2022-2029) because of the new product introductions by various market payers. For instance, in Oct 2020, CytoSMART Technologies launched Multi Lux, a new automated live-cell imaging system developed for long-term experiments, comparison studies, and large laboratory teams. Similarly,  in September 2021, PHC Corporation of North America and Screen Holdings Co., Ltd partnered to market the Screen Cell imager series of live cell imaging systems in North America. Additionally, in April 2022, CytoSMART technologies introduced the Omni FL, a new live-cell imaging analysis system containing red and green fluorescence channels, into its signature Omni product line for the first time. Furthermore,  in June 2021, Leica Microsystems introduced its Leica Nano workflow, a brand new live-cell correlative light and electron microscopy (CLEM) workflow solution developed to improve experimental success rates, reproducibility and simplify light and electron microscopy (EM) integration. Thus, the increasing product introduction for live cell and in vivo imaging ensures its dominance over the global automatic cell imaging system market during the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eGeographical Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe North America region holds the largest global automatic cell imaging system market share.\u003c\/p\u003e\n\n\u003cp\u003eThe North America automatic cell imaging system market is expected to grow at a high CAGR throughout the forecast period, owing to increasing initiatives by the government toward biomedical research. For instance, according to the American Association for the Advancement of Science, Congress created the Advanced Research Projects Agency for Health (ARPA-H), provided around $1 billion for startup investment, and has plans to provide $6.5 billion in funding. Furthermore, most of the key market players, such as Axion BioSystems, BD, BioTek Instruments, and Thermo Fisher Scientific, hold the majority of market share through various market strategies, ensuring the growth of the North America automatic cell imaging systems. For instance, in March 2022, Axion BioSystems, a leading life sciences tools company focused on advanced live-cell assay systems, acquired the Netherlands-based CytoSMART Technologies, an innovator in kinetic live-cell imaging analysis. Thus, the data above indicates that North America will hold most of the global automatic cell imaging systems market throughout the forecasted period (2022-2029).\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eThe automatic cell imaging system market is moderately competitive due to crucial local and global players involved in the research and innovation of new developments. Some of the key players include Axion BioSystems, Leica Microsystems, GE Healthcare Life Sciences, Olympus, BD, BioTek Instruments, PerkinElmer Inc., HORIBA Medical, Oxford Instruments, and Thermo Fisher Scientific. These key players hold the major share of the market through innovations, product launches, collaborations, acquisitions, and alliances. For instance, in May 2020, CytoSMART Technologies introduced a new live-cell imaging system. The CytoSMART Lux2 Duo Kit offers a straightforward, cost-effective solution to researchers carrying out immediate side-by-side comparisons between cell cultures.\u003c\/p\u003e\n\n\u003cp\u003eThermoFisher Scientific\u003c\/p\u003e\n\n\u003cp\u003eOverview:\u003c\/p\u003e\n\n\u003cp\u003eThermoFisher is a U.S.-based company founded in 1956. It is the world leader in serving science with annual revenue of approx. $40 billion has industry-leading brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.\u003c\/p\u003e\n\n\u003cp\u003eProduct Portfolio:\u003c\/p\u003e\n\n \u003cp\u003eThe product portfolio of ThermoFisher for Automatic Cell Imaging System has EVOS Cell Imaging Systems: EVOS imaging systems contain high-resolution cameras, bright and digitally controlled LED light sources, and automatic software to help capture stunning, publication-quality images in just a few clicks. These fully automated, multichannel fluorescence or brightfield microscopes feature advanced imaging tools to handle time-lapse movies, multiwell plate scanning, image stitching and tiling, and cell counting.\u003c\/p\u003e\n\n\u003cp\u003eThe global automatic cell imaging system market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 200 Pages \/ MCW16225184","offer_id":47639643717938,"sku":null,"price":5220.0,"currency_code":"USD","in_stock":true}]},{"product_id":"2023-global-forecast-for-spectrophotometric-instruments-2024-2029-outlook-manufacturing-markets-report","title":"2023 Global Forecast for Spectrophotometric instruments (2024-2029 Outlook)-Manufacturing \u0026 Markets Report","description":"\u003cp\u003eThe 2023 Global Forecast for Spectrophotometric instruments (2024-2029 Outlook)-Manufacturing \u0026amp; Markets Report, published by Barnes Reports, contains timely and accurate market statistics and forecasts on the market for over 40 countries.\u003c\/p\u003e\n\n\u003cp\u003eEstimates on equipment or material sales (product shipments value) are published historically for 2019 to 2020, projections for 2021 to 2023 and forecasts for 2024 to 2029. Product shipments include the total value of all products produced and shipped by all producers. For selected products, this can represent value of receipts, value of production, or value of work done. More than 140 countries are featured in this report as well as global and regional summaries. Product shipments value are presented in US Dollars and local currency units for historical and forecast years.\u003c\/p\u003e\n\n\u003cp\u003ePublished annually, this report provides a unique and accurate estimate on market sizing for this equipment\/material using a proprietary economic model that integrates historical trends (horizontal analysis) and longitudinal analysis of incorporated industries (vertical analysis).\u003c\/p\u003e\n\n\u003cp\u003eRegional summaries include North America, Europe, Asia-Pacific, Latin America, Africa, and Middle East. Percent shares are presented for each region as a share of the global market.\u003c\/p\u003e\n\n\u003cp\u003eProduct shipments values are also broken down by related costs, such as cost of materials, cost of fuels\/electricity, contract work and value added, as well as capital expenditures, such as expenditures on buildings, machinery, vehicles and computers.\u003c\/p\u003e\n\n\u003cp\u003eThese estimates product shipment values are also considered \"\"market potentials\"\" because the calculations assume efficient, free markets. Estimates can vary in countries with inefficient, closed markets with such issues as oppressive regulations and tariffs, black markets, and political problems impacted a regular business cycle.\u003c\/p\u003e\n\n\u003cp\u003eThis report does not list key players\/companies in the market but focuses on a top-down and outlook view of the market despite the existing and entering of market companies.\u003c\/p\u003e\n\n\u003cp\u003eBarnes Reports' Manufacturing \u0026amp; Markets reports are an essential part of any GAP analysis, benchmarking project, SWOT analysis, business plan, risk analysis, or growth-share matrix.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 132 Pages \/ MCW16225185","offer_id":47639643750706,"sku":null,"price":1140.0,"currency_code":"USD","in_stock":true}]},{"product_id":"2023-global-forecast-for-digestive-system-enzymes-2023-2028-outlook-manufacturing-markets-report","title":"2023 Global Forecast for Digestive system enzymes (2023-2028 Outlook)-Manufacturing \u0026 Markets Report","description":"\u003cp\u003eThe 2023 Global Forecast for Digestive system enzymes (2023-2028 Outlook)-Manufacturing \u0026amp; Markets Report, published by Barnes Reports, contains timely and accurate market statistics and forecasts on the market for over 40 countries.\u003c\/p\u003e\n\n\u003cp\u003eEstimates on equipment or material sales (product shipments value) are published historically for 2016 to 2020, projections for 2021 to 2023 and forecasts for 2024 to 2028. Product shipments include the total value of all products produced and shipped by all producers. For selected products, this can represent value of receipts, value of production, or value of work done. More than 140 countries are featured in this report as well as global and regional summaries. Product shipments value are presented in US Dollars and local currency units for historical and forecast years.\u003c\/p\u003e\n\n\u003cp\u003ePublished annually, this report provides a unique and accurate estimate on market sizing for this equipment\/material using a proprietary economic model that integrates historical trends (horizontal analysis) and longitudinal analysis of incorporated industries (vertical analysis).\u003c\/p\u003e\n\n\u003cp\u003eRegional summaries include North America, Europe, Asia-Pacific, Latin America, Africa, and Middle East. Percent shares are presented for each region as a share of the global market.\u003c\/p\u003e\n\n\u003cp\u003eProduct shipments values are also broken down by related costs, such as cost of materials, cost of fuels\/electricity, contract work and value added, as well as capital expenditures, such as expenditures on buildings, machinery, vehicles and computers.\u003c\/p\u003e\n\n\u003cp\u003eThese estimates product shipment values are also considered \"\"market potentials\"\" because the calculations assume efficient, free markets. Estimates can vary in countries with inefficient, closed markets with such issues as oppressive regulations and tariffs, black markets, and political problems impacted a regular business cycle.\u003c\/p\u003e\n\n\u003cp\u003eThis report does not list key players\/companies in the market but focuses on a top-down and outlook view of the market despite the existing and entering of market companies.\u003c\/p\u003e\n\n\u003cp\u003eBarnes Reports' Manufacturing \u0026amp; Markets reports are an essential part of any GAP analysis, benchmarking project, SWOT analysis, business plan, risk analysis, or growth-share matrix.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 132 Pages \/ MCW16225186","offer_id":47639643816242,"sku":null,"price":1140.0,"currency_code":"USD","in_stock":true}]},{"product_id":"north-america-hemoglobinopathies-market-size-share-industry-trends-analysis-report-by-type-thalassemia-sickle-cell-disease-by-distribution-channel-by-therapy-monoclonal-antibody-medication-hydroxyurea-ace-inhibitors-by-country-and-growth-fore","title":"North America Hemoglobinopathies Market Size, Share \u0026 Industry Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Distribution Channel, By Therapy (Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors), By Country and Growth Fore","description":"\u003cp\u003eNorth America Hemoglobinopathies Market Size, Share \u0026amp; Industry Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Distribution Channel, By Therapy (Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors), By Country and Growth Forecast, 2022 - 2028\u003c\/p\u003e\n\n\u003cp\u003eThe North America Hemoglobinopathies Market would witness market growth of 5.1% CAGR during the forecast period (2022-2028).\u003c\/p\u003e\n\n\u003cp\u003eTetramer hemoglobin consists of two alpha globin and two non-alpha globin chains, and Heme works together to deliver oxygen into the blood. ?A2 and ?A2 represent normal adult hemoglobin (HbA). Gene abnormalities are the cause of variant hemoglobin which affects the alpha globin genes (HBA1 or HBA2) or beta-globin (HBB) structural gene (exons). More than thousands of different variants of hemoglobin related to changes in globin chains have been found.\u003c\/p\u003e \n\n\u003cp\u003eQualitative abnormalities like amino acid substitution cause hemoglobinopathies. Thalassemia corresponds to quantitative alterations like amino acid insertions, mutations, or deletions in the adjacent sequences (introns), which decrease the globin chain synthesis. Alterations in the Alpha globin genes cause Alpha thalassemia. The four alleles of HBA1 and HBA2 control the synthesis of alpha-globin.\u003c\/p\u003e \n\n\u003cp\u003eThe number of alpha gene deletions depends upon the degree of the disease in the deletion type alpha thalassemia. Deletion of one alpha globin (also known as the silent carrier) gene is ordinary. In contrast, two alpha globin gene deletions (alpha thalassemia trait) and three alpha globin gene deletions (HbH disease) will have different hematological and clinical features. A four alpha-globin gene (Hb Bart’s Hydrops fetalis) deletion is severe and lethal for patients.\u003c\/p\u003e\n\n\u003cp\u003eNumerous newborn screening programs are being conducted in the United States with the target of finding out the rate of complications and the actual usage of early medications like pneumococcal vaccination and penicillin prophylaxis to find out the usage and effectiveness of the prevention programs among the large population of infants with hemoglobinopathy. Every newborn in Illinois, New York, and California are scanned for hemoglobinopathies. Screening programs were implemented in California, New York, and Illinois between the years 1975 and 1990.\u003c\/p\u003e\n\n\u003cp\u003eThe US market dominated the North America Hemoglobinopathies Market by Country in 2021; thereby, achieving a market value of $1.6 Million by 2028. The Canada market is experiencing a CAGR of 7.5% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 6.5% during (2022 - 2028).\u003c\/p\u003e\n\n\u003cp\u003eBased on Type, the market is segmented into Thalassemia, Sickle Cell Disease and Others. Based on Distribution Channel, the market is segmented into Drug Stores \u0026amp; Retail Pharmacy, Hospital Pharmacy and Online Providers. Based on Therapy, the market is segmented into Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.\u003c\/p\u003e\n\n\u003cp\u003eThe market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Sanofi S.A., Danaher Corporation, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Merck \u0026amp; Co., Inc., Bristol Myers Squibb Company, Alnylam Pharmaceuticals, Inc., Emmaus Life Sciences, Inc., Biogen, Inc. and Canthera Discovery Ltd.\u003c\/p\u003e\n\n\u003cp\u003eScope of the Study\u003c\/p\u003e\n\n\u003cp\u003eMarket Segments covered in the Report:\u003c\/p\u003e\n\n\u003cp\u003eBy TypeThalassemiaSickle Cell DiseaseOthersBy Distribution ChannelDrug Stores \u0026amp; Retail PharmacyHospital PharmacyOnline ProvidersBy TherapyMonoclonal Antibody MedicationHydroxyureaACE InhibitorsOthersBy CountryUS Canada Mexico Rest of North America Companies ProfiledAbbott LaboratoriesSanofi S.A.Danaher CorporationPfizer, Inc. (Global Blood Therapeutics, Inc.)Merck \u0026amp; Co., Inc.Bristol Myers Squibb CompanyAlnylam Pharmaceuticals, Inc.Emmaus Life Sciences, Inc.Biogen, Inc.Canthera Discovery Ltd.Unique Offerings from KBV ResearchExhaustive coverage Highest number of market tables and figures Subscription based model availableGuaranteed best priceAssured post sales research support with 10% customization free\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 76 Pages \/ MCW16225187","offer_id":47639643849010,"sku":null,"price":1800.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-hemoglobinopathies-market-size-share-industry-trends-analysis-report-by-type-thalassemia-sickle-cell-disease-by-distribution-channel-by-therapy-monoclonal-antibody-medication-hydroxyurea-ace-inhibitors-by-regional-outlook-and-forecast","title":"Global Hemoglobinopathies Market Size, Share \u0026 Industry Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Distribution Channel, By Therapy (Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors), By Regional Outlook and Forecast,","description":"\u003cp\u003eGlobal Hemoglobinopathies Market Size, Share \u0026amp; Industry Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Distribution Channel, By Therapy (Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors), By Regional Outlook and Forecast, 2022 - 2028\u003c\/p\u003e\n\n\u003cp\u003eThe Global Hemoglobinopathies Market size is expected to reach $6.0 billion by 2028, rising at a market growth of 5.6% CAGR during the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eIn its stable state, normal human hemoglobin’s are tetrameric protein composed of two globin chains, each of which has an alpha (?-like) chain and a beta (?-like) chain. Every globin chain is attached to a heme moiety that contains iron. The synthesis of alpha-like and beta-like (also known as non-alpha-like) is maintained throughout the lifetime, so their ratio remains constant. In the human body, hemoglobin is used to transport oxygen from the lungs to tissues.\u003c\/p\u003e \n\n\u003cp\u003eThis happens as the globin chains enable the molecules to take up more oxygen in places with high oxygen concentrations and release oxygen in areas with low oxygen concentrations. Hemoglobin also transports carbon dioxide and nitric oxides. Hemoglobinopathies are a set of hereditary diseases. In these diseases, there is an abnormal synthesis or structure of the hemoglobin molecules.\u003c\/p\u003e \n\n\u003cp\u003eFor example, one such blood condition caused due to unstable hemoglobin that deforms or damages the red blood cells is called sickle cell disease (SCD). The unusual red blood cell breakdown causes anemia and clogs the blood vessels, leading to multi-organ ischemic damage and acute pain. Millions of individuals are affected by SCD, especially those whose ancestral origin is from Western Hemisphere (Central America, Caribbean, and South America), Sub-Saharan Africa, India, Saudi Arabia, and Mediterranean counties like Greece, Italy, and Turkey.\u003c\/p\u003e \n\n\u003cp\u003eBone marrow transplants and blood stem cells are used to treat Children with sickle cell disease. The clinical intensity of SCD varies, ranging from minor problems that sometimes go unnoticed to severe effects that need urgent hospitalization. There are medications for symptomatic effects. Also, newborn screening (NBS) can help discover SCD to lessen some of the disease’s impact on children and newborns.\u003c\/p\u003e\n\n\u003cp\u003eCOVID – 19 Impact Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe COVID-19 pandemic has affected nearly all industries; it has forced healthcare organizations to concentrate the majority of funds and time on fighting COVID-19, due to a significant drop in the hemoglobinopathies market and many other sectors, especially in health and pharmaceutical, was reported. The interruptions in treating hemoglobinopathy patients were primarily due to the risk of infection in the hospitals. Special health needs are required for patients with hemoglobinopathy. The demand for several drugs and treatments has significantly increased during the pandemic. Still, due to the shutdown of factories and other restrictions, production was unable to meet the required needs.\u003c\/p\u003e\n\n\u003cp\u003eMarket Growth Factors\u003c\/p\u003e\n\n\u003cp\u003eThe rising cases of hemoglobinopathy in under-developed countries\u003c\/p\u003e\n\n\u003cp\u003eThere is a limitation in data related to the exact number of inherited hemoglobin illnesses, but still, they are certainly going to be a major burden for healthcare resources. The public healthcare system in under-developed countries is also improving, and with that, the survival rate of children suffering from these diseases is also increasing, which means more patients will be available for later treatments. Inherited hemoglobin disorder is considered to be the most common monogenic illness.\u003c\/p\u003e\n\n\u003cp\u003eHigh investments in research and development\u003c\/p\u003e\n\n\u003cp\u003eThe growth of tissue-oriented, safe, and efficient gene editing technology has contributed to the development of various gene therapy types for hemoglobin-related illnesses. Gene therapy has the potential to treat patients. As new and promising therapeutic options appear, the overall cost of treatment is expected to get more affordable. Presently, an increasing number of trials to find the efficiency and safety of these gene editing and addition technologies to rescue hemoglobin production in beta laminopathies are going on.\u003c\/p\u003e\n\n\u003cp\u003eMarket Restraining Factors\u003c\/p\u003e\n\n\u003cp\u003eFailure of the clinical trials and high risk in treatment\u003c\/p\u003e\n\n\u003cp\u003eA hematopoietic stem cell transplant is currently the only available treatment for Sickle Cell Disease. This approach has evolved enough to have resulted in practice guidelines for its indication and management. But despite the numerous protocols, the number of patients treated with them is only a few. Moreover, the long-term side effects of solid tumors in transplanted Sickle cell patients are also an area of concern. Although there is constant advancement in the medical sector, there is still a lack of permanent treatment for hemoglobinopathy illness.\u003c\/p\u003e\n\n\u003cp\u003eType Outlook\u003c\/p\u003e\n\n\u003cp\u003eBased on the Type, the Hemoglobinopathy Market is segmented into Thalassemia, Sickle Cell Disease and Others. The thalassemia segment acquired the highest revenue share in the hemoglobinopathies market in 2021. It is because thalassemia is a type of blood disorder that is caused by the alteration in the gene. There are two primary types of thalassemia. One is alpha thalassemia which occurs when the alpha globin protein gene or genes are missing or mutated. And the other one is Beta thalassemia which is due to the change in the production of beta globin protein.\u003c\/p\u003e \n\n\u003cp\u003eDistribution Channel Outlook\u003c\/p\u003e\n\n\u003cp\u003eBy Distribution channel, the is classified into Hospital Pharmacy, Online Providers and Drug Stores and Retail Pharmacy. The Hospital pharmacy segment recorded a significant revenue share in the hemoglobinopathies market in 2021. Due to the composition of the healthcare services, which includes the practice, preparing, compounding, storing, dispensing medicines and medical devices, and patient counseling. Also, they have healthcare professionals like doctors and nurses for effective, safe, and efficient use. In health facilities, a hospital pharmacy is a specialized field of pharmacy which is a part of the patient’s health care.\u003c\/p\u003e\n\n\u003cp\u003eTherapy Outlook\u003c\/p\u003e\n\n\u003cp\u003eOn the basis of Therapy, the hemoglobinopathy market is divided into Monoclonal Antibody Medication, ACE inhibitors, Hydroxyurea and Others. The Monoclonal Antibody Medication segment procured the largest revenue share in the hemoglobinopathy market in 2021. It is because of the sufficient medications available for the therapy and also because thalassemia patients show healthy recovery by monoclonal antibody medication. Monoclonal antibodies are similar to antibodies that a human body develops, which mimic the activity of the immune system. They are created through a process in which specific antibodies are drawn out of the blood and then cloned.\u003c\/p\u003e\n\n\u003cp\u003eRegional Outlook\u003c\/p\u003e\n\n\u003cp\u003eRegion-wise, the hemoglobinopathies market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region acquired the largest revenue share in the hemoglobinopathies market in 2021. Due to the awareness programs initiated by the different organizations in which they spread awareness about the diseases related to hemoglobinopathy and the need to research and find new therapies for its treatment. Also, the rising immigration to the region from areas where this disease is widely found and the availability of new and enhanced medications are expected to fuel the market growth.\u003c\/p\u003e\n\n\u003cp\u003eThe market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Sanofi S.A., Danaher Corporation, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Merck \u0026amp; Co., Inc., Bristol Myers Squibb Company, Alnylam Pharmaceuticals, Inc., Emmaus Life Sciences, Inc., Biogen, Inc. and Canthera Discovery Ltd.\u003c\/p\u003e\n\n\u003cp\u003eScope of the Study\u003c\/p\u003e\n\n\u003cp\u003eMarket Segments covered in the Report:\u003c\/p\u003e\n\n\u003cp\u003eBy TypeThalassemiaSickle Cell DiseaseOthersBy Distribution ChannelDrug Stores \u0026amp; Retail PharmacyHospital PharmacyOnline ProvidersBy TherapyMonoclonal Antibody MedicationHydroxyureaACE InhibitorsOthersBy GeographyNorth America US Canada Mexico Rest of North AmericaEurope Germany UK France Russia Spain Italy Rest of EuropeAsia Pacific China Japan India South Korea Singapore Malaysia Rest of Asia Pacific LAMEA Brazil Argentina UAE Saudi Arabia South Africa Nigeria Rest of LAMEA Companies ProfiledAbbott LaboratoriesSanofi S.A.Danaher CorporationPfizer, Inc. (Global Blood Therapeutics, Inc.)Merck \u0026amp; Co., Inc.Bristol Myers Squibb CompanyAlnylam Pharmaceuticals, Inc.Emmaus Life Sciences, Inc.Biogen, Inc.Canthera Discovery Ltd.Unique Offerings from KBV ResearchExhaustive coverage Highest number of market tables and figures Subscription based model availableGuaranteed best priceAssured post sales research support with 10% customization free\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 209 Pages \/ MCW16225188","offer_id":47639643881778,"sku":null,"price":4320.0,"currency_code":"USD","in_stock":true}]},{"product_id":"europe-hemoglobinopathies-market-size-share-industry-trends-analysis-report-by-type-thalassemia-sickle-cell-disease-by-distribution-channel-by-therapy-monoclonal-antibody-medication-hydroxyurea-ace-inhibitors-by-country-and-growth-forecast-2","title":"Europe Hemoglobinopathies Market Size, Share \u0026 Industry Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Distribution Channel, By Therapy (Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors), By Country and Growth Forecast, 2","description":"\u003cp\u003eEurope Hemoglobinopathies Market Size, Share \u0026amp; Industry Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Distribution Channel, By Therapy (Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors), By Country and Growth Forecast, 2022 - 2028\u003c\/p\u003e\n\n\u003cp\u003eThe Europe Hemoglobinopathies Market would witness market growth of 5.2% CAGR during the forecast period (2022-2028).\u003c\/p\u003e\n\n\u003cp\u003eHbS, HbD, HbE, and HbG are more frequently seen as beta-globin variants. A mutation in one beta globin component generates a blend of regular and variant hemoglobin, which creates a heterozygote state, commonly known as a trait or carrier status. Mutations in both beta globin components are because of diseases based on a homozygous or heterozygous expression. Mutations are homozygous with a synthesis of HbS in the case of sickle cell anemia (HbSS).\u003c\/p\u003e \n\n\u003cp\u003eNo matter whether it is an alpha globin or beta globin variant, the seriousness of the disease can be inconsequential or fatal. Therefore, it is necessary to identify it through newborn screening. In 2006, the Recommended Uniform Screening Panel (RUSP) added Hemoglobinopathies, specially HbSS, HbSC disease, and Hbs\/beta-thalassemia, to their list.\u003c\/p\u003e \n\n\u003cp\u003eJointly the Maternal and Child Health Bureau of the Health Resources and Services Administration (HRSA) of the United States and the American College of Medical Genetics (ACMG) concluded that these illnesses are clinically severe and can be easily identified during newborn screening. Depending upon the severity of the disease connected with sickle cell disorder, they were added. Extreme pain, anemia, and vaso occlusive crisis, which in the end affects multiple organ systems and eventually worsens with time, are some of its symptoms.\u003c\/p\u003e\n\n\u003cp\u003eThe Pediatric and Adult hemoglobinopathy Outpatients Units of the University Hospital of Essen conducted a study and summarized the outcomes of hemoglobinopathies which was before the introduction of the general newborn screening for SCD in Germany. A total of 339 patients were diagnosed by molecular analysis, out of which 182 were minors (50.5% males) and 157 adults (75.8% females). Due to the migration and the late diagnosis of second\/third-generation migrants, hemoglobinopathy is posing serious health problems in Germany.\u003c\/p\u003e\n\n\u003cp\u003eThe Germany market dominated the Europe Hemoglobinopathies Market by Country in 2021; thereby, achieving a market value of $399.3 Million by 2028. The UK market is exhibiting a CAGR of 4.3% during (2022 - 2028). Additionally, The France market would experience a CAGR of 5.9% during (2022 - 2028).\u003c\/p\u003e\n\n\u003cp\u003eBased on Type, the market is segmented into Thalassemia, Sickle Cell Disease and Others. Based on Distribution Channel, the market is segmented into Drug Stores \u0026amp; Retail Pharmacy, Hospital Pharmacy and Online Providers. Based on Therapy, the market is segmented into Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.\u003c\/p\u003e\n\n\u003cp\u003eThe market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Sanofi S.A., Danaher Corporation, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Merck \u0026amp; Co., Inc., Bristol Myers Squibb Company, Alnylam Pharmaceuticals, Inc., Emmaus Life Sciences, Inc., Biogen, Inc. and Canthera Discovery Ltd.\u003c\/p\u003e\n\n\u003cp\u003eScope of the Study\u003c\/p\u003e\n\n\u003cp\u003eMarket Segments covered in the Report:\u003c\/p\u003e\n\n\u003cp\u003eBy TypeThalassemiaSickle Cell DiseaseOthersBy Distribution ChannelDrug Stores \u0026amp; Retail PharmacyHospital PharmacyOnline ProvidersBy TherapyMonoclonal Antibody MedicationHydroxyureaACE InhibitorsOthersBy CountryGermany UK France Russia Spain Italy Rest of Europe Companies ProfiledAbbott LaboratoriesSanofi S.A.Danaher CorporationPfizer, Inc. (Global Blood Therapeutics, Inc.)Merck \u0026amp; Co., Inc.Bristol Myers Squibb CompanyAlnylam Pharmaceuticals, Inc.Emmaus Life Sciences, Inc.Biogen, Inc.Canthera Discovery Ltd.Unique Offerings from KBV ResearchExhaustive coverage Highest number of market tables and figures Subscription based model availableGuaranteed best priceAssured post sales research support with 10% customization free\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 86 Pages \/ MCW16225189","offer_id":47639643914546,"sku":null,"price":1800.0,"currency_code":"USD","in_stock":true}]},{"product_id":"bcl-2-like-protein-1-apoptosis-regulator-bclx-or-bclx-or-bcl2l1-drugs-in-development-by-stages-target-moa-roa-molecule-type-and-key-players-2022-update","title":"Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update","description":"\u003cp\u003eBcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update\u003c\/p\u003e\n\n\u003cp\u003eSummary\u003c\/p\u003e\n\n\u003cp\u003eBcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Bcl-2-like protein 1 is a protein encoded by the BCL2L1 gene. It belongs to BCL-2 family. It is a potent inhibitor of cell death. It inhibits activation of caspases. It regulate cell death by blocking the voltage-dependent anion channel by binding to it and preventing the release of the caspase activator (CYC1) from the mitochondrial membrane. It acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.\u003c\/p\u003e \n\n\u003cp\u003eBcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities\/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 3 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease and Musculoskeletal Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Hepatocellular Carcinoma, Small-Cell Lung Cancer, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)\/Immunoblastic Lymphadenopathy, Bladder Cancer, Blood Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelomonocytic Leukemia (CMML), Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Fibrosis, Follicular Lymphoma, Gastric Cancer, Head And Neck Cancer, Hematological Tumor, Hormone-Sensitive Prostate Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lymphoblastic Lymphoma, Mantle Cell Lymphoma, Metastatic Melanoma, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Myelodysplastic Syndrome, Myelofibrosis, Natural Killer Cell Lymphomas, Neuroendocrine Tumors, Nodal Marginal Zone B-Cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Sezary Syndrome, Splenic Marginal Zone B-Cell Lymphoma, T-Cell Lymphomas and Unspecified B-Cell Lymphomas.\u003c\/p\u003e \n\n\u003cp\u003eThe latest report, outlays comprehensive information on the Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics development with respective active and dormant or discontinued projects.\u003c\/p\u003e\n\n\u003cp\u003eThe report is built using data and information sourced from proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company\/university sites and industry-specific third party sources.\u003c\/p\u003e\n\n\u003cp\u003eNote:Certain content \/ sections in the pipeline guide may be removed or altered based on the availability and relevance of data.\u003c\/p\u003e\n\n\u003cp\u003eScopeThe report provides a snapshot of the global therapeutic landscape for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)The report reviews Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics under development by companies and universities\/research institutes based on information derived from company and industry-specific sources The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R\u0026amp;D brief, licensing and collaboration details \u0026amp; other developmental activities The report reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics and enlists all their major and minor projects The report assesses Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type The report summarizes all the dormant and discontinued pipeline projects The report reviews latest news and deals related to Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeuticsReasons to BuyGain strategically significant competitor information, analysis, and insights to formulate effective R\u0026amp;D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Identify and understand the targeted therapy areas and indications for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)Identify the use of drugs for target identification and drug repurposingIdentify potential new clients or partners in the target demographicDevelop strategic initiatives by understanding the focus areas of leading companies Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeuticsDevise corrective measures for pipeline projects by understanding Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) development landscape Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 70 Pages \/ MCW16225190","offer_id":47639643947314,"sku":null,"price":4200.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-biosimulation-market-2022-edition-analysis-by-component-software-service-application-drug-discovery-pre-clinical-clinical-end-user-by-region-by-country-market-insights-and-forecast-2018-2028","title":"Global Biosimulation Market (2022 Edition) – Analysis By Component (Software, Service), Application (Drug Discovery, Pre-Clinical, Clinical), End-User, By Region, By Country: Market Insights and Forecast (2018-2028)","description":"\u003cp\u003eGlobal Biosimulation Market (2022 Edition) – Analysis By Component (Software, Service), Application (Drug Discovery, Pre-Clinical, Clinical), End-User, By Region, By Country: Market Insights and Forecast (2018-2028)\u003c\/p\u003e\n\n\u003cp\u003eExecutive Summary\u003c\/p\u003e\n\n\u003cp\u003eAccording to a research report published by Azoth Analytics in November 2022, the Global Biosimulation Market was valued at USD 3011.50 Million in the year 2021. Biosimulation helps to increase the probability of success in human clinical trials, the most expensive part of drug development. Biosimulation helps to optimize dosing for different populations for enhanced safety and efficacy. New drugs can cause significant increases in retail spending because they are more expensive, in high demand, or both. Currently, In-Silico methods are outpacing various stages of drug discovery, particularly in biomedicine sciences.\u003c\/p\u003e\n\n\u003cp\u003eBiosimulation drug discovery offers numerous opportunities for error elimination through computer simulation, which can improve drug performance and accuracy. In the forthcoming years, there will be more potential for the Biosimulation market to flourish due to the expanding applications and rising use of personalized medicine and biosimulation solutions for the development of paediatric drugs. Companies around the world use key strategies such as Component launches, business expansions, mergers and acquisitions, patents and approvals, agreements and collaborations.\u003c\/p\u003e\n\n\u003cp\u003eThe key software methods for developing a drug are structure-based drug design, molecular modelling, structure-based virtual screening, ligand interaction, and molecular dynamics. New technologies such as virtual reality and artificial intelligence (AI) are expanding the opportunities for drug discovery. Americas has the lucrative growth in the Biosimulation industry and the United States remains the country with the earliest launches accounting for 72 NASs launched in 2021.\u003c\/p\u003e\n\n\u003cp\u003eScope of the Report The report presents the analysis of the Biosimulation market for the historical period of 2018-2021, the estimated year 2022 and the forecast period of 2023-2028. The report analyses the Biosimulation Market by Value (USD Million). The report analyses the Biosimulation Market by Component (Software, Service) The report analyses the Biosimulation Market by Application (Drug Discovery, Pre-Clinical, Clinical) The report analyses the Biosimulation Market by End-User (Academic \u0026amp; Government Research Institutes, Pharmaceutical \u0026amp; Biotech Companies, Contract Research Organization, Regulatory Authorities) The Global Biosimulation Market has been analysed by countries (United States, Canada, Mexico, Germany, United Kingdom, France, Italy, China, Japan, India)  The attractiveness of the market has been presented by region, by Component, Application and End-User.  Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.  The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include – Certara, Inc., Simulations Plus, Inc., Schrödinger, Inc., Dassault Systèmes, Physiomics plc, Thermo Fisher Scientific, Instem plc, Advanced Chemistry Development, Inc., Chemical Computing Group, OptibriumKey Target Audience Pharmaceutical and Healthcare Companies  Pharmaceutical Research and Development Companies Consulting and Advisory Firms Government and Policy Makers Regulatory Authorities\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 270 Pages \/ MCW16225191","offer_id":47639643980082,"sku":null,"price":2880.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-atopic-dermatitis-drugs-market-size-share-industry-trends-analysis-report-by-route-of-administration-by-class-biologics-calcineurin-inhibitors-corticosteroids-pde4-inhibitors-by-regional-outlook-and-forecast-2022-2028","title":"Global Atopic Dermatitis Drugs Market Size, Share \u0026 Industry Trends Analysis Report By Route of Administration, By Class (Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors), By Regional Outlook and Forecast, 2022 - 2028","description":"\u003cp\u003eGlobal Atopic Dermatitis Drugs Market Size, Share \u0026amp; Industry Trends Analysis Report By Route of Administration, By Class (Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors), By Regional Outlook and Forecast, 2022 - 2028\u003c\/p\u003e\n\n\u003cp\u003eThe Global Atopic Dermatitis Drugs Market size is expected to reach $22 billion by 2028, rising at a market growth of 9.2% CAGR during the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eEczema, commonly referred to as atopic dermatitis, is a skin ailment that affects the skin and results in itching, dryness, and inflammation. The illness has a potential for chronicity and occasionally flares up and spreads. Drugs for atopic dermatitis, such as atopic eczema steroids, are utilized to treat eczema, lessen itching, and treat other atopic dermatitis-related disorders.\u003c\/p\u003e\n\n\u003cp\u003eAtopic dermatitis patients run the risk of acquiring asthma, hay fever, and food allergies. Regular moisturizing and other skin care practices help reduce itching and stop future outbreaks. Medicated lotions or ointments may also be used during treatment. It causes skin that is scratchy, red, swollen, and cracked. The damaged sites may leak a clear fluid that thickens over time.\u003c\/p\u003e \n\n\u003cp\u003eAlthough the disorder can strike at any age, it usually first manifests in childhood and varies in severity throughout time. Much of the body may be impacted in youngsters under the age of one year. The areas on the inside of the knees and elbows are most frequently affected as kids age. Adults are more frequently afflicted in the hands and feet.\u003c\/p\u003e \n\n\u003cp\u003eScratching the affected regions makes the symptoms worse, and individuals who are scratching have a higher chance of developing skin infections. Atopic dermatitis frequently leads to the development of asthma or hay fever. Avoiding things that aggravate the illness, regular bathing followed by the use of moisturizing cream, using steroid creams when flare-ups happen, and drugs to relieve itching are all part of the treatment.\u003c\/p\u003e \n\n\u003cp\u003eWool garments, soaps, fragrances, dust, chlorine, and cigarette smoke are a few things that frequently aggravate it. Some people may benefit from phototherapy. If other treatments are ineffective, steroid tablets or lotions based on calcineurin inhibitors may occasionally be employed. If a bacterial infection manifests, antibiotics (by mouth or topically) could be required. Only if food allergies are detected are dietary modifications required.\u003c\/p\u003e\n\n\u003cp\u003eCOVID-19 Impact Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe coronavirus is still creating trouble in people's lives on a worldwide scale, disrupting everything from social interactions to how they seek medical care and see the outside world. Every industry has experienced a profit or output decrease as a result of the pandemic epidemic. However, the market for treating atopic dermatitis has anticipated a substantial impact because of the irregularity of hospital visits by patients. Teledermatology has grown during the crisis when the majority of patients continue to receive generalized care and\/or additional consultative therapies without seeing a doctor in person.\u003c\/p\u003e \n\n\u003cp\u003eMarket Growth Factors\u003c\/p\u003e\n\n\u003cp\u003eGrowing Demand For Biologics\u003c\/p\u003e\n\n\u003cp\u003eThe treatment of dermatological disorders, particularly atopic dermatitis, has changed as a result of the use of biologic drugs in dermatology. Biologics have demonstrated a good response to atopic dermatitis, improving the overall quality of life. As a result, there is now a greater demand for biologic treatments for atopic dermatitis. In the upcoming several years, this pattern is probably going to continue. For the time being, only one biologic product has been authorized for the treatment of atopic dermatitis. Many more are currently through phase II clinical studies and will probably be approved soon.\u003c\/p\u003e\n\n\u003cp\u003eRising Prevalence Of Atopic Dermatitis\u003c\/p\u003e\n\n\u003cp\u003eThe increasing prevalence of atopic dermatitis medications around the world is anticipated to be the main factor driving the market for atopic dermatitis medications. A large number of people suffer with atopic dermatitis which is expected to rise even more in upcoming years. Geographical location, climatic circumstances, socioeconomic level, lifestyle, age, gender, inheritance, and individual behaviors all have an impact on the prevalence of dermatological problems around the world. An individual with atopic dermatitis must deal with allergies on a daily basis.\u003c\/p\u003e \n\n\u003cp\u003eMarket Restraining Factors\u003c\/p\u003e\n\n\u003cp\u003eSide Effects Of Topical Steroids\u003c\/p\u003e\n\n\u003cp\u003eTopical steroid treatments lasting fewer than four weeks are often risk-free and trouble-free. Long-term topical steroid use or frequent repetition of short doses of harsher steroids may cause issues. The primary issue is the prolonged usage of potent steroids. Mild topical steroids rarely have side effects. Topical steroids may have local or systemic side effects. Systemic refers to an issue that affects the entire individual, whereas local refers to that particular area of skin.\u003c\/p\u003e\n\n\u003cp\u003eClass Outlook\u003c\/p\u003e\n\n\u003cp\u003eBased on class, the atopic dermatitis drugs market is segmented into corticosteroids, calcineurin inhibitors, PDE4 inhibitors, biologics and others. In 2021, the corticosteroids segment acquired a substantial revenue share in the atopic dermatitis drugs market. Many conditions, such as inflammatory bowel disease, rashes, and asthma, can be successfully treated with corticosteroid medications, such as cortisone, hydrocortisone, and prednisone.\u003c\/p\u003e \n\n\u003cp\u003eRoute Of Administration Outlook\u003c\/p\u003e\n\n\u003cp\u003eOn the basis of route of administration, the atopic dermatitis drugs market is fragmented into topical, injectable and oral. In 2021, the injectable segment held the largest revenue share in the atopic dermatitis drugs market. This is due to the rising popularity of injectable drugs like Dupilumab. Tofacitinib and ruxolitinib are other injectable biologics being studied in clinical trials. In the near future, biologics are anticipated to alter the therapy landscape for AD.\u003c\/p\u003e \n\n\u003cp\u003eRegional Outlook\u003c\/p\u003e\n\n\u003cp\u003eRegion wise, the atopic dermatitis drugs market is analyzed across North America, Europe, Asia Pacific and LAMEA.  In 2021, the North America region led the atopic dermatitis drugs market by generating the highest revenue share. The availability of a well-established R\u0026amp;D infrastructure and kind reimbursement rules are two major factors contributing to the region's sustained dominance. Additionally, the regulatory and reimbursement environment is constantly changing to keep up with the rapid advancement of research in this field.\u003c\/p\u003e\n\n\u003cp\u003eThe major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Pfizer, Inc. and Novartis AG are the forerunners in the Atopic Dermatitis Drugs Market. Companies such as AbbVie, Inc., Sanofi SA, Regeneron Pharmaceuticals Inc. are some of the key innovators in Atopic Dermatitis Drugs Market.\u003c\/p\u003e\n\n\u003cp\u003eThe market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer Inc., Sanofi SA, AbbVie Inc., Galderma S.A., Eli Lilly and Company, Leo Pharma A\/S, Regeneron Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Novartis AG, and Incyte Corporation.\u003c\/p\u003e\n\n\u003cp\u003eRecent Strategies Deployed in Atopic Dermatitis Drugs Market\u003c\/p\u003e\n\n\u003cp\u003eMergers and Acquisitions:\u003c\/p\u003e\n\n\u003cp\u003eOct-2022: Incyte completed the acquisition of Villaris Therapeutics, an asset-centric biopharmaceutical company. This acquisition would complement Incyte's current portfolio, providing Incyte the opportunity to improve treatment options for people with vitiligo, that leverage the expertise established in the dermatology space.\u003c\/p\u003e\n\n\u003cp\u003eJun-2022: Pfizer took over ReViral, a privately held, clinical-stage Biopharmaceutical Company. This acquisition further demonstrates Pfizer's commitment to advancing pioneering science both through its in-house expertise and work with leading, innovative companies – with the aim to deliver breakthroughs to patients suffering from severe infectious diseases.\u003c\/p\u003e  \n\n\u003cp\u003eMar-2022: Pfizer completed the acquisition of Arena Pharmaceuticals, an American biopharmaceutical company. Through this acquisition, Pfizer would add the impressive experience and pipeline of Arena Pharmaceuticals to Pfizer’s Inflammation \u0026amp; Immunology therapeutic area, helping the company further its purpose of developing breakthroughs to change the lives of those with immuno-inflammatory diseases.\u003c\/p\u003e\n\n\u003cp\u003eJan-2022: Galderma took over ALASTIN Skincare, a specialty aesthetics company. This acquisition aimed at enhancing Galderma’s integrated dermatology platform with a comprehensive collection of scientifically-approved products for daily skincare regimens and peri-procedural use. Also, the acquisition would underscore Galderma’s commitment to being the partner of choice for aesthetic professionals.\u003c\/p\u003e      \n\n\u003cp\u003eDec-2021: AbbVie took over Soliton, a medical device company. The acquisition would complement Allergan Aesthetics' portfolio of non-invasive body contouring treatments to include a proven treatment for the appearance of cellulite.\u003c\/p\u003e\n\n\u003cp\u003eNov-2021: Sanofi completed the acquisition of Translate Bio, a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases. The acquisition support Sanofi’s mRNA Center of Excellence, which plans to explore the potential of enhanced mRNA vaccines \u0026amp; other key areas that includes immunology, oncology, and rare diseases.\u003c\/p\u003e\n\n\u003cp\u003eNov-2021: Sanofi took over Kadmon Holdings, which operates as a biopharmaceutical company. This acquisition would strengthen the expansion \u0026amp; growth of the general medicines portfolio.\u003c\/p\u003e\n\n\u003cp\u003eJul-2019: LEO Pharma completed the acquisition of Bayer. LEO Pharma advances significantly towards its goal of helping 125 million patients by 2025. With this acquisition, the LEO considerably improve its size in key markets like Austria, Brazil, and South Africa – underlining its ambition to become a global leader in medical dermatology.\u003c\/p\u003e   \n\n\u003cp\u003eApprovals and Trials:\u003c\/p\u003e\n\n\u003cp\u003eOct-2022: LEO Pharma got European approval for Adtralza, a drug to treat moderate-to-severe AD in adolescents. The approval would address LEO's relentless commitment to bringing the latest treatment options for those living with atopic dermatitis. This approval enables LEO to address the unmet needs of a broader patient population as it looks forwards to work with key stakeholders across the Europe region.\u003c\/p\u003e\n\n\u003cp\u003eJun-2022: Sanofi got FDA approval for Dupixent, a biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood. The approval would enable the availability of Dupixent for young people with the disease.\u003c\/p\u003e\n\n\u003cp\u003eJan-2022: Pfizer got FDA approval for CIBINQO, an oral, once-daily, Janus kinase 1 (JAK1) inhibitor. CIBINQO would offer the treatment of adults living with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products. CIBINQO would provide an important latest oral option that would help those who have yet to find relief.\u003c\/p\u003e     \n\n\u003cp\u003eJan-2022: AbbVie got FDA approval for RINVOQ, a once-daily oral option that can significantly enhance the debilitating itch \u0026amp; skin symptoms of atopic dermatitis. Through this acquisition, AbbVie would continue its efforts to enhance care in this disease state \u0026amp; other chronic, immune-mediated conditions.\u003c\/p\u003e    \n\n\u003cp\u003eDec-2021: Leo Pharma got FDA approval for Adbry, an eczema drug. The injected antibody drug would address adults and older who don’t get proper relief from topical prescription therapies. Adbry would signify important progress in LEO's aim of enhancing the standard of care in medical dermatology.\u003c\/p\u003e\n\n\u003cp\u003eSep-2021: Otsuka got FDA approval for Moizerto Ointment, a treatment for atopic dermatitis. Otsuka expects that Moizerto Ointment would serve as the latest treatment option for people having atopic dermatitis in Japan.\u003c\/p\u003e  \n\n\u003cp\u003eSep-2021: Incyte got FDA approval for Opzelura, a topical JAK inhibitor to treat AD. With this approval, the company looks forward to bringing Opzelura to the patient community and also continuing to explore its potential in other skin diseases.\u003c\/p\u003e\n\n\u003cp\u003eScope of the Study\u003c\/p\u003e\n\n\u003cp\u003eMarket Segments covered in the Report:\u003c\/p\u003e\n\n\u003cp\u003eBy Route of AdministrationInjectableOralTopicalBy ClassBiologicsCalcineurin InhibitorsCorticosteroidsPDE4 InhibitorsOthersBy GeographyNorth America US Canada Mexico Rest of North AmericaEurope Germany UK France Russia Spain Italy Rest of EuropeAsia Pacific China Japan India South Korea Singapore Malaysia Rest of Asia Pacific LAMEA Brazil Argentina UAE Saudi Arabia South Africa Nigeria Rest of LAMEA Companies ProfiledPfizer Inc.Sanofi SAAbbVie Inc.Galderma S.A.Eli Lilly and CompanyLeo Pharma A\/SRegeneron Pharmaceuticals Inc.Otsuka Pharmaceutical Co. Ltd.Novartis AGIncyte CorporationUnique Offerings from KBV ResearchExhaustive coverage Highest number of market tables and figures Subscription based model availableGuaranteed best priceAssured post sales research support with 10% customization free\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 175 Pages \/ MCW16225192","offer_id":47639644012850,"sku":null,"price":4320.0,"currency_code":"USD","in_stock":true}]},{"product_id":"myelodysplastic-syndrome-drugs-in-development-by-stages-target-moa-roa-molecule-type-and-key-players-2022-update","title":"Myelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update","description":"\u003cp\u003eMyelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update\u003c\/p\u003e\n\n\u003cp\u003eSummary\u003c\/p\u003e\n\n\u003cp\u003eGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome - Drugs In Development, 2022, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.\u003c\/p\u003e\n\n\u003cp\u003eMyelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.\u003c\/p\u003e \n\n\u003cp\u003eReport Highlights\u003c\/p\u003e\n\n\u003cp\u003eGlobal Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.\u003c\/p\u003e\n\n\u003cp\u003eThe Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies \/Universities \/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND\/CTA Filed, Preclinical and Discovery stages are 21, 93, 98, 1, 10, 36 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 8, 11, 1, 4 and 4 molecules, respectively.\u003c\/p\u003e\n\n\u003cp\u003eMyelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company\/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.\u003c\/p\u003e\n\n\u003cp\u003eNote:Certain content \/ sections in the pipeline guide may be removed or altered based on the availability and relevance of data.\u003c\/p\u003e\n\n\u003cp\u003eScopeThe pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology).The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities\/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R\u0026amp;D brief, MoA \u0026amp; other developmental activities.The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects.The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology)Reasons to BuyProcure strategically important competitor information, analysis, and insights to formulate effective R\u0026amp;D strategies.Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.Find and recognize significant and varied types of therapeutics under development for Myelodysplastic Syndrome (Oncology).Classify potential new clients or partners in the target demographic.Develop tactical initiatives by understanding the focus areas of leading companies.Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.Formulate corrective measures for pipeline projects by understanding Myelodysplastic Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 499 Pages \/ MCW16225193","offer_id":47639644045618,"sku":null,"price":3000.0,"currency_code":"USD","in_stock":true}]},{"product_id":"starpharma-holdings-ltd-spl-financial-and-strategic-swot-analysis-review","title":"Starpharma Holdings Ltd (SPL) - Financial and Strategic SWOT Analysis Review","description":"\u003cp\u003eStarpharma Holdings Ltd (SPL) - Financial and Strategic SWOT Analysis Review\u003c\/p\u003e\n\n \u003cp\u003e- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.\u003c\/p\u003e\n\n\u003cp\u003eThe profile contains critical company information including:Business description – A detailed description of the company’s operations and business divisions.Corporate strategy – Analyst’s summarization of the company’s business strategy.SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.Company history – Progression of key events associated with the company.Major products and services – A list of major products, services and brands of the company.Key competitors – A list of key competitors to the company.Key employees – A list of the key executives of the company.Executive biographies – A brief summary of the executives’ employment history.Key operational heads – A list of personnel heading key departments\/functions.Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly\/semi-annual financial statements published by the company for 5 interims history.Highlights\u003c\/p\u003e\n\n\u003cp\u003eStarpharma Holdings Ltd (Starpharma) is a biotechnology company, which researches, develops and manufactures dendrimer products for pharmaceutical, life sciences and other applications. Dendrimers are synthetic nanoscale polymers with pharmaceutical and medical uses. The company’s development programs include its DEP drug delivery, which is built around dendrimers and VivaGel portfolio. Its flagship product candidate, VivaGel, is a gel-based formulation for the treatment and prevention of bacterial vaginosis (BV) and it is also used as a vaginal microbicide to prevent sexually transmitted infections including HIV and genital herpes. It has license arrangements with several partners including Okamoto Industries and AstraZeneca among others. The company has research facilities in Melbourne, Australia. Starpharma is headquartered in Abbotsford, Victoria, Australia\u003c\/p\u003e\n\n\u003cp\u003eStarpharma Holdings Ltd Key Recent Developments\u003c\/p\u003e\n\n\u003cp\u003eJun 27,2022: Starpharma signs expanded DEP research agreement with US Biopharma Co\u003cbr\u003e\nApr 27,2022: Starpharma to present DEP at Boston ADC summit\u003cbr\u003e\nFeb 24,2022: Dr Jeff Davies appointed as non-executive director\u003cbr\u003e\nDec 08,2021: Starpharma Holdings: US biopharma DEP research agreement – additional information\u003c\/p\u003e\n\n\u003cp\u003eKey benefits of buying this profile include:\u003c\/p\u003e\n\n\u003cp\u003eYou get detailed information about the company and its operations to identify potential customers and suppliers.\u003cbr\u003e\nThe profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.\u003c\/p\u003e\n\n\u003cp\u003eUnderstand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.\u003cbr\u003e\nThe company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.\u003c\/p\u003e\n\n\u003cp\u003eEquip yourself with information that enables you to sharpen your strategies and transform your operations profitably.\u003cbr\u003e\nOpportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and\/or technological threats are highlighted.\u003c\/p\u003e\n\n\u003cp\u003eScout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.\u003cbr\u003e\nFinancial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.\u003c\/p\u003e\n\n\u003cp\u003eGain key insights into the company for academic or business research.\u003cbr\u003e\n Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.\u003c\/p\u003e\n\n\u003cp\u003eNote:Some sections may be missing if data is unavailable for the company\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 44 Pages \/ MCW16225194","offer_id":47639644078386,"sku":null,"price":150.0,"currency_code":"USD","in_stock":true}]},{"product_id":"mrna-vaccines-and-therapeutics-market-growth-trends-covid-19-impact-and-forecasts-2022-2027","title":"mRNA Vaccines and Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)","description":"\u003cp\u003eThe mRNA vaccines and therapeutics market is expected to register a CAGR of 7.2% over the forecast period (2022-2027).\u003c\/p\u003e\n\n \u003cp\u003eWhile the sudden outbreak of the COVID-19 pandemic negatively affected most business sectors, the mRNA vaccines and therapeutics market showed significant growth in 2020 and 2021. The market under study continues to flourish with the detection of a new COVID-19 variant. The increase in demand for the development of new vaccines to control the spread of the coronavirus disease has led to the growth of the market under study. Demand for mRNA vaccines and therapeutics has increased during the pandemic because they are designed to trigger an immune response only to the viral spike protein, which is only one component of the viral membrane and allows the virus to invade target cells. According to data from the Centers for Disease Control and Prevention (CDC), updated in January 2022, the use of mRNA vaccines is safe and effective, and the safety of which has been rigorously tested to help with the COVID-19 pandemic. Therefore, COVID-19 has shown a significant positive impact on the market under review.\u003c\/p\u003e\n\n \u003cp\u003eGrowth in research and development (R\u0026amp;D), collaborations, and strategic partnerships along with growing demand for new vaccines and therapeutics and increasing chronic and infectious diseases are expected to drive the growth of the studied market. For example, in January 2021 Ribometrix, Inc. and Genentech (a member of the Roche Group) announced an exclusive worldwide license and collaboration agreement to discover, develop and commercialize novel RNA-targeted small molecule therapeutics against multiple targets. As part of this collaboration, Genentech paid Ribometrix USD 25.0 million upfront and received exclusive rights to several pre-defined targets, including an exclusive global license to develop and commercialize the molecules.\u003c\/p\u003e\n\n \u003cp\u003eIn addition, in February 2022, Eli Lilly and Company invested USD 700.0 million to build a facility at the Port of Boston to support its RNA-based research and development activities. Therefore, the increase in research and development activities, collaborations, and strategic partnerships of major players is expected to drive the growth of the study market during the forecast period. However, strict legal requirements and frameworks and high prices associated with mRNA-based vaccines and therapeutics are likely to hinder the market growth.\u003c\/p\u003e\n\n\u003cp\u003eKey Market Trends\u003c\/p\u003e\n\n\u003cp\u003eInfectious Disease Segment is Expected to Occupy a Significant Share in the mRNA Vaccines and Therapeutics Market Over Forecast Period\u003c\/p\u003e\n\n \u003cp\u003eInfectious diseases by application segment are expected to witness significant growth during the forecast period. The increasing prevalence of Ebola, influenza, human immunodeficiency virus (HIV), and other viral infections including Covid-19 act as major driving factors for this segment. Earlier in 2020, the outbreak of Covid-19 sparked demand for mRNA vaccines and therapeutics. Several major players are actively involved in the research and development of vaccines to combat the Covid-19 infection. Covid-19 has shown a significant positive impact on the infectious diseases segment of applications.\u003c\/p\u003e\n\n \u003cp\u003eIn addition, non-covid-19 mRNA vaccines for HIV, influenza, and other viral infections are currently in development and clinical trials. For example, in April 2022, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), launched a Phase 1 clinical trial to evaluate three experimental messenger RNA (mRNA)-based HIV vaccines. platform. The HVTN 302 study is sponsored by NIAID and conducted by the NIAID-funded HIV Vaccine Trials Network (HVTN) based at the Fred Hutchinson Cancer Research Center in Seattle. Additionally, in July 2021, Moderna announced that the first participants had been dosed in Phase 1 and 2 clinical trials of its quadrivalent influenza candidate, mRNA-1010. Approximately 180 healthy adults in the United States participated in the study and were fully enrolled in early September 2021. Therefore, these increasing mRNA vaccine and therapeutics developments and clinical trials for several infectious diseases are anticipated to grow over the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eNorth America Region is Expected to Dominate the mRNA Vaccines and Therapeutics Market\u003c\/p\u003e\n\n \u003cp\u003eNorth America is expected to dominate the mRNA vaccines and therapeutics market during the forecast period. An increasing number of research and development (R\u0026amp;D) activities and investments in the sector, new product launches, and an increasing number of chronic diseases are the major factors attributed to the growth of the market in the region. For instance, according to the Pfizer Inc. annual report for 2022, their research and development expenditure has increased over the years from USD 9,393 million in 2020 to USD 13,829 million in 2021. Hence, increasing research and development expenditure of the key companies in the region is expected to boost growth in the mRNA vaccines and therapeutics market over the forecast period.\u003c\/p\u003e\n\n \u003cp\u003eIn addition, through the Immunization Partnership Fund (IPF), the Government of Canada has reached populations with lower vaccine uptake by enabling informed vaccination choices. In 2020 and 2021, IPF received USD 45.5 million in additional funding over 2.5 years to allow the Public Health Agency of Canada to continue supporting vaccination efforts across Canada. Through these initiatives, the Government of Canada is working to increase vaccine confidence, uptake, and access to COVID-19 vaccines across Canada. Additionally, in May 2021, the Government of Canada announced an investment of up to USD 199.16 million in Resilience Biotechnologies Inc. to increase its manufacturing and filling\/finishing capacity for several vaccines and therapeutics that use new technologies such as mRNA. Therefore, these countries' health care and drug spending and increasing government activities in the region are expected to increase in the region over the next few years.\u003c\/p\u003e\n\n \u003cp\u003eStrategic activities such as new product development, approvals, collaborations, and acquisitions in the United States are driving the growth of the mRNA therapeutics market. For example, in June 2021, Cambridge, Massachusetts, United States-based Strand Therapeutics raised USD 52.0 million to “program” new cancer therapies. The company entered into an option and license agreement with BeiGene to develop and commercialize Strand's innovative, multifunctional mRNA therapeutics for solid tumors. Therefore, strategic activities by major players are increasing in the region and are anticipated to grow, hence, driving the market growth over the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Landscape\u003c\/p\u003e\n\n \u003cp\u003eThe market for mRNA vaccines and therapeutics is fragmented in nature due to the presence of several companies globally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known including AstraZeneca, Pfizer Inc., Johnson \u0026amp; Johnson, Bayer AG, Moderna, BioNTech, GlaxoSmithKline, Boehringer Ingelheim, and Eli Lilly, among others.\u003c\/p\u003e\n\n\u003cp\u003eAdditional Benefits:\u003c\/p\u003e\n\n  \u003cp\u003eThe market estimate (ME) sheet in Excel format \u003cbr\u003e\n 3 months of analyst support\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 156 Pages \/ MCW16225195","offer_id":47639644111154,"sku":null,"price":5700.0,"currency_code":"USD","in_stock":true}]},{"product_id":"dna-methylation-market-share-size-trends-industry-analysis-report-by-technology-pcr-microarray-sequencing-by-application-gene-therapy-diagnostics-by-product-by-end-use-by-region-segment-forecast-2022-30","title":"DNA Methylation Market Share, Size, Trends, Industry Analysis Report, By Technology (PCR, Microarray, Sequencing), By Application (Gene Therapy, Diagnostics), By Product, By End-use, By Region; Segment Forecast, 2022-30","description":"\u003cp\u003eDNA Methylation Market Share, Size, Trends, Industry Analysis Report, By Technology (PCR, Microarray, Sequencing), By Application (Gene Therapy, Diagnostics), By Product, By End-use, By Region; Segment Forecast, 2022-30\u003c\/p\u003e\n\n\u003cp\u003eThe global DNA methylation market size is expected to reach USD 3,840.53 million by 2030, according to a new study by Polaris Market Research. The report “DNA Methylation Market Share, Size, Trends, Industry Analysis Report, By Technology; By Product; By Application; By End-use; By Region; Segment Forecast, 2022-2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.\u003c\/p\u003e\n\n\u003cp\u003eHigh consciousness and awareness about diseases, and literacy among the population are the main growth factors. Using the DNA methylation analysis method, researchers can identify possible biomarkers and understand how genes are regulated. Obesity, cancer, and other disease processes are related to abnormal DNA methylation.\u003c\/p\u003e\n\n\u003cp\u003eThe widespread commercialization of nucleic acid-based diagnostic tests \u0026amp; kits, along with the significant rise in the adoption of epigenetics-based treatment techniques, is anticipated to fuel market expansion. However, the expansion can be constrained by a lack of experience in DNA methylation investigations. The relatively small pool of qualified specialists continues to be a barrier to progress, despite the use of DNA methylation in a variety of biotechnological applications.\u003c\/p\u003e\n\n\u003cp\u003eThe growing use of DNA methylation in the field of agricultural genomics continues to be a highly impart force for the expansion. Additionally, it offers the possibility for use in agronomic research to examine how crops react to drought, temperature extremes, and other environmental disturbances. For instance, according to a study report in MDPI in June 2022, epigenetic marks in plants and other eukaryotes are where DNA methylation is most frequently examined. It is used as a sustainable source of diversity that supports healthy crop growth.\u003c\/p\u003e\n\n\u003cp\u003eThe widespread commercialization of nucleic acid-based diagnostic tests \u0026amp; kits, along with the significant rise in the adoption of epigenetics-based treatment techniques, is anticipated to fuel market expansion.\u003c\/p\u003e\n\n\u003cp\u003eDNA Methylation Market Report Highlights\u003c\/p\u003e\n\n\u003cp\u003eSequencing technology segment is anticipated to grow at a CAGR over the forecast period owing to the rising use of DNA methylation in sequencing analysis\u003c\/p\u003e\n\n\u003cp\u003eConsumables accounted for a significant percentages of global revenue share which is accelerated by the increasing usage of the consumables during the DNA methylation process to avoid contamination\u003c\/p\u003e\n\n\u003cp\u003eClinical research sector is expected to hold a significant market share, over the forecast period due to the rising drug discovery coupled\u003c\/p\u003e\n\n\u003cp\u003eNorth America is expected to grow at a considerable CAGR over the projected period on account of the increasing adoption of DNA methylation by hospitals and pathology laboratories for diagnostics of chronic diseases\u003c\/p\u003e\n\n\u003cp\u003eThe global players include Abcam, Thermo-Fisher Scientific, and Zymo Research Corp.\u003c\/p\u003e\n\n\u003cp\u003ePolaris Market Research has segmented the DNA methylation market report based on technology, product, application, end-use, and region:\u003c\/p\u003e\n\n\u003cp\u003eDNA Methylation, Technology Outlook (Revenue – USD Million, 2018 – 2030)\u003c\/p\u003e\n\n\u003cp\u003ePolymerase Chain Reaction (PCR)\u003c\/p\u003e\n\n\u003cp\u003eMicroarray\u003c\/p\u003e\n\n\u003cp\u003eSequencing\u003c\/p\u003e\n\n\u003cp\u003eOther\u003c\/p\u003e\n\n\u003cp\u003eDNA Methylation, Product Outlook (Revenue – USD Million, 2018 – 2030)\u003c\/p\u003e\n\n\u003cp\u003eConsumables\u003c\/p\u003e\n\n\u003cp\u003eKits \u0026amp; Reagents\u003c\/p\u003e\n\n\u003cp\u003eEnzymes\u003c\/p\u003e\n\n\u003cp\u003eInstrument and Software\u003c\/p\u003e\n\n\u003cp\u003eDNA Methylation, Application Outlook (Revenue – USD Million, 2018 – 2030)\u003c\/p\u003e\n\n\u003cp\u003eGene Therapy\u003c\/p\u003e\n\n\u003cp\u003eClinical Research\u003c\/p\u003e\n\n\u003cp\u003eDiagnostics\u003c\/p\u003e\n\n\u003cp\u003eOthers\u003c\/p\u003e\n\n\u003cp\u003eDNA Methylation, End-Use Outlook (Revenue – USD Million, 2018 – 2030)\u003c\/p\u003e\n\n\u003cp\u003eHospital \u0026amp; Diagnostic Laboratories\u003c\/p\u003e\n\n\u003cp\u003ePharmaceutical \u0026amp; Biotechnology Companies\u003c\/p\u003e\n\n\u003cp\u003eResearch \u0026amp; Academia\u003c\/p\u003e\n\n\u003cp\u003eDNA Methylation, Regional Outlook (Revenue – USD Million, 2018 – 2030)\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003c\/p\u003e\n\n\u003cp\u003eU.S\u003c\/p\u003e\n\n\u003cp\u003eCanada\u003c\/p\u003e\n\n\u003cp\u003eEurope\u003c\/p\u003e\n\n\u003cp\u003eGermany\u003c\/p\u003e\n\n\u003cp\u003eUK\u003c\/p\u003e\n\n\u003cp\u003eFrance\u003c\/p\u003e\n\n\u003cp\u003eItaly\u003c\/p\u003e\n\n\u003cp\u003eSpain\u003c\/p\u003e\n\n\u003cp\u003eRussia\u003c\/p\u003e\n\n\u003cp\u003eNetherlands\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific\u003c\/p\u003e\n\n\u003cp\u003eChina\u003c\/p\u003e\n\n\u003cp\u003eIndia\u003c\/p\u003e\n\n\u003cp\u003eJapan\u003c\/p\u003e\n\n\u003cp\u003eSouth Korea\u003c\/p\u003e\n\n\u003cp\u003eIndonesia\u003c\/p\u003e\n\n\u003cp\u003eMalaysia\u003c\/p\u003e\n\n\u003cp\u003eLatin America\u003c\/p\u003e\n\n\u003cp\u003eArgentina\u003c\/p\u003e\n\n\u003cp\u003eBrazil\u003c\/p\u003e\n\n\u003cp\u003eMexico\u003c\/p\u003e\n\n\u003cp\u003eMiddle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eUAE\u003c\/p\u003e\n\n\u003cp\u003eSaudi Arabia\u003c\/p\u003e\n\n\u003cp\u003eIsrael\u003c\/p\u003e\n\n\u003cp\u003eSouth Africa\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 119 Pages \/ MCW16225196","offer_id":47639644143922,"sku":null,"price":5100.0,"currency_code":"USD","in_stock":true}]},{"product_id":"birtamimab-emerging-drug-insight-and-market-forecast-2032","title":"Birtamimab Emerging Drug Insight and Market Forecast – 2032","description":"\u003cp\u003eBirtamimab Emerging Drug Insight and Market Forecast – 2032\u003c\/p\u003e\n\n\u003cp\u003e“Birtamimab Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about Birtamimab for AL Amyloidosis in the 7MM. A detailed picture of the Birtamimab for AL Amyloidosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Birtamimab for AL Amyloidosis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Birtamimab market forecast, analysis for AL Amyloidosis in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in AL Amyloidosis.\u003c\/p\u003e\n\n\u003cp\u003eDrug Summary\u003c\/p\u003e\n\n\u003cp\u003eBirtamimab, formerly known as NEOD001, is an investigational monoclonal antibody designed to specifically and selectively target and clear the amyloid that accumulates and causes organ dysfunction and failure in patients with AL amyloidosis.\u003c\/p\u003e\n\n\u003cp\u003eIn preclinical studies, birtamimab has been shown to broadly react with a “cryptic” epitope exposed to misfolded kappa and lambda light chains that misfold and form amyloid. The proposed mechanism of action of birtamimab is to clear amyloid from organs and neutralize soluble aggregates that circulate in the bloodstream.\u003c\/p\u003e \n\n\u003cp\u003eBirtamimab has been tested in nearly 300 patients with AL amyloidosis at the intended clinical dose of 24 mg\/kg and was shown to be generally safe and well-tolerated in the clinical studies conducted to date. Birtamimab was previously evaluated in Phase III VITAL Study, a global multi-center, randomized, double-blind, placebo-controlled clinical study of newly diagnosed, treatment naïve patients with AL amyloidosis and cardiac involvement. Results from the analysis of patients categorized as Mayo Stage IV at baseline in the VITAL study revealed a significant survival benefit favoring birtamimab in these patients, with 74% of birtamimab-treated patients alive at 9 months versus 49% of patients in the control group.\u003c\/p\u003e\n\n\u003cp\u003eBirtamimab is the only investigational therapeutic that has shown a significant survival benefit in Mayo Stage IV patients with AL amyloidosis in a placebo-controlled study.\u003c\/p\u003e \n\n\u003cp\u003eScope of the Report\u003c\/p\u003e\n\n\u003cp\u003eThe report provides insights into:\u003c\/p\u003e\n\n\u003cp\u003eA comprehensive product overview including the Birtamimab description, mechanism of action, dosage and administration, research and development activities in AL Amyloidosis.\u003c\/p\u003e\n\n\u003cp\u003eElaborated details on Birtamimab regulatory milestones and other development activities have been provided in this report.\u003c\/p\u003e\n\n\u003cp\u003eThe report also highlights the Birtamimab research and development activity in AL Amyloidosis details across the United States, Europe and Japan.\u003c\/p\u003e\n\n\u003cp\u003eThe report also covers the patents information with expiry timeline around Birtamimab.\u003c\/p\u003e\n\n\u003cp\u003eThe report contains forecasted sales of Birtamimab for AL Amyloidosis till 2032.\u003c\/p\u003e\n\n\u003cp\u003eComprehensive coverage of the late-stage emerging therapies for AL Amyloidosis.\u003c\/p\u003e\n\n\u003cp\u003eThe report also features the SWOT analysis with analyst views for Birtamimab in AL Amyloidosis.\u003c\/p\u003e\n\n\u003cp\u003eMethodology\u003c\/p\u003e\n\n\u003cp\u003eThe report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.\u003c\/p\u003e\n\n\u003cp\u003eBirtamimab Analytical Perspective by DelveInsight\u003c\/p\u003e\n\n\u003cp\u003eIn-depth Birtamimab Market Assessment\u003c\/p\u003e\n\n\u003cp\u003eThis report provides a detailed market assessment of Birtamimab in AL Amyloidosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.\u003c\/p\u003e\n\n\u003cp\u003eBirtamimab Clinical Assessment\u003c\/p\u003e\n\n\u003cp\u003eThe report provides the clinical trials information of Birtamimab for AL Amyloidosis covering trial interventions, trial conditions, trial status, start and completion dates.\u003c\/p\u003e\n\n\u003cp\u003eReport Highlights\u003c\/p\u003e \n\n\u003cp\u003eIn the coming years, the market scenario for AL Amyloidosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.\u003c\/p\u003e  \n\n\u003cp\u003eThe companies are developing therapies that focus on novel approaches to treat\/improve the disease condition, assess challenges, and seek opportunities that could influence Birtamimab dominance.\u003c\/p\u003e\n\n\u003cp\u003eOther emerging products for AL Amyloidosis are expected to give tough market competition to Birtamimab and launch of late-stage emerging therapies in the near future will significantly impact the market.\u003c\/p\u003e \n\n\u003cp\u003eA detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Birtamimab in AL Amyloidosis.\u003c\/p\u003e\n\n\u003cp\u003eOur in-depth analysis of the forecasted sales data of Birtamimab from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Birtamimab in AL Amyloidosis.\u003c\/p\u003e \n\n\u003cp\u003eKey Questions\u003c\/p\u003e\n\n\u003cp\u003eWhat is the product type, route of administration and mechanism of action of Birtamimab?\u003c\/p\u003e\n\n\u003cp\u003eWhat is the clinical trial status of the study related to Birtamimab in AL Amyloidosis and study completion date?\u003c\/p\u003e\n\n\u003cp\u003eWhat are the key collaborations, mergers and acquisitions, licensing and other activities related to the Birtamimab development?\u003c\/p\u003e\n\n\u003cp\u003eWhat are the key designations that have been granted to Birtamimab for AL Amyloidosis?\u003c\/p\u003e\n\n\u003cp\u003eWhat is the forecasted market scenario of Birtamimab for AL Amyloidosis?\u003c\/p\u003e\n\n\u003cp\u003eWhat are the forecasted sales of Birtamimab in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?\u003c\/p\u003e \n\n\u003cp\u003eWhat are the other emerging products available in AL Amyloidosis and how are they giving competition to Birtamimab for AL Amyloidosis?\u003c\/p\u003e\n\n\u003cp\u003eWhich are the late-stage emerging therapies under development for the treatment of AL Amyloidosis?\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 30 Pages \/ MCW16225197","offer_id":47639644176690,"sku":null,"price":3900.0,"currency_code":"USD","in_stock":true}]},{"product_id":"humira-market-drug-insight-and-market-forecast-2032","title":"HUMIRA Market Drug Insight and Market Forecast - 2032","description":"\u003cp\u003eHUMIRA Market Drug Insight and Market Forecast ? 2032\u003c\/p\u003e\n\n\u003cp\u003e“HUMIRA Market Drug Insight and Market Forecast – 2032” report provides comprehensive insights about HUMIRA for Ulcerative Colitis (UC) in the seven major markets. A detailed picture of the HUMIRA for ulcerative colitis in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the HUMIRA for ulcerative colitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the HUMIRA market forecast analysis for ulcerative colitis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in ulcerative colitis.\u003c\/p\u003e\n\n\u003cp\u003eDrug Summary\u003c\/p\u003e\n\n\u003cp\u003eAdalimumab is a tumor necrosis factor blocker. Adalimumab is a recombinant human IgG1 monoclonal antibody created using phage display technology resulting in an antibody with human-derived heavy and light chain variable regions and human IgG1 constant regions. Adalimumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary (CHO)) expression system and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilo Daltons. HUMIRA (adalimumab) injection is supplied as a sterile, preservative-free solution for subcutaneous administration. It is currently approved by the US FDA to treat both CD and UC, among a few other indications.\u003c\/p\u003e\n\n\u003cp\u003eDosage\u003c\/p\u003e\n\n\u003cp\u003eThe recommended HUMIRA dose regimen for adult patients with UC is 160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29), continue with a dose of 40 mg every other week. HUMIRA should be continued only in patients who have shown evidence of clinical remission by 8 weeks (Day 57) of therapy. Aminosalicylates and\/or corticosteroids may be continued during treatment with HUMIRA. Azathioprine and 6-mercaptopurine (6-MP) may be continued during treatment with HUMIRA if necessary.\u003c\/p\u003e\n\n\u003cp\u003eMechanism of action\u003c\/p\u003e\n\n\u003cp\u003eAdalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. Adalimumab does not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine involved in normal inflammatory and immune responses. Elevated levels of TNF are found in the synovial fluid of patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of the diseases. The relationship between these pharmacodynamic activities and the mechanism(s) by which HUMIRA exerts its clinical effects is unknown. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC 50 of 1–2 × 10-10 M).\u003c\/p\u003e\n\n\u003cp\u003eScope of the Report\u003c\/p\u003e\n\n\u003cp\u003eThe report provides insights into:\u003c\/p\u003e\n\n\u003cp\u003eA comprehensive product overview including the HUMIRA description, mechanism of action, dosage and administration, research and development activities in ulcerative colitis.\u003c\/p\u003e\n\n\u003cp\u003eElaborated details on HUMIRA regulatory milestones and other development activities have been provided in this report.\u003c\/p\u003e\n\n\u003cp\u003eThe report also highlights the HUMIRA research and development activities in ulcerative colitis across the United States, Europe and Japan.\u003c\/p\u003e\n\n\u003cp\u003eThe report also covers the patents information with expiry timeline around HUMIRA.\u003c\/p\u003e\n\n\u003cp\u003eThe report contains forecasted sales of for ulcerative colitis till 2032.\u003c\/p\u003e\n\n\u003cp\u003eComprehensive coverage of the late-stage emerging therapies for ulcerative colitis.\u003c\/p\u003e\n\n\u003cp\u003eThe report also features the SWOT analysis with analyst views for HUMIRA in ulcerative colitis.\u003c\/p\u003e\n\n\u003cp\u003eMethodology\u003c\/p\u003e\n\n\u003cp\u003eThe report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.\u003c\/p\u003e\n\n\u003cp\u003eHUMIRA Analytical Perspective by DelveInsight\u003c\/p\u003e\n\n\u003cp\u003eIn-depth HUMIRA Market Assessment\u003c\/p\u003e\n\n\u003cp\u003eThis report provides a detailed market assessment of HUMIRA for ulcerative colitis in the seven major markets, i.e., United States, EU4 (Germany, France, Italy, Spain), the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.\u003c\/p\u003e\n\n\u003cp\u003eHUMIRA Clinical Assessment\u003c\/p\u003e\n\n\u003cp\u003eThe report provides the clinical trials information of HUMIRA for ulcerative colitis covering trial interventions, trial conditions, trial status, start and completion dates.\u003c\/p\u003e\n\n\u003cp\u003eReport Highlights\u003c\/p\u003e  \n\n\u003cp\u003eIn the coming years, the market scenario for ulcerative colitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.\u003c\/p\u003e   \n\n\u003cp\u003eThe companies are developing therapies that focus on novel approaches to treat\/improve the disease condition, assess challenges, and seek opportunities that could influence HUMIRA dominance.\u003c\/p\u003e\n\n\u003cp\u003eOther emerging products for ulcerative colitis are expected to give tough market competition to HUMIRA and launch of late-stage emerging therapies in the near future will significantly impact the market.\u003c\/p\u003e \n\n\u003cp\u003eA detailed description of regulatory milestones, and developmental activities, provide the current development scenario of HUMIRA in ulcerative colitis.\u003c\/p\u003e\n\n\u003cp\u003eOur in-depth analysis of the forecasted sales data of HUMIRA from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the HUMIRA in ulcerative colitis.\u003c\/p\u003e \n\n\u003cp\u003eKey Questions\u003c\/p\u003e\n\n\u003cp\u003eWhat is the product type, route of administration and mechanism of action of HUMIRA?\u003c\/p\u003e\n\n\u003cp\u003eWhat is the clinical trial status of the study related to HUMIRA in ulcerative colitis and study completion date?\u003c\/p\u003e\n\n\u003cp\u003eWhat are the key collaborations, mergers and acquisitions, licensing and other activities related to the HUMIRA development?\u003c\/p\u003e\n\n\u003cp\u003eWhat are the key designations that have been granted to HUMIRA for ulcerative colitis?\u003c\/p\u003e\n\n\u003cp\u003eWhat is the forecasted market scenario of HUMIRA for ulcerative colitis?\u003c\/p\u003e\n\n\u003cp\u003eWhat are the forecasted sales of HUMIRA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?\u003c\/p\u003e  \n\n\u003cp\u003eWhat are the other emerging products available and how are these giving competition to HUMIRA for ulcerative colitis?\u003c\/p\u003e\n\n\u003cp\u003eWhich are the late-stage emerging therapies under development for the treatment of ulcerative colitis?\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 30 Pages \/ MCW16225198","offer_id":47639644209458,"sku":null,"price":3300.0,"currency_code":"USD","in_stock":true}]},{"product_id":"pharmaceutical-biopharmaceutical-contract-manufacturing-market-global-industry-size-share-trends-opportunity-and-forecast-2018-2028","title":"Pharmaceutical \u0026 Biopharmaceutical Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028","description":"\u003cp\u003ePharmaceutical \u0026amp; Biopharmaceutical Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028\u003c\/p\u003e\n\n\u003cp\u003eGlobal pharmaceutical \u0026amp; biopharmaceutical contract manufacturing market is expected to register significant growth during the forecast period, 2024-2028. The increasing focus on contract manufacturing companies in expanding their capabilities to manufacture biological drugs, along with establishing new services to meet the growing demand of biopharmaceutical companies, which is expected to bolster the growth of the market. Further, the increasing investment in advanced manufacturing technologies by Contract Development \u0026amp; Manufacturing Organizations (CDMOs) is a major factor, which is anticipated to drive the market growth in coming years. Also, increasing drug development and manufacturing activities by pharmaceutical companies is propelling the growth of global pharmaceutical \u0026amp; biopharmaceutical contract manufacturing market. For instance, in 2022, INCOG BioPharma Services, the Indiana-based contract development and manufacturing organization (CDMO) which specialize in sterile injectables, unveiled that the construction of its manufacturing facility and global headquarters in Fishers, is almost completed.\u003c\/p\u003e\n\n\u003cp\u003eContract manufacturing is a form of outsourcing where a manufacturing company enters into an agreement with another manufacturing firm to develop innovative products and services.\u003c\/p\u003e \n\n\u003cp\u003eGlobal pharmaceutical \u0026amp; biopharmaceutical contract manufacturing market is segmented into sector, product type, service, drug type, company, and region. Based on service type, the market is segmented into pharmaceutical manufacturing services, biologics manufacturing services and drug development services. The pharmaceutical manufacturing services is further segmented into pharmaceutical API manufacturing services and pharmaceutical FDF manufacturing services. Similarly, the biologics manufacturing services is segmented into biologic FDF manufacturing services and biologics API manufacturing services. Among these, the pharmaceutical manufacturing services holds largest market share and is expected to witness fastest growth during the forecast period. This is attributed to the increasing number of sterile formulations and intensive drug development activities.\u003c\/p\u003e \n\n\u003cp\u003eBased on region, Asia Pacific is expected to register fastest growth during the forecast period owing to improving healthcare infrastructure and availability of highly skilled workforce. Many pharmaceutical companies are setting up their manufacturing units in countries such as China and India, due to low manufacturing and operational costs. Therefore, making Asian countries hub for outsourcing.\u003c\/p\u003e \n\n\u003cp\u003eMajor companies operating in global pharmaceutical \u0026amp; biopharmaceutical contract manufacturing market include Jubilant Pharmova Limited, JRS PHARMA GmbH \u0026amp; Co, Boehringer Ingelheim GmbH, Lonza Group, Rentschler Biotechnologie GmbH, Inno Biologics Sdn Bhd, INCOG BioPharma Services, Baxter Biopharma Solutions, Catalent Pharma Solutions, and Kemwell Biopharma Private Limited. Leading companies are continuously carrying out research and development activities to bring new medicines. Also, favourable regulations by government in regions such as Asia Pacific is enabling manufacturers to expand their businesses efficiently.\u003c\/p\u003e \n\n\u003cp\u003eObjective of the Study: To analyze and forecast the market size of global pharmaceutical \u0026amp; biopharmaceutical contract manufacturing market.To forecast global pharmaceutical \u0026amp; biopharmaceutical contract manufacturing market based on sector, product type, service, drug type and regional distribution.To identify drivers and challenges for global pharmaceutical \u0026amp; biopharmaceutical contract manufacturing market. To examine competitive developments such as expansions, new product launches, mergers \u0026amp; acquisitions etc. in global pharmaceutical \u0026amp; biopharmaceutical contract manufacturing market.To identify and analyze the profile of leading players operating in the global pharmaceutical \u0026amp; biopharmaceutical contract manufacturing market.TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of pharmaceutical \u0026amp; biopharmaceutical manufacturing companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.\u003c\/p\u003e \n\n\u003cp\u003eTechSci Research calculated global pharmaceutical \u0026amp; biopharmaceutical contract manufacturing market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analysing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.\u003c\/p\u003e\n\n\u003cp\u003eKey Target Audience:Pharmaceutical \u0026amp; biopharmaceutical manufacturers\/companies and other stakeholdersGovernment bodies such as regulating authorities and policy makersOrganizations, industry associations, forums and alliances related to pharmaceutical \u0026amp; biopharmaceutical contract manufacturing Market research and consulting firmsThe study is useful in providing answers to several critical questions that are important for the industry stakeholders such as pharmaceutical \u0026amp; biopharmaceutical contract manufacturing companies, partners, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.\u003c\/p\u003e \n\n\u003cp\u003eReport Scope:\u003c\/p\u003e\n\n\u003cp\u003eIn this report, global pharmaceutical \u0026amp; biopharmaceutical contract manufacturing market has been segmented into following categories, in addition to the industry trends which have also been detailed below:Global Pharmaceutical \u0026amp; Biopharmaceutical Contract Manufacturing Market, By Sector:PharmaceuticalBiopharmaceuticalGlobal Pharmaceutical \u0026amp; Biopharmaceutical Contract Manufacturing Market, By Product Type:Active Pharmaceutical Ingredients (API)Finished Dosage FormulationTabletCapsuleOral LiquidsParenteral\/InjectablesOthersAdvanced Drug Delivery ProductsOver the Counter (OTC) MedicinesNutritional ProductsOthersGlobal Pharmaceutical \u0026amp; Biopharmaceutical Contract Manufacturing Market, By Service:Pharmaceutical Manufacturing ServicesPharmaceutical API Manufacturing ServicesPharmaceutical FDF Manufacturing ServicesBiologics Manufacturing ServicesBiologics FDF Manufacturing ServicesBiologics API Manufacturing ServicesDrug Development ServicesGlobal Pharmaceutical \u0026amp; Biopharmaceutical Contract Manufacturing Market, By Drug Type:Originator \/ PatentedGenericsBiosimilarGlobal Pharmaceutical \u0026amp; Biopharmaceutical Contract Manufacturing Market, By Region:Asia-PacificChinaJapanIndia  South KoreaAustraliaEurope FranceGermanyUnited KingdomItalySpainNorth AmericaUnited StatesMexicoCanadaSouth AmericaBrazilArgentinaColombiaMiddle East \u0026amp; AfricaUAESouth AfricaSaudi ArabiaCompetitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eCompany Profiles: Detailed analysis of the major companies present in global pharmaceutical \u0026amp; biopharmaceutical contract manufacturing market.\u003c\/p\u003e\n\n\u003cp\u003eCompany InformationDetailed analysis and profiling of additional market players (up to five).Profit Margin AnalysisProfit margin analysis in case of direct and indirect sales channel.Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 112 Pages \/ MCW16225199","offer_id":47639644242226,"sku":null,"price":5880.0,"currency_code":"USD","in_stock":true}]},{"product_id":"preclinical-cro-market-size-by-service-bioanalysis-dmpk-studies-toxicology-testing-by-end-use-biopharmaceutical-companies-government-academic-institutes-medical-device-companies-industry-analysis-report-regional-outlook-u-s-canada-german","title":"Preclinical CRO Market Size By Service (Bioanalysis \u0026 DMPK Studies, Toxicology Testing), By End-use (Biopharmaceutical Companies, Government \u0026 Academic Institutes, Medical Device Companies), Industry Analysis Report, Regional Outlook (U.S., Canada, German","description":"\u003cp\u003ePreclinical CRO Market Size By Service (Bioanalysis \u0026amp; DMPK Studies, Toxicology Testing), By End-use (Biopharmaceutical Companies, Government \u0026amp; Academic Institutes, Medical Device Companies), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Spain, Japan, China, India, Australia, Mexico, Brazil, South Africa, Saudi Arabia), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share \u0026amp; Forecast, 2023 - 2032\u003c\/p\u003e\n\n\u003cp\u003ePreclinical CRO Market is slated to grow at a robust rate through 2032 owing to the increasing usage of drugs during preclinical trials given the rising cases of chronic diseases and an increasing demand for effective treatment for the same. Besides, various biotechnology and pharmaceutical companies, quite often, opt for outsourcing to attain the medical needs for preclinical validations to fasten up the whole process. This has significantly propelled the number of drugs entering the preclinical phase.\u003c\/p\u003e\n\n\u003cp\u003eOverall, the preclinical CRO market has been bifurcated in terms of end-use, service, and region.\u003c\/p\u003e \n\n\u003cp\u003eWithin the service segment, the others subsegment is slated to grow at a steady rate of more than 7% CAGR through the estimated timeframe. The other services in the preclinical CRO market comprise bioavailability testing, bioequivalence testing, drug-interaction testing services, etc.\u003c\/p\u003e\n\n\u003cp\u003eBased on end-use, the preclinical CRO market has been divided into government \u0026amp; academic institutes, biopharmaceutical companies, medical device companies, and others. Among them, the government \u0026amp; academic institutes segment held more than 14.5% market share in 2022. The growth can be primarily attributed to the increasing number of research and R\u0026amp;D activities that are outsourced to academic institutes. Besides, academic institutes and the governments are also providing diagnosis and access to treatments under preclinical trials, which is likely to propel the preclinical CRO industry growth in the upcoming time.\u003c\/p\u003e\n\n\u003cp\u003eIn the regional landscape, the preclinical CRO market has been broadly categorized into North America, Europe, LATAM, MEA, and Asia Pacific. Among them, the preclinical CRO market in the Asia Pacific region is anticipated to grow at a steady rate over the estimated timeframe. The increasing geriatric population in this region and rising cases of chronic diseases like diabetes, cancer, and cardiac diseases are anticipated to supplement the market growth.\u003c\/p\u003e \n\n\u003cp\u003eAdditionally, an increase in the number of investigational compounds and ongoing preclinical trials in oncology in Asia Pacific will boost the preclinical CRO business size in this region.\u003c\/p\u003e\n\n\u003cp\u003eMeanwhile, the preclinical CRO market in the LATAM region is also slated to grow at a robust rate through the analysis timeframe. The healthcare infrastructure in this region is well-developed and it also boasts a well-established regulatory environment. These factors enable Latin America to be a fertile landscape to allow preclinical research to be conducted easily.\u003c\/p\u003e\n\n\u003cp\u003eSome of the key companies operating in the preclinical CRO market are Laboratory Corporation of America Inc., Charles River Laboratory Inc., Pharmaceutical Product Development (PPD) LLC, ICON plc, Eurofins Scientific, Parexel International Corporation, Medpace, Inc., WuXi AppTec, SGS SA, Altasciences Company, Inc.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 104 Pages \/ MCW16225200","offer_id":47639644274994,"sku":null,"price":6180.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-electrochemical-biosensors-industry-research-report-growth-trends-and-competitive-analysis-2022-2028","title":"Global Electrochemical Biosensors Industry Research Report, Growth Trends and Competitive Analysis 2022-2028","description":"\u003cp\u003eGlobal Electrochemical Biosensors Industry Research Report, Growth Trends and Competitive Analysis 2022-2028\u003c\/p\u003e\n\n\u003cp\u003eMarket Analysis and Insights: Global Electrochemical Biosensors Market\u003c\/p\u003e\n\n\u003cp\u003eDue to the COVID-19 pandemic, the global Electrochemical Biosensors market size was US$ 7,750.7 million in 2021 and is forecast to a readjusted size of US$ 14,135.4 million by 2028 with a CAGR of 8.93% during the forecast period 2022-2028.\u003c\/p\u003e \n\n\u003cp\u003eIn terms of production side, this report researches the Electrochemical Biosensors capacity, production, growth rate, market share by manufacturers and regional level and country level, from 2020 to 2022, and forecast to 2028.\u003c\/p\u003e\n\n\u003cp\u003eIn terms of sales side, this report focuses on the sales of Electrochemical Biosensors by regions (countries), company, by Type and by Application. from 2020 to 2022 and forecast to 2028.\u003c\/p\u003e\n\n\u003cp\u003eThe global Electrochemical Biosensors market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Electrochemical Biosensors market. These figures have been provided in terms of both revenue and volume for the period 2017-2028. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.\u003c\/p\u003e\n\n\u003cp\u003eSegment by Type\u003c\/p\u003e\n\n\u003cp\u003ePotentiometric Biosensor\u003c\/p\u003e\n\n\u003cp\u003eAmperometric Biosensor\u003c\/p\u003e\n\n\u003cp\u003eConductometric Biosensor\u003c\/p\u003e\n\n\u003cp\u003eSegment by Application\u003c\/p\u003e\n\n\u003cp\u003eMedical\u003c\/p\u003e\n\n\u003cp\u003eFood and Beverage\u003c\/p\u003e\n\n\u003cp\u003eIndustrial\u003c\/p\u003e\n\n\u003cp\u003eOthers\u003c\/p\u003e\n\n\u003cp\u003eBy Company\u003c\/p\u003e\n\n\u003cp\u003eAbbott Laboratories\u003c\/p\u003e\n\n\u003cp\u003eDexcom\u003c\/p\u003e\n\n\u003cp\u003eMedtronic\u003c\/p\u003e\n\n\u003cp\u003eAscensia Diabetes Care\u003c\/p\u003e\n\n\u003cp\u003eRoche\u003c\/p\u003e\n\n\u003cp\u003eLifeScan\u003c\/p\u003e\n\n\u003cp\u003eARKRAY\u003c\/p\u003e\n\n\u003cp\u003eSinocare\u003c\/p\u003e\n\n\u003cp\u003eNova Biomedical\u003c\/p\u003e\n\n\u003cp\u003eB. Braun\u003c\/p\u003e\n\n\u003cp\u003eI-SENS\u003c\/p\u003e\n\n\u003cp\u003eProduction by Region\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003c\/p\u003e\n\n\u003cp\u003eEurope\u003c\/p\u003e\n\n\u003cp\u003eChina\u003c\/p\u003e\n\n\u003cp\u003eJapan\u003c\/p\u003e\n\n\u003cp\u003eRest of World\u003c\/p\u003e\n\n\u003cp\u003eSales by Region\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003c\/p\u003e\n\n\u003cp\u003eUnited States\u003c\/p\u003e\n\n\u003cp\u003eCanada\u003c\/p\u003e\n\n\u003cp\u003eMexico\u003c\/p\u003e\n\n\u003cp\u003eAsia-Pacific\u003c\/p\u003e\n\n\u003cp\u003eChina\u003c\/p\u003e  \n\n\u003cp\u003eJapan\u003c\/p\u003e\n\n\u003cp\u003eKorea\u003c\/p\u003e\n\n\u003cp\u003eIndia\u003c\/p\u003e\n\n\u003cp\u003eSoutheast Asia\u003c\/p\u003e\n\n\u003cp\u003eAustralia\u003c\/p\u003e\n\n\u003cp\u003eRest of Asia-Pacific\u003c\/p\u003e\n\n\u003cp\u003eEurope\u003c\/p\u003e\n\n\u003cp\u003eGermany\u003c\/p\u003e  \n\n\u003cp\u003eUK\u003c\/p\u003e\n\n\u003cp\u003eFrance\u003c\/p\u003e \n\n\u003cp\u003eRussia\u003c\/p\u003e\n\n\u003cp\u003eItaly\u003c\/p\u003e\n\n\u003cp\u003eSpain\u003c\/p\u003e\n\n\u003cp\u003eRest of Europe\u003c\/p\u003e\n\n\u003cp\u003eLatin America\u003c\/p\u003e\n\n\u003cp\u003eBrazil\u003c\/p\u003e\n\n\u003cp\u003eArgentina\u003c\/p\u003e\n\n\u003cp\u003eRest of Latin America\u003c\/p\u003e\n\n\u003cp\u003eMiddle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eMiddle East\u003c\/p\u003e\n\n\u003cp\u003eAfrica\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 142 Pages \/ MCW16225203","offer_id":47639644307762,"sku":null,"price":6720.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-organs-on-chips-ooc-industry-research-report-growth-trends-and-competitive-analysis-2022-2028","title":"Global Organs-on-Chips (OOC) Industry Research Report, Growth Trends and Competitive Analysis 2022-2028","description":"\u003cp\u003eGlobal Organs-on-Chips (OOC) Industry Research Report, Growth Trends and Competitive Analysis 2022-2028\u003c\/p\u003e\n\n\u003cp\u003eThe global Organs-on-chips (OOC) market size is projected to reach US$ 487 million by 2028, from US$ 60 million in 2021, at a CAGR of 33.03% during 2022-2028.\u003c\/p\u003e\n\n\u003cp\u003eThe market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Organs-on-chips (OOC) market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Organs-on-chips (OOC) market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Organs-on-chips (OOC) market. Readers of the report can become informed about current and future trends of the global Organs-on-chips (OOC) market and how they will impact market growth during the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eSegment by Type\u003c\/p\u003e\n\n\u003cp\u003eBrain-on-a-chip\u003c\/p\u003e\n\n\u003cp\u003eLiver-on-a-chip\u003c\/p\u003e\n\n\u003cp\u003eKidney-on-a-chip\u003c\/p\u003e\n\n\u003cp\u003eLung-on-a-chip\u003c\/p\u003e\n\n\u003cp\u003eHeart-on-a-chip\u003c\/p\u003e\n\n\u003cp\u003eIntestine-on-a-chip\u003c\/p\u003e\n\n\u003cp\u003eVessel-on-a-chip\u003c\/p\u003e\n\n\u003cp\u003eOther Organs\u003c\/p\u003e\n\n\u003cp\u003eSegment by Application\u003c\/p\u003e\n\n\u003cp\u003ePharmaceutical \u0026amp; Biotechnology Companies\u003c\/p\u003e\n\n\u003cp\u003eAcademic \u0026amp; Research Institutes\u003c\/p\u003e\n\n\u003cp\u003eCosmetics Industry\u003c\/p\u003e\n\n\u003cp\u003eOthers\u003c\/p\u003e\n\n\u003cp\u003eBy Company\u003c\/p\u003e\n\n\u003cp\u003eEmulate\u003c\/p\u003e\n\n\u003cp\u003eMimetas\u003c\/p\u003e\n\n\u003cp\u003eTissUse\u003c\/p\u003e\n\n\u003cp\u003eTara Biosystems\u003c\/p\u003e\n\n\u003cp\u003eCN Bio Innovations\u003c\/p\u003e\n\n\u003cp\u003eHesperos\u003c\/p\u003e\n\n\u003cp\u003eDraper Laboratory\u003c\/p\u003e\n\n\u003cp\u003eNortis\u003c\/p\u003e\n\n\u003cp\u003eMicronit Microtechnologies B.V.\u003c\/p\u003e\n\n\u003cp\u003eKirkstall\u003c\/p\u003e\n\n\u003cp\u003eCherry Biotech SAS\u003c\/p\u003e\n\n\u003cp\u003eElse Kooi Laboratory\u003c\/p\u003e\n\n\u003cp\u003eAltis Biosystems\u003c\/p\u003e\n\n\u003cp\u003eBi\/ond\u003c\/p\u003e\n\n\u003cp\u003eNetri\u003c\/p\u003e\n\n\u003cp\u003eBeijing Daxiang Biotech\u003c\/p\u003e\n\n\u003cp\u003eBy Region\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003c\/p\u003e\n\n\u003cp\u003eUnited States\u003c\/p\u003e\n\n\u003cp\u003eCanada\u003c\/p\u003e\n\n\u003cp\u003eAsia-Pacific\u003c\/p\u003e\n\n\u003cp\u003eChina\u003c\/p\u003e\n\n\u003cp\u003eJapan\u003c\/p\u003e\n\n\u003cp\u003eSouth Korea\u003c\/p\u003e\n\n\u003cp\u003eSoutheast Asia\u003c\/p\u003e\n\n\u003cp\u003eIndia\u003c\/p\u003e\n\n\u003cp\u003eRest of Asia-Pacific\u003c\/p\u003e\n\n\u003cp\u003eEurope\u003c\/p\u003e\n\n\u003cp\u003eGermany\u003c\/p\u003e\n\n\u003cp\u003eFrance\u003c\/p\u003e\n\n\u003cp\u003eU.K.\u003c\/p\u003e\n\n\u003cp\u003eNetherlands\u003c\/p\u003e\n\n\u003cp\u003eNordic Countries\u003c\/p\u003e\n\n\u003cp\u003eRest of Europe\u003c\/p\u003e\n\n\u003cp\u003eSouth America\u003c\/p\u003e\n\n\u003cp\u003eMexico\u003c\/p\u003e\n\n\u003cp\u003eBrazil\u003c\/p\u003e\n\n\u003cp\u003eRest of Latin America\u003c\/p\u003e\n\n\u003cp\u003eMiddle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eTurkey\u003c\/p\u003e\n\n\u003cp\u003eSaudi Arabia\u003c\/p\u003e\n\n\u003cp\u003eUAE\u003c\/p\u003e\n\n\u003cp\u003eRest of MEA\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 148 Pages \/ MCW16225204","offer_id":47639644340530,"sku":null,"price":6720.0,"currency_code":"USD","in_stock":true}]},{"product_id":"europe-biomarker-technologies-market-by-test-type-solid-biopsy-liquid-biopsy-by-technology-immunoassay-ddpcr-next-generation-sequencing-ngs-mass-spectrometry-dhplc-others-by-product-consumables-instruments-services-software-informatics","title":"Europe Biomarker Technologies Market, By Test Type (Solid Biopsy, Liquid Biopsy), By Technology (Immunoassay, DDPCR, Next Generation Sequencing (NGS), Mass Spectrometry, DHPLC, Others), By Product (Consumables, Instruments, Services, Software\/Informatics)","description":"\u003cp\u003eEurope Biomarker Technologies Market, By Test Type (Solid Biopsy, Liquid Biopsy), By Technology (Immunoassay, DDPCR, Next Generation Sequencing (NGS), Mass Spectrometry, DHPLC, Others), By Product (Consumables, Instruments, Services, Software\/Informatics), By Indication (Oncology, Infectious Diseases, Autoimmune Disorders, Cardiovascular Disorders, Others), By End User (Pharmaceutical Companies, Hospitals, CROs, Diagnostic Labs, Research Institutes), By Application (Clinical Diagnostics, Research, Drug Discovery \u0026amp; Development), By Country, Forecast \u0026amp; Opportunities, 2028\u003c\/p\u003e\n\n\u003cp\u003eEurope biomarker technologies market is expected to observe impressive growth during the forecast period, 2024-2028. Widespread incidences of various diseases such as cancer, diabetes, cardiovascular and neurological disorders, among others coupled with the growing technological advancements are expected to bolster the growth of the Europe biomarker technologies market. According to the IDF Diabetes Atlas, in 2021, about 61 million adults aged from 20 to 79 years were living with diabetes in the Europe. Besides, Europe has the highest number of children and adolescents with type 1 diabetes, accounting for 295,000 in total. Biomarker technologies are reliable and cost-effective which are used for diagnosis, drug development, and formulation. They are widely used for the early diagnosis of several diseases and disorders. The other factors supporting the market’s growth are rising number of individuals who are suffering from cancer, robust growth of the geriatric population, increase in healthcare expenditure, escalating demand for early and effective diagnosis, rising awareness about the early detection of cancer for better treatment, increasing investments in R\u0026amp;Ds in order to develop technologically advanced products, growing clinical trials for biomarker, and rising involvement from private sector and government. Additionally, governments across various European nations are also promoting biomarker technologies by increasing funding for biomarker research. Thus, increasing R\u0026amp;D activities is further expected to propel the growth of Europe biomarker technologies market in coming years. Moreover, growing adoption of biomarker technologies in drug development and genome mapping programs and increasing preference for personalized medicines is acting as major growth driver for Europe biomarker technologies market.\u003c\/p\u003e\n\n\u003cp\u003eEurope biomarker technologies market is segmented into test type, technology, product, indication, end user, application, and country. Based on indication, the market can be segmented into oncology, infectious diseases, autoimmune disorders, cardiovascular disorders and others. Among them, the cardiovascular disorders segment is expected to undergo fastest CAGR during the forecast period owing to rise in number of people suffering from cardiovascular diseases.\u003c\/p\u003e \n\n\u003cp\u003eBased on application, Europe biomarker technologies market is segmented into clinical diagnostics, research and drug discovery \u0026amp; development. Among these, the drug discovery segment is expected to witness significant growth through 2028 as biomarker technologies are helpful in drug discovery particularly for cancer and cardiovascular diseases.\u003c\/p\u003e \n\n\u003cp\u003eMajor players operating in the Europe biomarker technologies market are F. Hoffmann-La Roche AG, Merck KGAA, Beckman Coulter, Inc., Qiagen N.V., Biomérieux SA, Bio-Rad Laboratories N.V., Siemens AG, Abbott Molecular Inc., Danaher Corporation, and Epigenomics AG. The companies are undergoing growth strategies such as mergers \u0026amp; acquisitions and product innovation.\u003c\/p\u003e \n\n\u003cp\u003eObjective of the Study: To analyze and estimate the market size of Europe biomarker technologies market from 2018 to 2021.To estimate and forecast the market size of Europe biomarker technologies market from 2022 to 2028 and growth rate until 2028. To classify and forecast Europe biomarker technologies market based on test type, technology, product, indication, end user, application, company, and country.To identify dominant country or segment in the Europe biomarker technologies market.To identify drivers and challenges for Europe biomarker technologies market.To examine competitive developments such as expansions, mergers \u0026amp; acquisitions, etc., in Europe biomarker technologies market.To identify and analyze the profile of leading players operating in Europe biomarker technologies market.To identify key sustainable strategies adopted by market players in Europe biomarker technologies market.TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of biomarker technologies companies across Europe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies who could not be identified due to the limitations of secondary research. TechSci Research analyzed the presence of all major players across Europe.\u003c\/p\u003e\n\n\u003cp\u003eTechSci Research calculated the market size of Europe biomarker technologies market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these services and end users for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.\u003c\/p\u003e\n\n\u003cp\u003eKey Target Audience:Biomarker technology companies, vendors, end users and other stakeholdersGovernment bodies such as regulating authorities and policy makersOrganizations, forums, and alliances related to biomarker technologiesMarket research and consulting firmsThe study is useful in providing answers to several critical questions that are important for the industry stakeholders such as biomarker technology companies, vendors, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.\u003c\/p\u003e \n\n\u003cp\u003eReport Scope:\u003c\/p\u003e\n\n\u003cp\u003eIn this report, Europe biomarker technologies market has been segmented into following categories, in addition to the industry trends which have also been detailed below:Europe Biomarker Technologies Market, By Test Type:Solid BiopsyLiquid BiopsyEurope Biomarker Technologies Market, By Technology:ImmunoassayDDPCRNext Generation Sequencing (NGS)Mass SpectrometryDHPLCOthersEurope Biomarker Technologies Market, By Product:ConsumablesInstrumentsServicesSoftware\/InformaticsEurope Biomarker Technologies Market, By Indication:OncologyInfectious DiseasesAutoimmune DisordersCardiovascular DisordersOthersEurope Biomarker Technologies Market, By End User:Pharmaceutical CompaniesHospitalsCROsDiagnostic LabsResearch InstitutesEurope Biomarker Technologies Market, By Application:Clinical DiagnosticsResearchDrug Discovery \u0026amp; DevelopmentEurope Biomarker Technologies Market, By Country:ItalyFranceUnited KingdomGermanySpainBelgiumNetherlands Competitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eCompany Profiles: Detailed analysis of the major companies present in Europe biomarker technologies market.\u003c\/p\u003e\n\n\u003cp\u003eCompany InformationDetailed analysis and profiling of additional market players (up to five).Profit Margin AnalysisProfit margin analysis in case of direct and indirect sales channel.Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 85 Pages \/ MCW16225206","offer_id":47639644602674,"sku":null,"price":5880.0,"currency_code":"USD","in_stock":true}]},{"product_id":"rare-disease-treatment-market-growth-trends-covid-19-impact-and-forecasts-2022-a-2027","title":"Rare Disease Treatment Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 – 2027)","description":"\u003cp\u003eThe Rare Disease Treatment Market is projected to register a CAGR of 8.6% during the forecast period (2022 to 2027).\u003c\/p\u003e\n\n \u003cp\u003eThe healthcare system has witnessed enormous challenges due to the COVID-19 pandemic. All outpatient treatments were postponed or restricted during the COVID-19 pandemic to ?reduce the risk of viral transmission, as most chronic therapies were regarded as non-urgent. A review article titled “Research and Management of Rare Diseases in the COVID-19 Pandemic Era: Challenges and Countermeasures,” published in the journal of Frontiers in Public Health in April 2021, studied the challenges faced by patients affected by rare diseases. The article concluded that regular clinical services, counseling, and therapies were extremely inadequate. Also, the clinicians, researchers, and scientists working on rare genetic diseases face extra challenges due to the pandemic since research projects and clinical trials for rare and genetic diseases were stalled during the COVID-19 pandemic.\u003c\/p\u003e\n\n \u003cp\u003eThe definition of rare diseases has distinct in different parts of the world. The United States Food and Drug Administration defines a rare disease as a disease or condition that affects less than 200,000 people in the United States. The European Commission Public Health states that a rare disease affects no more than one person in 2000 in the European Union. According to Health Canada, the rare disease affects less than five persons in 10,000 in Canada. According to an article published in March 2021, titled “Epidemiology of rare diseases is important”, over 6,000 different rare diseases are thought to exist and more than 70% of rare diseases are hereditary, and the majority of them have a chronic course. According to the February 2022 update of the rarediseaseday.org, about 300 million people around the world are living with rare diseases which is quite a high and thus, the demand for effective and advanced treatment solutions for rare diseases is expected to increase due to the high burden and growing awareness about these diseases which is expected to fuel growth in the studied market over forecast period.\u003c\/p\u003e\n\n \u003cp\u003eAn article in the journal of Diseases in November 2020 titled “Precision Medicine in Rare Diseases” discussed using precision or personalized medicine to treat rare diseases. The study indicated that more than 90% of rare diseases do not have an effective treatment method. This inadequacy in the therapies for rare diseases necessitates novel treatment methods, which is expected to propel the growth of the rare disease treatment market in the forecast period.\u003c\/p\u003e\n\n \u003cp\u003eVarious governments around the world have been formulating several initiatives for the treatment of rare diseases. For instance, the Indian government Ministry of Health and Family Welfare’s National Policy for Rare Diseases, 2021 aimed at lowering the incidence and prevalence of rare diseases based on an integrated and comprehensive preventive strategy encompassing awareness generation, premarital, post-marital, pre-conception, and post-conception screening and counseling programs to prevent births of children with rare diseases, and within the constraints on resources and competing health care priorities, enable access to affordable health care to patients of rare diseases which are amenable to one-time treatment or relatively low-cost therapy.\u003c\/p\u003e\n\n \u003cp\u003eThe increase in the necessity of rare disease treatment worldwide is expected to propel the growth of the rare disease treatment market.? However, a lack of awareness regarding rare disease treatment and the high cost of treatment is expected to hinder the market growth during the study period.\u003c\/p\u003e\n\n\u003cp\u003eKey Market Trends\u003c\/p\u003e\n\n\u003cp\u003eThe Biologics Segment is Expected to Hold a Major Market Share in the Rare disease treatment Market.\u003c\/p\u003e\n\n \u003cp\u003eBiologics occupy a major segment in the rare disease treatment market. Over the years, various market players have invested in researching and developing new biologics for the treatment of rare diseases. For example, CHIESI Farmaceutici S.p.A. in February 2020, Chiesi launched Global Rare Diseases, a new business unit segment focused on the research, development, and commercialization of treatments and patient support services for rare and ultra-rare disorders. In May 2020, Chiesi Global Rare Diseases, together with Protalix BioTherapeutics, announced the submission of a biologics license application to the US Food and Drug Administration for Pegunigalsidase Alfa for the treatment of Fabry disease. Upon approval of the biologics license application, Protalix BioTherapeutics will be eligible for a breakthrough payment from Chiesi to assist in the next phase III study of the drug. Increasing investment in treating rare diseases such as Fabry disease is expected to fuel the growth of the market under study.?\u003c\/p\u003e\n\n \u003cp\u003eAn article titled “Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions,” published in the MDPI journal of Biologics in August 2021, studied the main biological treatments currently available for inflammatory bowel disease treatment due to the extremely important current role of biologics. The study showed that various biologic therapies such as anti-TNF-? therapy, anti-integrin therapy, anti-cytokine therapy, and other new biologics are widely used to treat rare inflammatory bowel disease. The study indicated that further studies are needed to better understand the action mechanism of the biological drugs, which will help understand how to improve the efficacy and safety of the treatment methods.?\u003c\/p\u003e\n\n \u003cp\u003eAnother article presented in the Orphanet Journal of Rare Diseases titled “Essential list of medicinal products for rare diseases: recommendations from the IRDiRC Rare Disease Treatment Access Working Group,” published in July 2021, studied the list of biologics approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) and China’s National Medical Products Administration (NMPA), which are useful against the rare diseases. The goal of the list was to further accelerate interactions among patient organizations, health care providers, industry, and government agencies to improve standards of care for rare diseases by promoting access to treatments.\u003c\/p\u003e\n\n \u003cp\u003eThe increasing research on the study of biologics for rare disease treatment is expected to boost the growth of the studied market over the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eNorth America is Expected to Hold a Significant Share in the Rare Disease Treatment Market\u003c\/p\u003e\n\n \u003cp\u003eThe North American region is expected to occupy a major share in the rare disease treatment market owing to the high prevalence of the rare diseases in the region such as Huntington's disease, spina bifida, fragile X syndrome, Guillain-Barré syndrome, Crohn's disease, cystic fibrosis, and Duchenne muscular dystrophy, high awareness about these diseases and presence of robust healthcare system for the diagnosis and treatment of rare diseases. For instance, according to the 2021 report of the Canadian Organization for Rare Disorders (CORD), every year about 1 in 12 people in Canada are affected by rare diseases, and about 80% of these diseases are caused due to genetic changes. Hence, owing to the high burden of rare diseases in the region, it is expected to have significant growth over the forecast period.\u003c\/p\u003e\n\n \u003cp\u003eIn the North American region, the United States is expected to have a significant share owing to the high demand for treatment of rare diseases due to high prevalence, ongoing research, and development activities new investments in the area, and other factors. For instance, according to the February 2020 report of the Center for Disease Control and Prevention (CDC) on rare diseases, about 30 million people are affected by approximately 7,000 rare diseases in the country, with the majority of them being children and thus, the demand for effective and advanced therapeutics is very high in the country which is expected to boost growth in the studied market. Further, the research budget for rare diseases in the United States is one of the highest compared to other parts of the world and positive result from these research activities is expected to have a significant impact on the studied market in the United States. For example, as per the May 2022 report of the National Institute of Health of the United States, about USD 6,191 million was spent on rare disease research activities in 2021 and it is expected to increase to USD 6,482 million in 2022. Therefore, owing to the above-mentioned factors, the North American region is expected to grow and occupy a significant share of the studied market.\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Landscape\u003c\/p\u003e\n\n \u003cp\u003eThe Rare disease treatment Market is competitive and consists of several major players. In terms of market share, a few major players dominate the market. Some companies currently dominating the market are Amgen, Inc., Alexion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Biomarin Pharmaceuticals, Bayer AG, and others. Market players readily adopt multiple initiatives such as mergers and acquisitions and product launches to strengthen their position in the market.\u003c\/p\u003e\n\n\u003cp\u003eAdditional Benefits:\u003c\/p\u003e\n\n  \u003cp\u003eThe market estimate (ME) sheet in Excel format \u003cbr\u003e\n 3 months of analyst support\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 186 Pages \/ MCW16225207","offer_id":47639644635442,"sku":null,"price":5700.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-bacteriophage-market-report-history-and-forecast-2017-2028","title":"Global Bacteriophage Market Report, History and Forecast 2017-2028","description":"\u003cp\u003eGlobal Bacteriophage Market Report, History and Forecast 2017-2028\u003c\/p\u003e\n\n\u003cp\u003eAs the global economy mends, the 2022 growth of Bacteriophage will have significant change from previous year. According to our (LP Information) latest study, the global Bacteriophage market size will be USD 36.79 million in 2022 from USD 31.64 million in 2021, with a change of 16.28% between 2021 and 2022. The global Bacteriophage market size will reach USD 103.44 million in 2028, growing at a CAGR of 18.80% over the analysis period.\u003c\/p\u003e\n\n\u003cp\u003eReport Scope\u003c\/p\u003e\n\n\u003cp\u003eThis report aims to provide a comprehensive presentation of the global market for Bacteriophage, with both quantitative and qualitative analysis, to help readers develop business\/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bacteriophage.\u003c\/p\u003e\n\n\u003cp\u003eThe Bacteriophage market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Bacteriophage market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.\u003c\/p\u003e\n\n\u003cp\u003eFor a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.\u003c\/p\u003e\n\n\u003cp\u003eThis report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bacteriophage market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation\u003c\/p\u003e\n\n\u003cp\u003eThis report covers the Bacteriophage segments by company, by Type, by Application, by region and country, and provides market size and CAGR for the history and forecast period (2017-2022, 2023-2028), considering 2021 as the base year. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.\u003c\/p\u003e\n\n\u003cp\u003eSegment by Type\u003c\/p\u003e\n\n\u003cp\u003eDsDNA Bacteriophage\u003c\/p\u003e\n\n\u003cp\u003eSsDNA Bacteriophage\u003c\/p\u003e\n\n\u003cp\u003eSsRNA Bacteriophage\u003c\/p\u003e\n\n\u003cp\u003eOther\u003c\/p\u003e\n\n\u003cp\u003eSegment by Application\u003c\/p\u003e\n\n\u003cp\u003eAnimal Health\u003c\/p\u003e\n\n\u003cp\u003eAquaculture\u003c\/p\u003e\n\n\u003cp\u003eAgriculture\u003c\/p\u003e\n\n\u003cp\u003eFood Industry\u003c\/p\u003e\n\n\u003cp\u003eHuman Health\u003c\/p\u003e\n\n\u003cp\u003eOthers\u003c\/p\u003e\n\n\u003cp\u003eBy Company\u003c\/p\u003e\n\n\u003cp\u003eNPO Microgen\u003c\/p\u003e\n\n\u003cp\u003eProteon Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003ePhagelux\u003c\/p\u003e\n\n\u003cp\u003eIntralytix\u003c\/p\u003e\n\n\u003cp\u003eMicreos\u003c\/p\u003e\n\n\u003cp\u003eEliava BioPreparations\u003c\/p\u003e\n\n\u003cp\u003eLocus Biosciences, Inc\u003c\/p\u003e\n\n\u003cp\u003ePharmex Group, LLC\u003c\/p\u003e\n\n\u003cp\u003ePherecydes Pharma\u003c\/p\u003e\n\n\u003cp\u003eAPS Biocontrol Ltd. (APS)\u003c\/p\u003e\n\n\u003cp\u003eQingdao Phagepharm Bio-tech\u003c\/p\u003e\n\n\u003cp\u003eFixed-Phage Limited\u003c\/p\u003e\n\n\u003cp\u003eZeptometrix\u003c\/p\u003e\n\n\u003cp\u003ePhage International, Inc.\u003c\/p\u003e\n\n\u003cp\u003eMicroMir\u003c\/p\u003e\n\n\u003cp\u003eiNtODEWORLD, Inc.\u003c\/p\u003e\n\n\u003cp\u003eNEXTBIOTICS\u003c\/p\u003e\n\n\u003cp\u003eArmata Pharmaceuticals, Inc.\u003c\/p\u003e\n\n\u003cp\u003eInnophage\u003c\/p\u003e\n\n\u003cp\u003eAdaptive Phage Therapeutics\u003c\/p\u003e\n\n\u003cp\u003eTechnoPhage\u003c\/p\u003e\n\n\u003cp\u003eBy Region\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003c\/p\u003e\n\n\u003cp\u003eUnited States\u003c\/p\u003e\n\n\u003cp\u003eCanada\u003c\/p\u003e\n\n\u003cp\u003eAsia-Pacific\u003c\/p\u003e\n\n\u003cp\u003eChina\u003c\/p\u003e\n\n\u003cp\u003eJapan\u003c\/p\u003e\n\n\u003cp\u003eSouth Korea\u003c\/p\u003e\n\n\u003cp\u003eSoutheast Asia\u003c\/p\u003e\n\n\u003cp\u003eIndia\u003c\/p\u003e\n\n\u003cp\u003eAustralia\u003c\/p\u003e\n\n\u003cp\u003eEurope\u003c\/p\u003e\n\n\u003cp\u003eGermany\u003c\/p\u003e\n\n\u003cp\u003eFrance\u003c\/p\u003e\n\n\u003cp\u003eU.K.\u003c\/p\u003e\n\n\u003cp\u003eItaly\u003c\/p\u003e\n\n\u003cp\u003eRussia\u003c\/p\u003e\n\n\u003cp\u003eLatin America\u003c\/p\u003e\n\n\u003cp\u003eMexico\u003c\/p\u003e\n\n\u003cp\u003eBrazil\u003c\/p\u003e\n\n\u003cp\u003eArgentina\u003c\/p\u003e\n\n\u003cp\u003eMiddle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eTurkey\u003c\/p\u003e\n\n\u003cp\u003eSaudi Arabia\u003c\/p\u003e\n\n\u003cp\u003eUAE\u003c\/p\u003e\n\n\u003cp\u003eCore Chapters\u003c\/p\u003e\n\n\u003cp\u003eChapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2017-2022, 2023-2028). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.\u003c\/p\u003e\n\n\u003cp\u003eChapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.\u003c\/p\u003e\n\n\u003cp\u003eChapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.\u003c\/p\u003e\n\n\u003cp\u003eChapter Four: Detailed analysis of Bacteriophage companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.\u003c\/p\u003e\n\n\u003cp\u003eChapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.\u003c\/p\u003e\n\n\u003cp\u003eChapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East \u0026amp; Africa, revenue by country.\u003c\/p\u003e\n\n\u003cp\u003eChapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.\u003c\/p\u003e\n\n\u003cp\u003eChapter Twelve: Research Finding\/Conclusion\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 150 Pages \/ MCW16225208","offer_id":47639644668210,"sku":null,"price":4020.0,"currency_code":"USD","in_stock":true}]},{"product_id":"the-global-exosome-market-market-size-forecast-trials-and-trends-2022","title":"The Global Exosome Market – Market Size, Forecast, Trials and Trends, 2022","description":"\u003cp\u003eThe Global Exosome Market – Market Size, Forecast, Trials and Trends, 2022\u003c\/p\u003e\n\n\u003cp\u003eEXECUTIVE SUMMARY\u003c\/p\u003e\n\n\u003cp\u003eExosome technologies have been developing rapidly in recent years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine. In particular, cancer derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.\u003c\/p\u003e \n\n\u003cp\u003eExosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 150 nanometers. Exosomes are secreted by a wide range of cells, since virtually all living cells utilize exosome-mediated communication. Exosomes carry cell-specific cargos of proteins, lipids, and nucleic acids that are selectively taken up by recipient cells.\u003c\/p\u003e\n\n\u003cp\u003eThe cargo contained within exosomes can offer prognostic information for range of diseases—including cardiovascular, renal, neurodegenerative, and metabolic diseases—as well as cancer.  Researchers investigating exosome biomarkers have discovered, identified, and reported the presence of hundreds of biomolecules within the lumen of exosomes. This discovery has compelled a rapid rise in exosome-related cancer biomarker research, including the use of exosomes for the detection, monitoring, and treatment of a diverse range of oncologic conditions.\u003c\/p\u003e\n\n\u003cp\u003eImportantly, exosomes are present within a diverse range of biofluids, including serum, plasma, urine, seminal fluid, CSF, saliva, tears and breast milk. For this reason, exosome-based diagnostics are minimally invasive, offering ease of use and speed of detection. Exosomes can also act as prognostic indicators and predictors of a patient's response to a specific course of treatment.\u003c\/p\u003e\n\n\u003cp\u003eExosomes are also being explored for their use as cell-free therapeutics. For example, if a patient has a disease caused by a missing or defective protein or microRNA, the patient’s exosomes can be isolated, modified with the appropriate siRNA or protein, and then injected back into the patient for treatment. Many approaches are being researched for creating drug-loaded exosomes. Furthermore, exosomes themselves can exert powerful effects. For example, mesenchymal stem cell (MSC) derived exosomes have the capacity to suppress inflammation, prevent scar tissue formation, and mediate a healthy immune response.\u003c\/p\u003e\n\n\u003cp\u003eFor these reasons, exosomes have gone from being overlooked to rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering cells to patients. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits.\u003c\/p\u003e \n\n\u003cp\u003eWhen exosome publications are analyzed, U.S. authors have published approximately 40% of the articles and China comes in second place. When the term \"exosome\" is searched in the scientific literature, Dr. Susanne Gabrielsson from the Karolinska Institutet in Sweden is the leading author. When the term \"extracellular vesicles\" is searched, Unicyte AG, a regenerative medicine unit of Fresenius Medical Care, takes the lead. Headquartered in Switzerland, the company has published more than 100 papers on exosomes and extracellular vesicles in combination with Professor Giovanni Camussi.\u003c\/p\u003e\n\n\u003cp\u003eTo date, three pharma companies (Takeda, Jazz Pharmaceuticals, and Roche Pharmaceutical Company) have signed partnership deals with exosome companies offering payment terms structured to deliver at or around $1 billion dollars. Within the past few years, there has been at least 7 partnership deals within the exosome industry, 8 large venture capital events, and 2 landmark acquisitions.\u003c\/p\u003e\n\n\u003cp\u003eThe exosome industry has also achieved two landmark approvals of FDA-approved diagnostic tests: Bio-Techne's ExoDx Prostate IntelliScore Test for prostate cancer and Guardant's 360 CDx test for non-small cell lung cancer.\u003c\/p\u003e\n\n\u003cp\u003eExosome Market Forces\u003c\/p\u003e\n\n\u003cp\u003eTo characterize the rapidly expanding exosome market, BioInformant has released this global market report that explores growing demand for exosome therapeutics, diagnostics, research tools, and manufacturing technologies. The report reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials.\u003c\/p\u003e \n\n\u003cp\u003eIt highlights information about exosome industry partnerships, merger and acquisition (M\u0026amp;A) activity, and financing events. It features company profiles for 118 global competitors from across the exosome marketplace. Importantly, it presents market size determinations by market segment with forecasts through 2030.\u003c\/p\u003e \n\n\u003cp\u003eToday the exosome industry is witnessing:\u003c\/p\u003e\n\n\u003cp\u003eA surging number of scientific papers investigating exosomes and their applications\u003cbr\u003e\nRising numbers of clinicals trials investigating exosome therapeutics and diagnostics\u003cbr\u003e\nSwelling appetite among investors for exosome technologies\u003cbr\u003e\nAn increasingly competitive IP environment\u003cbr\u003e\nA diverse range of co-development partnerships\u003cbr\u003e\nProliferating numbers of exosome competitors in all major life science markets worldwide\u003c\/p\u003e\n\n\u003cp\u003eThis global strategic report about the exosome industry reveals:\u003c\/p\u003e\n\n\u003cp\u003e1.\tThe pipeline for exosome therapeutics\u003cbr\u003e\n2.\tClinical trial activity by type, region, phase, and sponsor\u003cbr\u003e\n3.\tExosome industry events, including M\u0026amp;A activity, financing events, and IPOs\u003cbr\u003e\n4.\tStrategic partnerships and co-development agreements\u003cbr\u003e\n5.\tCompetitors composing the global marketplace, including core technologies and products under development\u003cbr\u003e\n6.\tMarket size determinations by market segment, with forecasts through 2030\u003cbr\u003e\n7.\tExosome industry trends, competitive opportunities, and future directions for the global market\u003cbr\u003e\n8.\tAnd so much more\u003c\/p\u003e\n\n\u003cp\u003eClaim this global strategic report to:\u003c\/p\u003e\n\n\u003cp\u003e1.\tBecome immediately educated about the rapidly evolving exosome market\u003cbr\u003e\n2.\tIdentify opportunities for exosome product development\u003cbr\u003e\n3.\tReveal the identities of all known competitors developing exosome research products, diagnostics, therapeutics, and manufacturing technologies\u003cbr\u003e\n4.\tPurse external funding from investors\u003cbr\u003e\n5.\tMake strategic decisions faster and with less risk\u003c\/p\u003e\n\n\u003cp\u003eAbout BioInformant\u003c\/p\u003e\n\n\u003cp\u003eWith an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with 16+ years of experience. As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine, as well as cited in Tony Robbins best-selling book, Life Force. Headquartered in Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capitol Hill.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 312 Pages \/ MCW16225209","offer_id":47639644700978,"sku":null,"price":5396.0,"currency_code":"USD","in_stock":true}]},{"product_id":"europe-nerve-repair-regeneration-market-forecast-to-2028-covid-19-impact-and-regional-analysis-by-product-neurostimulation-neuromodulation-devices-internal-neurostimulation-devices-spinal-cord-stimulation-deep-brain-stimulation-vagus-nerve-st","title":"Europe Nerve Repair \u0026 Regeneration Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Neurostimulation \u0026 Neuromodulation Devices {Internal Neurostimulation Devices [Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve St","description":"\u003cp\u003eEurope Nerve Repair \u0026amp; Regeneration Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Neurostimulation \u0026amp; Neuromodulation Devices {Internal Neurostimulation Devices [Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, and Gastric Electrical Stimulation] and External Neurostimulation Devices [Transcutaneous Electrical Nerve Stimulation Devices, Transcranial Magnetic Stimulation Devices, Respiratory Electrical Stimulation Devices]} and Biomaterials), and Application (Neurostimulation \u0026amp; Neuromodulation Applications {Internal neurostimulation \u0026amp; neuromodulation, and External neurostimulation \u0026amp; neuromodulation}, and Nerve Repair \u0026amp; Regeneration Applications {Direct Nerve Repair\/Neurorrhaphy [Epineural Repair, Perineural Repair, and Group Fascicular Repair], Nerve Grafting [Autografts, Allografts, and Xenografts], and Stem cell therapy})\u003c\/p\u003e\n\n\u003cp\u003eThe nerve repair \u0026amp; regeneration market in Europe is expected to grow from US$ 1,537.23 million in 2022 to US$ 2,709.29 million by 2028; it is estimated to grow at a CAGR of 9.9% from 2022 to 2028.\u003c\/p\u003e\n\n\u003cp\u003eRising Prevalence of Age-associated Neurological Disorders among Geriatric Population Boosts Europe Nerve Repair \u0026amp; Regeneration Market Growth\u003c\/p\u003e\n\n\u003cp\u003eSome neurologic disorders such as neuropathy, Alzheimer's disease, Parkinson's disease, and strokes are more common in the elderly, and their prevalence is increasing with higher life expectancies. According to the WHO, the population is aging rapidly worldwide. Between 2015 and 2050, the world's population over 60 years will nearly double, from 12% to 22%, and mental and neurological disorders among older adults are likely to account for 6.6% of the total disability-adjusted life year (DALYs) for this age group. Also, as per the same source, approximately 15% of adults aged 60 and over have a mental disorder. The death rate due to neurological disorders is also increasing. For instance, according to the Alzheimer's Association, 1 in 3 seniors dies with Alzheimer's or dementia. Therefore, rising prevalence of age-associated neurological disorders increases demand for treatment of nerve repair \u0026amp; regeneration. This factor is propelling the growth of nerve repair \u0026amp; regeneration market.\u003c\/p\u003e\n\n\u003cp\u003eMarket Overview\u003c\/p\u003e\n\n\u003cp\u003eThe Europe nerve repair \u0026amp; regeneration market is further segmented into Germany, France, Italy, Spain, the UK, and the Rest of Europe. The Europe nerve repair \u0026amp; regeneration market growth is attributed to the growing geriatric population, increasing incidence of neurological disorders, high incidence of nerve injuries, and rising government support for neurological disorder studies. According to the German Alzheimer Society, in 2021, ~1.6 million people in Germany had dementia, and ~300,000 new cases are detected every year. Furthermore, the aging population is expected to increase from 2.4 in 2021 to 2.8 million by 2050, which is a major cause of dementia. Similarly, Parkinson’s disease is the second most common neurodegenerative disorder, which causes disability and movement disorder. According to Acta Neurologica Scandinavica, the number of people diagnosed with Parkinson’s disease will be doubled by 2050 in Europe. According to the German Society of Neurology, the prevalence of Parkinson’s disease is 1800 in every 100,000 persons. To control the growing prevalence of neurological disorders, the German Center for Neurodegenerative Diseases (DZNE) is investigating the major cause of nervous system diseases and various approaches for prevention, therapy, and care. Further, the DZNE, in collaboration with their university partners, promotes young researchers in studies of neurological disorders. Thus, the growing prevalence of neurological diseases and government-supported initiatives to combat the disease are driving the growth of the Europe nerve repair \u0026amp; regeneration market.\u003c\/p\u003e\n\n\u003cp\u003eEurope Nerve Repair \u0026amp; Regeneration Market Revenue and Forecast to 2028 (US$ Million)\u003c\/p\u003e\n\n\u003cp\u003eEurope Nerve Repair \u0026amp; Regeneration Market Segmentation\u003c\/p\u003e\n\n\u003cp\u003eThe Europe nerve repair \u0026amp; regeneration market is bifurcated on the basis of product and application.\u003c\/p\u003e\n\n\u003cp\u003eBased on product, the Europe nerve repair \u0026amp; regeneration market is segmented into neurostimulation and neuromodulation devices and biomaterials. The neurostimulation and neuromodulation devices segment accounted for a larger market share in 2022. Based on application, the Europe nerve repair \u0026amp; regeneration market is bifurcated into neurostimulation \u0026amp; neuromodulation applications and nerve repair \u0026amp; regeneration applications. The nerve repair \u0026amp; regeneration applications segment held a larger market share in 2022. Based on country, the Europe nerve repair \u0026amp; regeneration market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Further, Germany dominated the market in 2022.\u003c\/p\u003e\n\n\u003cp\u003eAxogen Corporation, Boston Scientific Corporation, Integra LifeSciences, Medtronic, Abbott Laboratories, Stryker Corporation, Neuronetics, LivaNova PLC, Baxter, and Polyganics BV are the leading companies operating in the nerve repair \u0026amp; regeneration market in Europe.\u003c\/p\u003e \n\n\u003cp\u003eReasons to Buy\u003c\/p\u003e\n\n\u003cp\u003eSave and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the MEA industrial insulation market.\u003cbr\u003e\nHighlights key business priorities to assist companies to realign their business strategies\u003cbr\u003e\nThe key findings and recommendations highlight crucial progressive industry trends in the MEA industrial insulation market, thereby allowing players across the value chain to develop effective long-term strategies\u003cbr\u003e\nDevelop\/modify business expansion plans by using substantial growth offering developed and emerging markets\u003cbr\u003e\nScrutinize in-depth MEA market trends and outlook coupled with the factors driving the industrial insulation market, as well as those hindering it\u003cbr\u003e\nEnhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 202 Pages \/ MCW16225210","offer_id":47639644733746,"sku":null,"price":3600.0,"currency_code":"USD","in_stock":true}]},{"product_id":"india-immunoglobulin-market","title":"India Immunoglobulin market","description":"\u003cp\u003eIndia Immunoglobulin market\u003c\/p\u003e\n\n\u003cp\u003eThe india Immunoglobulin market size was valued at $Million in 2021 growing at the CAGR of % from 2022 to 2032. This growth is attributed to several macro and microeconomic factors such as\u003c\/p\u003e \n\n\u003cp\u003eThe rapid increase in the geriatric population\u003cbr\u003e\nncreasing research \u0026amp; development activities related to pharmaceuticals\u003c\/p\u003e \n\n\u003cp\u003eFurther several factors restraining the market growth include\u003cbr\u003e\nThe high initial cost\u003c\/p\u003e\n\n\u003cp\u003eCollaborations and Alliances in the Immunoglobulin market is expected to generate higher avenues during the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eIn the wake of the COVID-19 pandemic, supply chain disruptions have led to supply shortages or lower demand in the Immunoglobulin market. The pandemic has caused a decline in new orders and a corresponding decrease in production.\u003c\/p\u003e\n\n\u003cp\u003eThis section will analyze how COVID-19 has impacted supply chains, leading to shortages and lower demand for Document Readerss.\u003c\/p\u003e\n\n\u003cp\u003eIn terms of COVID 19 impact, the Immunoglobulin market report also includes the following data points:\u003c\/p\u003e\n\n\u003cp\u003eImpact on Immunoglobulin market size\u003cbr\u003e\nOperating Weights Trend, Preferences, and Budget Impact\u003cbr\u003e\nRegulatory Framework\/Government Policies\u003cbr\u003e\nKey Players Strategy to Tackle Negative Impact\/Post-COVID Strategies\u003cbr\u003e\nOpportunity in Immunoglobulin market\u003c\/p\u003e\n\n\u003cp\u003eKey Insight in the report:\u003c\/p\u003e\n\n\u003cp\u003eThe india Immunoglobulin market report covers executive summary, market dynamics, COVID impact \u0026amp; post COVID scenario, market size and forecast, competitive intelligence, market positioning, and product offerings.\u003c\/p\u003e\n\n\u003cp\u003eOur report covers extensive competitive intelligence which includes the following data points:\u003c\/p\u003e\n\n\u003cp\u003eBusiness Overview\u003cbr\u003e\nBusiness Segment Data\u003cbr\u003e\nFinancial Data\u003cbr\u003e\nProduct Segment Analysis and Specification\u003cbr\u003e\nRecent Development and Company Strategy Analysis\u003cbr\u003e\nSWOT Analysis\u003c\/p\u003e\n\n\u003cp\u003eImmunoglobulin Market Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eProduct\u003cbr\u003e\nIgG\u003cbr\u003e\nIgA\u003cbr\u003e\nIgM\u003cbr\u003e\nIgE\u003cbr\u003e\nIgD\u003cbr\u003e\nApplication\u003cbr\u003e\nHypogammaglobulinemia\u003cbr\u003e\nChronic Inflammatory Demyelinating Polyneuropathy (CIDP)\u003cbr\u003e\nImmunodeficiency Disease\u003cbr\u003e\nMyasthenia Gravis\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eKey Players Analyzed in the Report:\u003c\/p\u003e\n\n\u003cp\u003eBaxter international Inc\u003cbr\u003e\nGrifols S.A\u003cbr\u003e\nBayer Healthcare\u003cbr\u003e\nTakeda Pharmaceutical Company Limited\u003cbr\u003e\nPlasmaGen BioSciences Pvt. Ltd. \u003cbr\u003e\nReliance Life Sciences \u003cbr\u003e\nBiocon Limited \u003cbr\u003e\nIntas Pharmaceuticals Ltd. \u003cbr\u003e\nBharat Serums and Vaccines Limited (BSV)\u003cbr\u003e\nVIRCHOW BIOTECH\u003c\/p\u003e \n\n\u003cp\u003eREPORT CONTENT:\u003c\/p\u003e\n\n\u003cp\u003eHigh-level analysis of the current and future market trends and opportunities\u003cbr\u003e\nDetailed analysis on current market drivers, restraining factors, and opportunities in the future\u003cbr\u003e\nImmunoglobulin market estimates for 2021 and forecast from 2022 to 2032\u003cbr\u003e\nVendor market share analysis at each product level\u003cbr\u003e\nCompetitor analysis with a detailed insight into its product segment, financial strength, and strategies adopted.\u003c\/p\u003e\n\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\n\u003cp\u003eManufacturers\u003cbr\u003e\nSuppliers and traders\u003cbr\u003e\nGovernment, associations, and industrial bodies\u003cbr\u003e\nInvestors and trade experts\u003cbr\u003e\nConsulting Firms or Individual Consultant\u003cbr\u003e\nAnyone interested in understanding the industry dynamics of the Immunoglobulin market\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 14 Pages \/ MCW16225211","offer_id":47639644766514,"sku":null,"price":1199.0,"currency_code":"USD","in_stock":true}]},{"product_id":"north-america-gene-synthesis-market-industry-trends-forecast-to-2029","title":"North America Gene Synthesis Market - Industry Trends Forecast to 2029","description":"\u003cp\u003eNorth America Gene Synthesis Market - Industry Trends Forecast to 2029\u003c\/p\u003e\n\n\u003cp\u003eNorth America gene synthesis market is projected to register a substantial CAGR of 23.4% from 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentations\u003c\/p\u003e \n\n\u003cp\u003eNorth America Gene Synthesis Market, By Component ( Synthesizer, Consumables, and  Software \u0026amp; Services), Gene Type (Standard Gene, Express Gene, Complex Gene, and Others),  Gene Synthesis Type (Gene Library Synthesis and Custom Gene Synthesis), Application (Synthetic Biology, Genetic Engineering, Vaccine Design, Therapeutic Antibodies, and Others), Method (Solid-Phase Synthesis, CHIP-Based DNA Synthesis, and PCR-Based Enzyme Synthesis), End User (Academic \u0026amp; Research Institutes, Diagnostic Laboratories, Biotech \u0026amp; Pharmaceutical Companies, and  Others),  Distribution Channel (Direct Tender, Online Distribution, and Third Party Distribution), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2029\u003c\/p\u003e        \n\n\u003cp\u003eSome of the major factors contributing to the growth of the North America gene synthesis market are:\u003cbr\u003e\n• Increased prevalence of chronic infectious diseases \u003cbr\u003e\n• Expansion of synthetic biology\u003cbr\u003e\n• Rising interest in gene synthesis in the field of molecular biology\u003cbr\u003e\n• Rising adoption of gene therapy\u003c\/p\u003e\n\n\u003cp\u003eMarket Players\u003c\/p\u003e\n\n\u003cp\u003eSome of the key market players in the North America gene synthesis market are listed below:\u003cbr\u003e\n• Thermo Fisher Scientific Inc.\u003cbr\u003e\n• General Biosystems, Inc.\u003cbr\u003e\n• Macrogen, Co, Ltd\u003cbr\u003e\n• Boster Biological Technology\u003cbr\u003e\n• Creative Biogen.\u003cbr\u003e\n• exonbio.\u003cbr\u003e\n• Twist Bioscience.\u003cbr\u003e\n• OriGene Technologies, Inc.\u003cbr\u003e\n• Integrated DNA Technologies, Inc.\u003cbr\u003e\n• Eurofins Scientific\u003cbr\u003e\n• NZYTech, Lda.\u003cbr\u003e\n• Ansa Biotechnologies, Inc.\u003cbr\u003e\n• GenScript\u003cbr\u003e\n• ProteoGenix\u003cbr\u003e\n• Bio Basic Inc.\u003cbr\u003e\n• ATG: biosynthetics GmbH\u003cbr\u003e\n• Merck KGaA\u003cbr\u003e\n• Ginkgo Bioworks\u003cbr\u003e\n• Evonetix\u003cbr\u003e\n• Kaneka Eurogentec S.A\u003cbr\u003e\n• ProMab Biotechnologies, Inc.\u003cbr\u003e\n• Synbio Technologies\u003cbr\u003e\n• CSBio\u003cbr\u003e\n• Azenta US, Inc.\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e\n\n\u003cp\u003ePlease note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 153 Pages \/ MCW16225212","offer_id":47639644799282,"sku":null,"price":4200.0,"currency_code":"USD","in_stock":true}]},{"product_id":"helicobacter-pylori-testing-global-market-outlook","title":"Helicobacter pylori Testing: Global Market Outlook","description":"\u003cp\u003eReport Scope:\u003c\/p\u003e\n\n\u003cp\u003eIn this report, the market has been segmented based on test type, end user, and geography. The report provides an overview of the global Helicobacter pylori testing market and analyzes market trends. Using 2021 as the base year, the report provides estimated market data for the forecast period of 2022 to 2027. Market values are estimated based on the total revenue of H. pylori testing product providers.\u003c\/p\u003e\n\n\u003cp\u003eThe report covers the market for Helicobacter pylori testing for the user base across different regions. It also highlights major trends and challenges that affect the market and the vendor landscape. The report estimates the global market for Helicobacter pylori testing in 2021 and provides projections for the expected market size through 2027. The scope of the study includes Helicobacter pylori testing products that are already available in the market as well as future prospects.\u003c\/p\u003e\n\n\u003cp\u003eReport Includes:\u003c\/p\u003e\n\n\u003cp\u003eAn overview of the global market outlook for Helicobacter pylori (H. pylori) testing\u003c\/p\u003e\n\n\u003cp\u003eAnalyses of the global market trends, with historic market revenue data for 2020 and 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027\u003c\/p\u003e\n\n\u003cp\u003eHighlights of the market potential for Helicobacter pylori testing products, industry growth drivers, and areas of focus to forecast this market into various segments and sub-segments\u003c\/p\u003e\n\n\u003cp\u003eEstimation of the actual market size and revenue forecast for helicobacter pylori testing market in USD million terms, and corresponding market share analysis by test type, end-user, and region\u003c\/p\u003e\n\n\u003cp\u003eIn-depth information (facts and figures) concerning the major market dynamics, industry structure, and competitive environment of the leading market participants\u003c\/p\u003e\n\n\u003cp\u003eMarket outlook and assessment of the recent strategic analysis in the global helicobacter pylori testing market with emphasis on key developments\u003c\/p\u003e\n\n\u003cp\u003eCompany profiles of the leading industry players\u003c\/p\u003e\n\n\u003cp\u003eCompanies Mentioned\u003c\/p\u003e\n\n\u003cp\u003eABBOTT\u003cbr\u003e\nADVACARE PHARMA\u003cbr\u003e\nAMA-MED OY\u003cbr\u003e\nBIOMERICA\u003cbr\u003e\nCERTEST BIOTEC SL\u003cbr\u003e\nCORIS BIOCONCEPT\u003cbr\u003e\nDIASORIN SPA\u003cbr\u003e\nJANT PHARMACAL CORP.\u003cbr\u003e\nMERIDIAN BIOSCIENCE Inc.\u003cbr\u003e\nSEKISUI DIAGNOSTICS\u003cbr\u003e\nTHERMO FISHER SCIENTIFIC\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 38 Pages \/ MCW16225213","offer_id":47639644832050,"sku":null,"price":4200.0,"currency_code":"USD","in_stock":true}]},{"product_id":"nanobots-market-global-industry-size-share-trends-opportunity-and-forecast-2017-2027-segmented-by-type-nanomanipulator-bio-nanorobotics-magnetically-guided-bacteria-based-others-by-application-nanomedicine-biomedical-mechanical-others","title":"Nanobots Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented by Type (Nanomanipulator, Bio-Nanorobotics, Magnetically Guided, Bacteria-Based, Others), By Application (Nanomedicine, Biomedical, Mechanical, Others),","description":"\u003cp\u003eNanobots Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented by Type (Nanomanipulator, Bio-Nanorobotics, Magnetically Guided, Bacteria-Based, Others), By Application (Nanomedicine, Biomedical, Mechanical, Others), By Region\u003c\/p\u003e\n\n\u003cp\u003eThe global nanobots market is anticipated to witness an impressive growth during the forecast period. This can be ascribed to the increasing usage of nanobots in the medical field across the world. Nanobots are robots that carry out a very specific function. They are not only used for drug delivery but also are used for monitoring important body parameters such as blood glucose levels when inserted into the blood under the skin. This in turn is expected to increase the demand for nanobots in the coming years. The growing adoption and number of personalized medicines is expected to create opportunities for the growth of global nanobots market. In 2020, the number of personalized medicines available in the United States were around 286. Also, growing popularity of regenerative medicine will further open growth prospects for the growth of global nanobots market in the next few years.\u003c\/p\u003e\n\n\u003cp\u003eIncreasing Use of Nanobots in Drug Delivery\u003c\/p\u003e\n\n\u003cp\u003eThe growing use of nanobots in drug delivery applications is expected to support the market growth. Normally, drugs work through the entire body before they reach the disease affected area. Nanobots help in targeted drug delivery to the precise location, making the drug more effective and reducing the chances of side effects. Nanobots used in drug delivery have walls that are just 5–10 atoms thick and the inner drug-filled cell is usually 50–100 nm wide. When they detect signs of the disease, thin wires in their walls emit an electrical pulse which causes the walls to dissolve and the drug to be released. Using this method of drug delivery, the amount and time of drug release can be easily controlled by controlling the electric pulse.\u003c\/p\u003e\n\n\u003cp\u003eIncreasing Research \u0026amp; Developments\u003c\/p\u003e\n\n\u003cp\u003eThe growing research \u0026amp; developments in the field of nanotechnology and nanobots is expected to create lucrative opportunities for the market growth. Various academic \u0026amp; research institutions and biotechnology \u0026amp; pharmaceutical companies are researching and developing new nanobots that could address different needs of the nanobots market. Additionally, research is being carried out to advance and improve the functioning of existing nanobots also. All this is leading to launch of clinical trials and is attracting a lot of fundings and investments, thereby creating new prospects of growth for global nanobots market. For instance, in February 2021, Tescan-Orsay announced the launch of nanomanipulator for applications performed in Tescan scanning electron microscope and FIB-SEM instruments.\u003c\/p\u003e  \n\n\u003cp\u003eMarket Segmentation\u003c\/p\u003e\n\n\u003cp\u003eGlobal nanobots market can be segmented by type, by application, by region. Based on type, the market can be categorized into nanomanipulator, bio-nanorobotics, magnetically guided, bacteria-based, and others. Based on application, the market can be segmented into Nanomedicine, Biomedical, Mechanical, Others. Regionally, North America dominated the market among Europe, Asia Pacific, Middle East \u0026amp; Africa and South America. Among the different countries, the United States dominated the global nanobots market on account of increasing research \u0026amp; development activities in the United States. It is projected that by the end of 2022, the United States would be generating a revenue of around USD8.11 billion from scientific research \u0026amp; development activities.\u003c\/p\u003e\n\n\u003cp\u003eMarket Players\u003c\/p\u003e\n\n\u003cp\u003eGinkgo Bioworks Inc., Imina Technologies S.A., Thermo Fischer Scientific, Inc., EV Group, Zymergen Inc., Nanoics Imaging Limited, Synthace Limited, Toronto Nano Instrumentation Inc., Oxford Instruments plc, Bruker Corporation are some of the leading players operating in the Global Nanobots Market.\u003c\/p\u003e\n\n\u003cp\u003eReport Scope:\u003c\/p\u003e\n\n\u003cp\u003eIn this report, global nanobots market has been segmented into following categories, in addition to the industry trends which have also been detailed below:Nanobots Market, By Type:NanomanipulatorBio-NanoroboticsMagnetically GuidedBacteria-BasedOthersNanobots Market, By Application:NanomedicineBiomedicalMechanicalOthersNanobots Market, By Region:North AmericaUnited StatesCanadaMexicoEuropeFranceGermanyUnited KingdomItaly SpainAsia PacificChinaIndiaJapanSouth KoreaAustraliaSouth AmericaBrazilArgentinaColombiaMiddle East \u0026amp; AfricaSouth AfricaSaudi ArabiaUAEEgyptTurkeyCompetitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eCompany Profiles: Detailed analysis of the major companies present in Global Nanobots Market.\u003c\/p\u003e\n\n\u003cp\u003eCompany InformationDetailed analysis and profiling of additional market players (up to five).Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.  Single User license will be delivered in PDF format without printing rights\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 117 Pages \/ MCW16225214","offer_id":47639644864818,"sku":null,"price":5880.0,"currency_code":"USD","in_stock":true}]},{"product_id":"carrier-screening-market-by-type-expanded-carrier-screening-targeted-disease-carrier-screening-by-technology-dna-sequencing-polymerase-chain-reaction-microarrays-others-by-end-user-hospitals-and-clinics-reference-laboratories-physician-office","title":"Carrier Screening Market By Type (Expanded Carrier Screening, Targeted Disease Carrier Screening), By Technology (DNA Sequencing, Polymerase Chain Reaction, Microarrays, Others), By End User (Hospitals and clinics, Reference Laboratories, Physician Office","description":"\u003cp\u003eCarrier Screening Market By Type (Expanded Carrier Screening, Targeted Disease Carrier Screening), By Technology (DNA Sequencing, Polymerase Chain Reaction, Microarrays, Others), By End User (Hospitals and clinics, Reference Laboratories, Physician Offices, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031\u003c\/p\u003e\n\n\u003cp\u003eThe global carrier screening market was valued at $1,849.36 million in 2021 and is projected to reach $6,454.60 million by 2031, registering a CAGR of 13.8% from 2022 to 2031. Genetic testing is done for checking if people have genetic conditions or diseases that may be present in the family history prior to the occurrence of the symptoms or if people can pass on that genetic condition to their children. Genetic counselors help people decide what tests to get and understand the meaning of tests. It can be done on amniotic fluid through amniocentesis or the placenta through chorionic villus sampling in pregnant women. It can also be done on an embryo during in vitro fertilization (IVF). Usually, it takes a few weeks for test results to be ready. Some of the diseases for which genetic testing is preferred include cystic fibrosis, Tay-Sachs disease, sickle cell disease, down syndrome, spina bifida, turner syndrome, von Willebrand disease, albinism, and Duchenne muscular dystrophy.\u003c\/p\u003e\n\n\u003cp\u003eAn increase in the incidence of genetic diseases, a rise in the number of advanced product launches, and a surge in the availability \u0026amp; affordability of tests are the factors responsible for driving the growth of the market. Moreover, an increase in the number of biotechnology companies adopting strategies like acquisition is expected to notably contribute toward market growth. For instance, in August 2021, DiaSorin S.p.A. announced that it has completed the acquisition of Luminex Corporation for a price of $37.00 per share which corresponds to a total equity value of approximately $1.8 billion. Through the acquisition, DiaSorin has gained access to Luminex’s multiplexing technology and a portfolio that will strengthen its existing offering, while expanding the Group presence in the U.S. In addition, the global carrier screening market growth is largely driven by factors such as an increase in preference of carrier screening in genetic disorder fields, various initiatives \u0026amp; funding from government \u0026amp; private bodies for large-scale carrier screening projects and decline in cost of screening. The key market players in the global carrier screening market have opted for various strategies such as investments in R\u0026amp;D for advancement in carrier screening to strengthen their position in the market and sustain the competitive environment. However, the high cost associated with carrier screening and the dearth of skilled professionals restricts the market growth. Conversely, various technological advancements such as the development of next-generation sequencing (NGS) techniques for genetic disease screening and DNA sequencing are expected to provide lucrative opportunities for the growth of the market in the coming years. The increase in the R\u0026amp;D activities in the field of bioinformatics and biotechnology along with significant improvement in medical infrastructure is anticipated to increase the opportunities of the market.\u003c\/p\u003e\n\n\u003cp\u003eThe carrier screening market is segmented based on type, technology, end-user, and region. On the basis of type, the market is bifurcated into expanded carrier screening and targeted disease carrier screening. On the basis of technology, the market is classified into DNA sequencing, polymerase chain reaction, microarrays, and others. On the basis of end users, the market is classified into hospitals \u0026amp; clinics, reference laboratories, physician offices, and others. Region-wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).\u003c\/p\u003e\n\n\u003cp\u003eMajor companies profiled in the report include Diasorin S.p.A (Luminex Corporation), Eurofins Scientific, Fulgent Genetics Inc., Illumina Inc., Invitae Corporation, Myriad Genetics Inc., Natera Inc., Opko Health Inc., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc.\u003c\/p\u003e\n\n\u003cp\u003eKey Benefits For Stakeholders\u003c\/p\u003e\n\n\u003cp\u003eThis report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the carrier screening market analysis from 2021 to 2031 to identify the prevailing carrier screening market opportunities.\u003c\/p\u003e\n\n\u003cp\u003eMarket research is offered along with information related to key drivers, restraints, and opportunities.\u003c\/p\u003e\n\n\u003cp\u003ePorter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.\u003c\/p\u003e\n\n\u003cp\u003eAn in-depth analysis of the carrier screening market segmentation assists to determine the prevailing market opportunities.\u003c\/p\u003e\n\n\u003cp\u003eMajor countries in each region are mapped according to their revenue contribution to the global market.\u003c\/p\u003e\n\n\u003cp\u003eMarket player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.\u003c\/p\u003e\n\n\u003cp\u003eThe report includes analysis of the regional as well as global carrier screening market trends, key players, market segments, application areas, and market growth strategies.\u003c\/p\u003e\n\n\u003cp\u003eKey Market Segments\u003c\/p\u003e\n\n\u003cp\u003eBy Type\u003c\/p\u003e\n\n\u003cp\u003eExpanded Carrier Screening\u003cbr\u003e\nTargeted Disease Carrier Screening\u003c\/p\u003e\n\n\u003cp\u003eBy Technology\u003c\/p\u003e\n\n\u003cp\u003eDNA Sequencing\u003cbr\u003e\nPolymerase Chain Reaction\u003cbr\u003e\nMicroarrays\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eBy End User\u003c\/p\u003e\n\n\u003cp\u003eHospitals and clinics\u003cbr\u003e\nReference Laboratories\u003cbr\u003e\nPhysician Offices\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eBy Region\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nUK\u003cbr\u003e\nItaly\u003cbr\u003e\nSpain\u003cbr\u003e\nRest of Europe\u003cbr\u003e\nAsia-Pacific\u003cbr\u003e\nJapan\u003cbr\u003e\nChina\u003cbr\u003e\nAustralia\u003cbr\u003e\nIndia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRest of Asia-Pacific\u003cbr\u003e\nLAMEA\u003cbr\u003e\nBrazil\u003cbr\u003e\nSaudi Arabia\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nRest of LAMEA\u003c\/p\u003e\n\n\u003cp\u003eKey Market Players\u003c\/p\u003e\n\n\u003cp\u003eFulgent Genetics Inc.\u003cbr\u003e\nIllumina Inc.\u003cbr\u003e\nDiasorin S.p.A.\u003cbr\u003e\nNatera Inc.\u003cbr\u003e\nThermo Fisher Scientific Inc.\u003cbr\u003e\nEurofins Scientific\u003cbr\u003e\nMyriad Genetics, Inc.\u003cbr\u003e\nOpko Health Inc\u003cbr\u003e\nQuest Diagnostics Inc.\u003cbr\u003e\nInVitae Corporation\u003c\/p\u003e\n\n\u003cp\u003ePlease Note: It will take 7-10 business days to complete the report upon order confirmation.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 350 Pages \/ MCW16225215","offer_id":47639644897586,"sku":null,"price":4608.0,"currency_code":"USD","in_stock":true}]},{"product_id":"bioreactors-market-size-by-product-single-use-reusable-by-cell-mammalian-cells-bacterial-cells-yeast-cells-by-molecule-monoclonal-antibodies-vaccines-recombinant-proteins-stem-cells-gene-therapy-by-usage-developmental-pre-clinical-clin","title":"Bioreactors Market Size By Product (Single-use, Reusable), By Cell (Mammalian Cells, Bacterial Cells, Yeast Cells), By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy), By Usage (Developmental, Pre-clinical \u0026 Clin","description":"\u003cp\u003eBioreactors Market Size By Product (Single-use, Reusable), By Cell (Mammalian Cells, Bacterial Cells, Yeast Cells), By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy), By Usage (Developmental, Pre-clinical \u0026amp; Clinical, Commercial Production), By End-use (R\u0026amp;D Organizations, Biopharma Manufacturers, Contract Manufacturing Organizations (CMOs)), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share \u0026amp; Forecast, 2023 - 2032\u003c\/p\u003e\n\n\u003cp\u003eGlobal bioreactors market is set to witness substantial growth between 2023 and 2032 primarily owing to the technological advancements in bioreactors. Increasing adoption of single-use bioreactors owing to their additional benefits like efficiency in air and gas transfer, proper mixing of cells, and flexible operating conditions for better results will fuel the product demand in near future.\u003c\/p\u003e \n\n\u003cp\u003eOverall, the bioreactors market has been bifurcated in terms of product, molecule, end-user, cell, usage, and region.\u003c\/p\u003e\n\n\u003cp\u003eBased on product, the bioreactors market is likely to be characterized by the single-use segment. This segment is likely to grow at 15.5% CAGR through the estimated timeframe owing to the increasing adoption of single-use bioreactors for research purposes and to produce vaccines for a range of infections including COVID-19. Besides, it comes with a range of benefits for the researchers as well which is likely propel its demand in the upcoming times.\u003c\/p\u003e\n\n\u003cp\u003eOn the basis of molecule, the stem cells segment is likely to grow at more than 12.5% CAGR over 2023-2032. There is a widespread adoption of stem cell therapy due to an increase in the number of cancer cases. Furthermore, supportive government initiatives, increasing R\u0026amp;D expenditure, and rising demand for cell-based products are likely to fuel the segmental expansion of stem cell-based products in the future.\u003c\/p\u003e\n\n\u003cp\u003eIn the context of end-user, the biopharma manufacturers segment is poised to witness substantial growth. This can be credited to the rising adoption of advanced technologies which can be used to ease complex manufacturing.\u003c\/p\u003e \n\n\u003cp\u003eWithin the category of cells, the bioreactors market will be driven by the bacterial cells segment. Bacterial cells are used to produce several pharmaceutical therapeutics. Increasing usage of them by research institutes and manufacturers will positively drive the market growth through the analysis timespan.\u003c\/p\u003e \n\n\u003cp\u003eBased on usage, the bioreactor market is likely to be driven by the commercial production segment. This segment will witness substantial growth due to the increasing burden of chronic diseases, introduction of new companies, and mass production of vaccines. Moreover, reusable bioreactors are cost-effective and convenient which will also enhance the segmental revenue through the stipulated timeframe.\u003c\/p\u003e \n\n\u003cp\u003eIn the regional landscape, the bioreactors market in the MEA region will grow at a robust rate through the estimated timeframe. Increasing cases of infectious diseases in African countries along with the rising demand for drugs to cure them will likely bolster the market scenario in the upcoming time.\u003c\/p\u003e\n\n\u003cp\u003eSome of the key players in the bioreactors market include Danaher Corporation, Thermo Fisher Scientific, Getinge (Applikon Biotechnology), CESCO Bioengineering Co. Ltd, Bbi Biotech, Shanghai Bailun Biotechnology co., Ltd., PBS Biotech, Pierre Guerin SAS (Engie), and Solaris Biotech Solutions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 213 Pages \/ MCW16225216","offer_id":47639644930354,"sku":null,"price":6180.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-in-vitro-fertilization-services-growth-opportunities","title":"Global in Vitro Fertilization Services Growth Opportunities","description":"\u003cp\u003eGlobal in Vitro Fertilization Services Growth Opportunities\u003c\/p\u003e \n\n\n\n\u003cp\u003eThis study analyzes the in vitro fertility (IVF) services market across the globe. With infertility rates increasing across the world, assisted reproductive technologies (ART), including IVF, are gaining prominence. With technology advancements, the IVF process has undergone several modifications, with mainstream service providers such as fertility clinics\/hospitals and surgical centers now being backed up by additional service providers such as cryobanks and fertility benefits service providers. Patients now have the provision to freeze their eggs, sperm, and embryos and use it at a later stage when parenthood is desired. Moreover, state-of-the-art technologies such as pre-implantation genetic testing have improved success rates, promoting better outcomes. The possibility of using artificial intelligence (AI) in predicting the likeliness of an embryo to develop enables the embryologist in the IVF procedure to select the best embryo for transfer. Many other innovations and techniques can now make diagnostic work-up and treatment through ART, including IVF, more affordable. Most of these developments are in the clinical trial stage. These innovations will boost the adoption of IVF in low- and middle-income countries. As IVF laws differ in different parts of the world, fertility tourism is on the rise in certain European countries, Asia, and the Middle East. It has particularly gained popularity amongst patients in advanced economies like the United States and Europe.\u003c\/p\u003e\n\n\n\n\u003cp\u003eThe study provides a global overview of the market with a focus on the current market scenario, the latest technologies, costs, and future growth opportunities. The study segments the IVF services market into the following categories:\u003c\/p\u003e\n\n\u003cp\u003eFresh IVF cycles\u003c\/p\u003e\n\n\u003cp\u003e• Thawed IVF cycles\u003c\/p\u003e\n\n\u003cp\u003e• Donor egg\/sperm IVF cycles\u003c\/p\u003e\n\n\u003cp\u003e• Other cycle types\u003c\/p\u003e\n\n\n\n\u003cp\u003eThe end-user analysis includes the growth potential of the market players in the following categories:\u003c\/p\u003e\n\n\u003cp\u003e• Fertility clinics\u003c\/p\u003e\n\n\u003cp\u003e• Hospitals and surgical centers\u003c\/p\u003e\n\n\n\n\u003cp\u003eThe study analyzes the key factors driving and restraining growth and identifies the key growth opportunities emerging from this space for market players and stakeholders to leverage. The base year is 2022, and the forecast period is 2023 to 2027.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 102 Pages \/ MCW16225218","offer_id":47639644963122,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-ivf-services-market","title":"Global IVF Services Market","description":"\u003cp\u003eGlobal IVF Services Market\u003c\/p\u003e\n\n\u003cp\u003eGlobal IVF Services Market By Cycle Type (Fresh IVF Cycles (Non-donor), Thawed IVF Cycles (Non-donor), Donor Egg IVF Cycles), By End-User (Fertility Clinics, Hospitals, Surgical Centers, Clinical Research Institutes) And By Geography – Covid-19 Impact Analysis, Post Covid Analysis, Opportunities, Trends And Forecast From 2020 to 2032\u003c\/p\u003e\n\n\u003cp\u003eThe global IVF Services market was valued at $14.13 Billion in 2021 and is anticipated to grow at a CAGR of 9.91% from 2020 to 2032. This growth is attributed to several macro and microeconomic factors such as\u003c\/p\u003e \n\n\u003cp\u003eThe surge in IVF success rate\u003c\/p\u003e\n\n\u003cp\u003eThe surge in the IVF success rate is the major factor driving the growth of the IVF services market. The success rate of IVF has been increasing steadily over the past few years, due to advances in technology and medical science. This has led to more and more couples opting for IVF to conceive, which in turn is boosting the demand for IVF services. Additionally, the rising awareness about IVF and its effectiveness is also playing a role in driving the growth of the IVF services market.\u003c\/p\u003e\n\n\u003cp\u003eFurther several factors restraining the market growth include\u003c\/p\u003e\n\n\u003cp\u003eRestrictive regulations and ethical concerns\u003c\/p\u003e\n\n\u003cp\u003eThe market for IVF services is highly regulated in many countries, with restrictive laws governing who can provide such services and how they can be provided. These regulations are often based on ethical concerns, as there is significant debate about the morality of using assisted reproductive technologies to create children. In addition, many people believe that IVF services should be available only to those who cannot conceive naturally, as it is seen as a last resort option. As a result of these factors, the market for IVF services is often quite small, with only a few providers offering such services in each country.\u003c\/p\u003e\n\n\u003cp\u003eCollaborations and Alliances in the IVF Services market is expected to generate higher avenues during the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eIn the wake of the COVID-19 pandemic, supply chain disruptions have led to supply shortages or lower demand in the IVF Services market. The pandemic has caused a decline in new orders and a corresponding decrease in production.\u003c\/p\u003e\n\n\u003cp\u003eThis section will analyze how COVID-19 has impacted supply chains, leading to shortages and lower demand for IVF Services.\u003c\/p\u003e\n\n\u003cp\u003eIn terms of COVID 19 impact, the IVF Services market report also includes the following data points:\u003c\/p\u003e\n\n\u003cp\u003eImpact on IVF Services market size\u003cbr\u003e\nOperating Weights Trend, Preferences, and Budget Impact\u003cbr\u003e\nRegulatory Framework\/Government Policies\u003cbr\u003e\nKey Players Strategy to Tackle Negative Impact\/Post-COVID Strategies\u003cbr\u003e\nOpportunity in IVF Services market\u003c\/p\u003e\n\n\u003cp\u003eKey Insight in the report:\u003c\/p\u003e\n\n\u003cp\u003eThe global IVF Services market report covers executive summary, market dynamics, COVID impact \u0026amp; post COVID scenario, market size and forecast, competitive intelligence, market positioning, and product offerings.\u003c\/p\u003e\n\n\u003cp\u003eOur report covers extensive competitive intelligence which includes the following data points:\u003c\/p\u003e\n\n\u003cp\u003eBusiness Overview\u003cbr\u003e\nBusiness Segment Data\u003cbr\u003e\nFinancial Data\u003cbr\u003e\nProduct Segment Analysis and Specification\u003cbr\u003e\nRecent Development and Company Strategy Analysis\u003cbr\u003e\nSWOT Analysis\u003c\/p\u003e\n\n\u003cp\u003eIVF Services Market Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eCycle Type\u003cbr\u003e\nFresh IVF Cycles (Non-donor)\u003cbr\u003e\nThawed IVF Cycles (Non-donor)\u003cbr\u003e\nDonor Egg IVF Cycles\u003cbr\u003e\nEnd-User\u003cbr\u003e\nFertility Clinics\u003cbr\u003e\nHospitals\u003cbr\u003e\nSurgical Centers\u003cbr\u003e\nClinical Research Institutes\u003c\/p\u003e\n\n\u003cp\u003eRegion\/ Countries Covered:\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003cbr\u003e\nUS\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\nEurope\u003cbr\u003e\nUK\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nItaly\u003cbr\u003e\nRest of Europe\u003cbr\u003e\nAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nJapan\u003cbr\u003e\nIndia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRest of Asia Pacific\u003cbr\u003e\nRest of the World\u003cbr\u003e\nSouth America\u003cbr\u003e\nMiddle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eKey Players Analyzed in the Report:\u003c\/p\u003e\n\n\u003cp\u003eAmbroise Paré Group\u003cbr\u003e\nAmedes MVZ Cologne GmbH\u003cbr\u003e\nAMP Center St Roch\u003cbr\u003e\nAVA Clinic Scanfert\u003cbr\u003e\nBangkok IVF Center\u003cbr\u003e\nBetamedics\u003cbr\u003e\nBiofertility Center\u003cbr\u003e\nBloom Fertility and Healthcare\u003cbr\u003e\nBloom Fertility Center\u003cbr\u003e\nBourn Hall Fertility Center\u003c\/p\u003e\n\n\u003cp\u003eREPORT CONTENT:\u003c\/p\u003e\n\n\u003cp\u003eHigh-level analysis of the current and future market trends and opportunities\u003cbr\u003e\nDetailed analysis on current market drivers, restraining factors, and opportunities in the future\u003cbr\u003e\nIVF Services market estimates for 2019 and forecast from 2020 to 2027\u003cbr\u003e\nVendor market share analysis at each product level\u003cbr\u003e\nCompetitor analysis with a detailed insight into its product segment, financial strength, and strategies adopted.\u003c\/p\u003e\n\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\n\u003cp\u003eManufacturers\u003cbr\u003e\nSuppliers and traders\u003cbr\u003e\nGovernment, associations, and industrial bodies\u003cbr\u003e\nInvestors and trade experts\u003cbr\u003e\nConsulting Firms or Individual Consultant\u003cbr\u003e\nAnyone interested in understanding the industry dynamics of the IVF Services market\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 89 Pages \/ MCW16225219","offer_id":47639645028658,"sku":null,"price":4170.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-cell-culture-supplements-market-global-industry-size-share-trends-opportunity-and-forecast-2017-2027","title":"Recombinant Cell Culture Supplements Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027","description":"\u003cp\u003eRecombinant Cell Culture Supplements Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027\u003c\/p\u003e\n\n\u003cp\u003eThe global recombinant cell culture supplements market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include growing demand for animal free recombinant cell culture supplements and increase in investments in R\u0026amp;D are curbing the growth of the market. Cell culture is a process of removing cells from plant source or animal and rising subsequently under regulated conditions. Cell culture is an important technique used in the diagnostic laboratories, research institutes, pharmaceutical and biotechnology industries, for applications such as drug discovery, production, and diagnostic screening. The other factors supporting the market’s growth are, rise in demand in cell culture projects, increasing government investments, growing number of mergers and strategic acquisitions, and technological advancements.\u003c\/p\u003e \n\n\u003cp\u003eRising Demand for Recombinant Cell Culture Supplements\u003c\/p\u003e \n\n\u003cp\u003eOver the past few years, there is a surge in demand for recombinant cell culture supplements as cell culture is an essential part of manufacturing and drug research and development. It plays a vital role in enriching cell viability, providing a healthy culture, and customizing the cell culture in accordance with the requirements of the individual. Owing to various kinds of diseases such as infectious, communicable, non-infectious, chronic and others present across the world, the demand for variety of recombinant vaccines, advanced therapies, proteins, and biopharmaceuticals are rising. Furthermore, rising demand for stem cell therapy for clinical treatment of various diseases and growing patients acceptance are bolstering the growth of the market.\u003c\/p\u003e \n\n\u003cp\u003eIncreasing Investments and R\u0026amp;D Activities\u003c\/p\u003e\n\n\u003cp\u003eHuge investments are invested on various R\u0026amp;D activities by governments and key market players, which strengthens the market growth. Manufactures are focusing on expanding the production, which is driving the growth of the market. For instance, in 2019, FUJIFILM Irvine Scientific announced the construction of new cell culture production bases in Europe and Netherlands. The increasing investments and manufacturing capacity expansion is fueling the growth of the market. Recombinant cell culture supplements are a crucial part of cancer research. Therefore, rising R\u0026amp;D activities in oncology and stem cell research is propelling the growth of the market. Pharmaceutical and biotechnology companies majorly focus on research and development (R\u0026amp;D) activities in the life science sector, which is augmenting the growth of the market. In the U.S, the revenue in Scientific Research \u0026amp; Development is anticipated to amount to USD 8.11 billion by the end of 2022.\u003c\/p\u003e\n\n\u003cp\u003eIncreasing Demand for Animal-Free Recombinant Cell Culture Supplements\u003c\/p\u003e \n\n\u003cp\u003eOwing to the rising demand of animal free products, manufacturers are focusing on animal-free recombinant cell culture supplements. The surge in demand is attributed to the various factors such as they are manufactured using all human production system, it eliminates the risk of contamination, and no animals derived cells are used. Animal free recombinant cell culture supplements are free of any animal elements such as endotoxin, serum, and others. Moreover, animal-free growth factors \u0026amp; recombinant cell culture supplements are obtaining high acceptance in various research applications, which is fostering the growth of the market, globally.\u003c\/p\u003e \n\n\u003cp\u003eMarket Segmentation\u003c\/p\u003e\n\n\u003cp\u003eThe global recombinant cell culture supplements market is segmented into product, application, expression system, end user and company. Based on product, the market is divided into recombinant albumin, recombinant insulin, recombinant epidermal growth factors, recombinant transferrin, recombinant trypsin, and others. Based on application, the market is divided into regenerative medicine and bio-production. Based on regenerative medicine, the market is further segmented into stem cell therapies, cell therapies, and gene therapies. Based on bio-production, the market is further divides into monoclonal antibodies, recombinant proteins, hormones, vaccines, and others. Based on expression system, the market is divided into mammalian expression system, E.coli expression system, yeast expression system, and others. Based on end user, the market is divided into academic \u0026amp; research institutions, biotechnology \u0026amp; pharmaceutical companies, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising demand for animal free recombinant cell culture supplements in the country.\u003c\/p\u003e \n\n\u003cp\u003eMarket Players\u003c\/p\u003e\n\n\u003cp\u003eAbcam plc., Corning Incorporated, BBI Solutions OEM Limited, FUJIFILM Irvine Scientific, Inc., Gemini Bioproducts, LLC, HiMedia Laboratories, LLC, Kingfisher Biotech, Inc., Lonza Group AG, Merck KGaA, and Novus Biologicals, LLC are some of the leading companies operating in the market.\u003c\/p\u003e\n\n\u003cp\u003eReport Scope:\u003c\/p\u003e\n\n\u003cp\u003eIn this report, global recombinant cell culture supplements market has been segmented into following categories, in addition to the industry trends which have also been detailed below:Recombinant Cell Culture Supplements Market, By Product:Recombinant AlbuminRecombinant InsulinRecombinant Epidermal Growth FactorsRecombinant TransferrinRecombinant TrypsinOthers    Recombinant Cell Culture Supplements Market, By ApplicationRegenerative MedicineStem Cell TherapiesCell TherapiesGene TherapiesBio-ProductionMonoclonal AntibodiesRecombinant ProteinsHormonesVaccinesOthersRecombinant Cell Culture Supplements Market, By Expression System:Mammalian Expression SystemE. coli Expression SystemYeast Expression SystemOthersRecombinant Cell Culture Supplements Market, By End User:Academic \u0026amp; Research InstitutionsBiotechnology \u0026amp; Pharmaceutical CompaniesOthersRecombinant Cell Culture Supplements Market, By Region:North AmericaUnited StatesCanadaMexicoAsia-PacificChinaIndiaJapanAustraliaSouth KoreaEurope \u0026amp; CIS GermanyFranceUnited KingdomSpainItalySouth AmericaBrazilArgentinaColombiaMiddle East \u0026amp; AfricaSouth AfricaSaudi ArabiaUAECompetitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eCompany Profiles: Detailed analysis of the major companies present in Global Recombinant Cell Culture Supplements Market\u003c\/p\u003e \n\n\u003cp\u003eCompany InformationDetailed analysis and profiling of additional market players (up to five).Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.  Single User license will be delivered in PDF format without printing rights\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 119 Pages \/ MCW16225220","offer_id":47639645061426,"sku":null,"price":5880.0,"currency_code":"USD","in_stock":true}]},{"product_id":"laboratory-mixers-market-by-product-shaker-rocker-roller-magnetic-stirrer-vortex-mixer-accessories-platform-digital-operability-linear-orbital-end-user-research-labs-pharma-biotech-cros-environmental-testing-global-forecasts-to-2027","title":"Laboratory Mixers Market by product (Shaker (Rocker, Roller) Magnetic Stirrer, Vortex Mixer, Accessories), Platform (Digital), Operability (Linear, Orbital), End User (Research Labs, Pharma-Biotech, CROs, Environmental Testing) - Global Forecasts to 2027","description":"\u003cp\u003eLaboratory Mixers Market by product (Shaker (Rocker, Roller) Magnetic Stirrer, Vortex Mixer, Accessories), Platform (Digital), Operability (Linear, Orbital), End User (Research Labs, Pharma-Biotech, CROs, Environmental Testing) - Global Forecasts to 2027\u003c\/p\u003e\n\n\u003cp\u003eFrom the year 2022 to 2027, the global laboratory mixer market is projected to reach USD 2.4 billion by 2027 from USD 2.0 billion in 2022, at a CAGR of 3.5%. Factors such as technological advancements and ongoing pharmaceutical and biotechnology industry research activities are driving the market growth.\u003c\/p\u003e \n\n\u003cp\u003e“The shakers laboratory segment to hold the largest share of the market in 2022”\u003c\/p\u003e\n\n\u003cp\u003eThe shakers market is further segmented into orbital shakers, rockers, rollers\/rotators, and other shakers. The shakers segment accounted for the largest market share in 2021. In 2021, the shaker goods sector accounted for the biggest market share for laboratory mixers. The expanding technical advancements and expanded pharmaceutical and biotechnology sector research activities can be a reason for the huge share of this market.\u003c\/p\u003e\n\n\u003cp\u003e“The digital devices segment is projected to register the highest CAGR during the forecast period”\u003c\/p\u003e\n\n\u003cp\u003eBased on platform, the laboratory mixer market is segmented into digital and analog devices. By platform, the analog devices segment is anticipated to hold a significant market share for laboratory mixers by 2027. The availability of preprogramming options and the far easier and more efficient work function of digital devices can be linked to the significant market share.\u003c\/p\u003e\n\n\u003cp\u003e“The orbital movement segment is projected to register the highest CAGR during the forecast period”\u003c\/p\u003e\n\n\u003cp\u003eBased on Mode of Operation, the laboratory mixer market is segmented into gyratory, linear, rocking\/tilting, and orbital movement mixers. Orbital movement laboratory mixers are predicted to make the highest percentage of all laboratory mixers in 2022. These mixers have a sizable market share thanks to features including as compact, space-saving designs, digital speed controls, built-in timers, and optional tier systems for increased capacity.\u003c\/p\u003e\n\n\u003cp\u003e“The research laboratories \u0026amp; institutes segment is projected to register the highest CAGR during the forecast period”\u003c\/p\u003e\n\n\u003cp\u003eThe research laboratories \u0026amp; institutes, pharmaceutical \u0026amp; biotechnology firms, clinical research organisations, environmental testing laboratories, food testing laboratories, diagnostic \u0026amp; pathology laboratories, and other end users are the market segments for laboratory mixers based on end user. By end users, the research laboratories \u0026amp; institutions segment is anticipated to have the highest market share for laboratory mixers in 2022. The significant component of this market may be attributed to the expansion of research facilities in developing countries as well as the growth of financing for life sciences research from governmental and non-profit organizations.\u003c\/p\u003e\n\n\u003cp\u003e“The market in the Asia Pacific region is expected to hold significant market share for laboratory mixers in 2022.”\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific is expected to hold a significant market share for laboratory mixers in 2022. The significant representation of this regional category is due to the rising demand for biopharmaceuticals and rising R\u0026amp;D expenditure by biopharmaceutical companies. The large share of the regional market can primarily be attributed to the high adoption rate of novel technologies and the increasing number of life science research studies.\u003c\/p\u003e\n\n\u003cp\u003eA breakdown of the primary participants referred to for this report is provided below:\u003c\/p\u003e\n\n\u003cp\u003eBy Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%\u003c\/p\u003e\n\n\u003cp\u003eBy Designation: C-level–10%, Director-level–14%, and Others–76%\u003c\/p\u003e\n\n\u003cp\u003eBy Region: North America–40%, Europe–32%, Asia Pacific–20%, Latin America–5%, and the Middle East \u0026amp; Africa–3%\u003c\/p\u003e\n\n\u003cp\u003eThe prominent players in the laboratory mixer market are Thermo Fisher Scientific, Inc. (US), Eppendorf AG (Germany), IKA Works (Germany), Cole-Parmer (Germany), Avantor, Inc. (US), Remi Group (India), Bio-Rd Laboratories, Inc. (US), Corning, Inc. (US), Scientific Industries, Inc (US), Silverson Machines (UK), and Sarstedt (Germany) among others.\u003c\/p\u003e\n\n\u003cp\u003eResearch Coverage\u003c\/p\u003e\n\n\u003cp\u003eThis report studies the laboratory mixer market based on product, platform, Mode of Operation, end user and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).\u003c\/p\u003e\n\n\u003cp\u003eReasons to Buy the Report\u003c\/p\u003e \n\n\u003cp\u003eThe report will enable established firms as well as entrants\/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.\u003c\/p\u003e\n\n\u003cp\u003eThis report provides insights on the following pointers:\u003c\/p\u003e\n\n\u003cp\u003eMarket Penetration: Comprehensive information on the product portfolios offered by the top players in the laboratory mixer market\u003c\/p\u003e\n\n\u003cp\u003eProduct Development\/Innovation: Detailed insights on the upcoming trends, R\u0026amp;D activities, and product launches in the laboratory mixer market\u003c\/p\u003e\n\n\u003cp\u003eMarket Development: Comprehensive information on lucrative emerging regions\u003c\/p\u003e\n\n\u003cp\u003eMarket Diversification: Exhaustive information about new products, growing geographies, and recent developments in the laboratory mixer market\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 210 Pages \/ MCW16225222","offer_id":47639645159730,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}]},{"product_id":"the-world-market-for-liquid-biopsy-2023","title":"The World Market for Liquid Biopsy, 2023","description":"\u003cp\u003eThe World Market for Liquid Biopsy, 2023\u003c\/p\u003e\n\n\u003cp\u003eDramatic changes have occurred in the liquid biopsy market, necessitating a resource to provide perspective on the market opportunity. This new report from Kalorama assesses the Liquid Biopsy Market now and in 2027.  The report can be useful for business planning, market share assessment, competitive research, and due diligence for mergers and acquisitions and other partnerships.\u003c\/p\u003e \n\n\u003cp\u003eLiquid biopsy is gaining acceptance each year.  Even through the COVID-19 pandemic, announcements of new liquid biopsy products were made and studies conducted to assess the capability of these tests in clinical diagnostics uses.  While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care.\u003c\/p\u003e\n\n\u003cp\u003eThis report, The World Liquid Biopsy Market, 2023, from Kalorama Information, contains up-to-date information and useful data points for business planning:\u003c\/p\u003e\n\n\u003cp\u003eThe Market for Liquid Biopsy by RegionNorth AmericaEuropeAsiaRest of WorldThe Market for CTC-based Liquid BiopsyGrowth to 2027The Market for ctDNA-based Liquid BiopsyGrowth to 2027The Market for EV and Exosome-based Liquid BiopsyGrowth to 2027The Market for Multi-Analyte-based Liquid BiopsyGrowth to 2027The Market for Other Analytes Liquid BiopsyGrowth to 2027Liquid Biopsy Market by Type of Cancer BreastLungColorectalOvarianProstatePan-CancerOther CancerR\u0026amp;D: Selected ctDNA-based Liquid Biopsy Tests in Development\u003c\/p\u003e\n\n\u003cp\u003eOn the Market: Selected Market-Available CTC-based Liquid Biopsy Tests, 2021\u003c\/p\u003e\n\n\u003cp\u003eOn the Market: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021\u003c\/p\u003e\n\n\u003cp\u003eLiquid biopsy testing has many potential applications in aspects of clinical oncology, including:Early detection and diagnosis \/ screeningAlternative testing method when tissue biopsy is difficult\/impossible, or when the primary site of metastatic disease is unknownTherapy personalization and monitoring – by molecular characterization of a patient’s disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance ariseDisease monitoring – to observe disease progression, tumor evolution, residual disease, and early detection of recurrenceThese applications, increasing acceptance, the use of liquid biopsy in combination with other technologies.   This report contains market assessments for these application categories.\u003c\/p\u003e  \n\n\u003cp\u003eIn addition, the report profiles key companies in the market, including: Adaptive Biotechnologies\t   Agena Bioscience, Inc.\t    Angle, PLC\t    Aspira Women’s Health\t    Biocartis Group Nv\t    Biocept, Inc.\t   Biodesix\t    Cellmax Life\t   Circulogene\t   Diacarta, Inc.\t   Epic Sciences\t   Epigenomics AG\t    Exact Sciences\t   Exosome Diagnostics, Inc.\t   Foundation Medicine, Inc. (Roche)\t   Freenome, Inc.\t   Gilupi Gmbh\t   Grail (Illumina)\t   Guardant Health, Inc.\t    Hologic\t   Lunglife AI (Formerly Cynvenio Biosystems)\t   Menarini-Silicon Biosystems, SPA\t   Myriad Genetics, Inc.\t    Natera, Inc.\t     Neogenomics Laboratories, Inc.\t    Oncocyte Corporation\t     Oncodna S.A.\t    Personal Genome Diagnostics\t   Qiagen N.V.\t   Cell-Free DNA Technologies\t   Ctc Technologies\t   Exosome And Mirna Technologies\t   Resolution Biosciences (Agilent)\t   Roche Diagnostics\t   Sysmex-Inostics, Inc.\t    Tempus\t   \t    Volitionrx\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 211 Pages \/ MCW16225223","offer_id":47639645192498,"sku":null,"price":7200.0,"currency_code":"USD","in_stock":true}]},{"product_id":"dna-synthesis-market-size-share-trends-analysis-report-by-service-type-gene-synthesis-oligonucleotide-synthesis-by-application-research-and-development-therapeutics-by-end-use-by-region-and-segment-forecasts-2023-2030","title":"DNA Synthesis Market Size, Share \u0026 Trends Analysis Report By Service Type (Gene Synthesis, Oligonucleotide Synthesis), By Application (Research And Development, Therapeutics), By End-use, By Region, And Segment Forecasts, 2023 - 2030","description":"\u003cp\u003eDNA Synthesis Market Size, Share \u0026amp; Trends Analysis Report By Service Type (Gene Synthesis, Oligonucleotide Synthesis), By Application (Research And Development, Therapeutics), By End-use, By Region, And Segment Forecasts, 2023 - 2030\u003c\/p\u003e\n\n\u003cp\u003eDNA Synthesis Market Growth \u0026amp; Trends\u003c\/p\u003e\n\n\u003cp\u003eThe global DNA synthesis market size is expected to reach USD 12.76 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 19.63% from 2023 to 2030 owing to the rising focus on personalized genome sequencing that aids determine patient care. In addition, DNA synthesis has the capability to revolutionize biological research activities for widespread applications in disease monitoring, drug discovery, and pharmacogenomics.\u003c\/p\u003e  \n\n\u003cp\u003eThe COVID-19 pandemic positively impacted the adoption of mRNA-based vaccines for the treatment of COVID-19 infection and different types of cancers. The utility of mRNA boosts the demand for synthetic DNA. Furthermore, a major focus of Covid-19 research is DNA synthesis. Synthetic DNA is used in all PCR analyses. Patients need to use a DNA primer to identify any genomic DNA that may be present in the sample.\u003c\/p\u003e\n\n\u003cp\u003eProgress in enzyme engineering is boosting the development of different approaches for enzymatic DNA synthesis. It involves the use of enzymes to chain the nucleic acids together in the required sequence and requires further optimization for its widespread applications. Many market players are striving to devise novel technologies for efficient enzymatic production of nucleotides in the lowest turnaround time. For instance, in May 2021, Ribbon Biolabs set a mission of synthesizing DNA sequences of 10,000 base pairs and accomplished a milestone of a 20,000 base pair DNA molecule by December 2021.\u003c\/p\u003e\n\n\u003cp\u003eGene synthesis has a broad spectrum of applications in targeted mutagenesis with a specific sequence of nucleotides along with the regulation of a desired phenotypic expression. It forms the primary basis of genetic engineering, which has significantly leveraged the scope and quality of antibodies by the development of antibody fragments with high specificity.\u003c\/p\u003e\n\n\u003cp\u003eOligonucleotide synthesis is the laboratory-based production of relatively short fragments of nucleic acids in a required definitive sequence. The technique is an extremely robust practice that facilitates rapid and inexpensive access to the custom-made oligonucleotides of the desired sequence. Companies have devised their oligonucleotide libraries to aid their nucleotide synthesis processes. For instance, in July 2022, Ribbon Biolabs declared that it secured a U.S. Patent that comprises Ribbon Biolabs’ method for the synthesis of a nucleotide molecule using a diverse library of oligonucleotides. The approach comprises a pre-built library of oligonucleotides for efficient access.\u003c\/p\u003e\n\n\u003cp\u003eDNA Synthesis Market Report Highlights By service type, oligonucleotide synthesis held the largest share in 2022 due to the rising demand for synthetic nucleotide strands for their utility in research studies By application, the research and development segment dominated the market in 2022 due to the demand for synthetic nucleotides for a wide spectrum of applications in bioengineering and mRNA-based vaccines By end-use, the biopharmaceutical companies segment is expected to grow rapidly over the forecast period owing to a rise in the applications of synthetic nucleotides to leverage bio-molecular therapies. The rise in the demand for novel drug discovery also positively impacts the growth of this segment North America dominated the global market in 2022 owing to emerging advancements in life sciences research and rapidly growing demand for novel bio-therapeutics in the region Asia Pacific is expected to grow considerably due to a rise in the demand for biological research and novel drug discovery. Moreover, key market players are working towards entering the Asia Pacific market with their modern nucleotide production expertisePlease note The report will be delivered in 2-3 business days upon order notification.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 150 Pages \/ MCW16225226","offer_id":47639645225266,"sku":null,"price":7140.0,"currency_code":"USD","in_stock":true}]},{"product_id":"south-central-america-nerve-repair-regeneration-market-forecast-to-2028-covid-19-impact-and-regional-analysis-by-product-neurostimulation-neuromodulation-devices-internal-neurostimulation-devices-spinal-cord-stimulation-deep-brain-stimulatio","title":"South \u0026 Central America Nerve Repair \u0026 Regeneration Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Neurostimulation \u0026 Neuromodulation Devices {Internal Neurostimulation Devices [Spinal Cord Stimulation, Deep Brain Stimulatio","description":"\u003cp\u003eSouth \u0026amp; Central America Nerve Repair \u0026amp; Regeneration Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Neurostimulation \u0026amp; Neuromodulation Devices {Internal Neurostimulation Devices [Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, and Gastric Electrical Stimulation] and External Neurostimulation Devices [Transcutaneous Electrical Nerve Stimulation Devices, Transcranial Magnetic Stimulation Devices, Respiratory Electrical Stimulation Devices]} and Biomaterials), and Application (Neurostimulation \u0026amp; Neuromodulation Applications {Internal neurostimulation \u0026amp; neuromodulation, and External neurostimulation \u0026amp; neuromodulation}, and Nerve Repair \u0026amp; Regeneration Applications {Direct Nerve Repair\/Neurorrhaphy [Epineural Repair, Perineural Repair, and Group Fascicular Repair], Nerve Grafting [Autografts, Allografts, and Xenografts], and Stem cell therapy})\u003c\/p\u003e\n\n\u003cp\u003eThe nerve repair \u0026amp; regeneration market in South \u0026amp; Central America is expected to grow from US$ 343.17 million in 2022 to US$ 583.16 million by 2028; it is estimated to grow at a CAGR of 9.2% from 2022 to 2028.\u003c\/p\u003e\n\n\u003cp\u003eAdvancements in Stem Cell Therapy for Nerve Repair \u0026amp; Regeneration to Bolster Nerve Repair \u0026amp; Regeneration Market Growth in South \u0026amp; Central America during Forecast Period\u003c\/p\u003e\n\n\u003cp\u003eCell-based therapy improves the functional clinical outcome after nerve injury. In recent years, the technology in constructing tissue-engineered nerve grafts has seen significant progress. Incorporating stem cells such as embryonic stem cells, neural stem cells, bone marrow mesenchymal stem cells, adipose stem cells, skin-derived precursor stem cells, and induced pluripotent stem cells have enhanced the therapeutic effects of tissue-engineered nerve grafts. The high effectiveness of stem cells enlightens the optimistic future of the large-scale clinical use of stem cells. Incorporating stem cells as seed cells into the biomaterial-based scaffolds increases the effectiveness of tissue-engineered nerve grafts and boosts the regenerative process. Numerous stem cells such as neural stem cells, embryonic stem cells, adipose stem cells, skin-derived precursor stem cells, induced pluripotent stem cells, and bone marrow mesenchymal stem cells have been used in neural tissue engineering. Cell-based therapy improves neural regeneration after peripheral nerve injuries (PNIs); it has introduced a new perspective to regenerative medicine. The main mechanisms that highlight the valuable effects of stem cells on neural regeneration are augmenting axonal regeneration, remyelination, and muscle mass preservation. Thus, the advancements in stem cell therapy for nerve repair \u0026amp; regeneration are likely to offer growth opportunities for the nerve repair \u0026amp; regeneration market players operating in South \u0026amp; Central America.\u003c\/p\u003e\n\n\u003cp\u003eMarket Overview\u003c\/p\u003e\n\n\u003cp\u003eThe South \u0026amp; Central America nerve repair \u0026amp; regeneration market is segmented into Brazil, Argentina, and the Rest of South \u0026amp; Central America. Brazil accounted for a significant share of the market in 2021, followed by Argentina. The nerve repair \u0026amp; regeneration market in South \u0026amp; Central America is expected to grow due to the rising cases of Parkinson’s and Alzheimer’s diseases, a surge in the geriatric population, and a rising number of developments by various organizations in countries across the region.\u003c\/p\u003e\n\n\u003cp\u003eSouth \u0026amp; Central America Nerve Repair \u0026amp; Regeneration Market Revenue and Forecast to 2028 (US$ Million)\u003c\/p\u003e\n\n\u003cp\u003eSouth \u0026amp; Central America Nerve Repair \u0026amp; Regeneration Market Segmentation\u003c\/p\u003e\n\n\u003cp\u003eThe South \u0026amp; Central America nerve repair \u0026amp; regeneration market is bifurcated on the basis of product and application.\u003c\/p\u003e\n\n\u003cp\u003eBased on product, the South \u0026amp; Central America nerve repair \u0026amp; regeneration market is segmented into neurostimulation and neuromodulation devices and biomaterials. The neurostimulation and neuromodulation devices segment accounted for a larger market share in 2022. Based on application, the South \u0026amp; Central America nerve repair \u0026amp; regeneration market is bifurcated into neurostimulation \u0026amp; neuromodulation applications and nerve repair \u0026amp; regeneration applications. The nerve repair \u0026amp; regeneration applications segment held a larger market share in 2022. Based on country, the South \u0026amp; Central America nerve repair \u0026amp; regeneration market is segmented into Brazil, Argentina, and the Rest of South \u0026amp; Central America. Further, Brazil dominated the market in 2022. Axogen Corporation, Boston Scientific Corporation, Integra LifeSciences, Medtronic, Abbott Laboratories, Stryker Corporation, Neuronetics, LivaNova PLC, Baxter, and Polyganics BV are the leading companies operating in the nerve repair \u0026amp; regeneration market in South \u0026amp; Central America.\u003c\/p\u003e \n\n\u003cp\u003eReasons to Buy\u003c\/p\u003e\n\n\u003cp\u003eSave and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe laboratory information system (LIS) market\u003cbr\u003e\nHighlights key business priorities in order to assist companies to realign their business strategies\u003cbr\u003e\nThe key findings and recommendations highlight crucial progressive industry trends in the Europe laboratory information system (LIS) market, thereby allowing players across the value chain to develop effective long-term strategies\u003cbr\u003e\nDevelop\/modify business expansion plans by using substantial growth offering developed and emerging markets\u003cbr\u003e\nScrutinize in-depth Europe market trends and outlook coupled with the factors driving the laboratory information system (LIS) market, as well as those hindering it\u003cbr\u003e\nEnhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 181 Pages \/ MCW16225229","offer_id":47639645258034,"sku":null,"price":3600.0,"currency_code":"USD","in_stock":true}]},{"product_id":"australia-regenerative-medicine-market-by-type-cell-therapy-gene-modification-tissue-engineering-others-by-application-bone-graft-substitutes-osteoarticular-diseases-dermatology-cardiovascular-diseases-others-by-end-user-academic-v-s-commer","title":"Australia Regenerative Medicine Market, By Type (Cell Therapy, Gene Modification, Tissue Engineering, Others), By Application (Bone Graft Substitutes, Osteoarticular Diseases, Dermatology, Cardiovascular Diseases, Others), By End User (Academic v\/s Commer","description":"\u003cp\u003eAustralia Regenerative Medicine Market, By Type (Cell Therapy, Gene Modification, Tissue Engineering, Others), By Application (Bone Graft Substitutes, Osteoarticular Diseases, Dermatology, Cardiovascular Diseases, Others), By End User (Academic v\/s Commercial), By Region, Competition Forecast \u0026amp; Opportunities, 2027\u003c\/p\u003e\n\n\u003cp\u003eAustralia regenerative medicine market is anticipated to register growth with an impressive CAGR in the forecast period, 2023-2027, on the account of advancing medicines and growing expenses over advancement of the pharmaceutical products. Increasing evolution in pharmaceutical sector to design advanced drugs, and various other methods to better the existing treatment along with finding curative medicines for the unknown diseases, are anticipated to drive the growth of the Australia regenerative medicine market in the upcoming five years.\u003c\/p\u003e \n\n\u003cp\u003eRegenerative medicines are a class of drugs that help in the process of replacing, engineering or regenerating human cells or animal cells. The drugs help in restoring the normal functioning of the cells. To restore the functions, regenerative medicines stimulate the body’s own repair system to heal the irreparable tissues and organs. The regenerative medicine has potential that can be used for artificial generation of tissues and organs in laboratory that can later be implanted safely in case the body is unable to heal in certain conditions. Various biomedical techniques and clinical therapies are involved with regenerative medicine like cell therapy, immunomodulation therapy, and tissue engineering.\u003c\/p\u003e \n\n\u003cp\u003eBio-medical Advances Drive Market Growth\u003c\/p\u003e \n\n\u003cp\u003eRegenerative medicines are advanced pharmaceuticals that undergo consistent research and product development such that better healthcare and patient care services are provided. Biomedical methods like cell therapy, immunomodulation therapy, and tissue engineering are increasing with the advancement in medicine and driving the growth of the Australia regenerative medicine market in the upcoming five years.\u003c\/p\u003e \n\n\u003cp\u003eMoreover, increasing investment in these biomedical procedures and their research also aid the growth of the Australia regenerative medicine market in the next five years. Australian Government Department of Industry, Innovation and Science have funded Cooperative Research Center Program and amount of USD60 million through CTM CRC to develop integrated cost effective, and accessible cell therapies that have further revolutionized regenerative medicine.\u003c\/p\u003e \n\n\u003cp\u003eChronic Diseases Surges Demands For Regenerative Medicine\u003c\/p\u003e\n\n\u003cp\u003eIncrease in the instances of various neurological diseases and cancer, that are chronic and require advanced medicinal approach further support the growth of the Australia regenerative medicine market in the upcoming five years. Alzheimer’s disease, Parkinson’s disease, cardiovascular disorders (CVDs), osteoporosis and spinal cord injuries are being treated with regenerative medicine and thus supporting market growth.\u003c\/p\u003e \n\n\u003cp\u003eAlso, rising geriatric population in the country that is prone to diseases like musculoskeletal, oncological, dermatological and cardiological disorders are aiding the growth of the Australia regenerative medicine market in the next five years.\u003c\/p\u003e \n\n\u003cp\u003eMarket Segmentation\u003c\/p\u003e\n\n\u003cp\u003eThe Australia regenerative medicine market is segmented by type, application, end user, competitional landscape, and regional distribution. Based on type, the market is further differentiated into cell therapy, gene modification, tissue engineering, and others. On the basis of application, the market segment is bifurcated into bone graft substitutes, osteoarticular diseases, dermatology, cardiovascular diseases, and others. Market segments on the basis of end user, is further divided between academic and commercial end users. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among Northern territory region, New South Wales region, Victoria region, Western Australia region, Queensland region, Tasmania region, and the South Australia region.\u003c\/p\u003e \n\n\u003cp\u003eCompany Profile\u003c\/p\u003e\n\n\u003cp\u003eCell Therapies Pty Ltd., Hudson Institute, Orthocell Ltd., Q-Gen Cell Therapeutics, Westmead Viral Vector Facility, Sydney Cell \u0026amp; Gene Therapies, Auspep Holdings Ltd., Luina Bio Pty Ltd., among others is a partial list of major market players of the companies responsible for the growth of Australia regenerative medicine market.\u003c\/p\u003e \n\n\u003cp\u003eReport Scope:\u003c\/p\u003e\n\n\u003cp\u003eIn this report, Australia regenerative medicine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:Australia Regenerative Medicine Market, By Type:Cell TherapyGene ModificationTissue EngineeringOthersAustralia Regenerative Medicine Market, By Application:Bone Graft SubstitutesOsteoarticular DiseasesDermatologyCardiovascular DiseasesOthersAustralia Regenerative Medicine Market, By End User:AcademicCommercialAustralia Regenerative Medicine Market, By Region:Northern Territory RegionNew South Wales RegionVictoria RegionWestern Australia RegionQueensland RegionTasmania RegionSouth Australia RegionCompetitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eCompany Profiles: Detailed analysis of the major companies present in Australia regenerative medicine market.\u003c\/p\u003e\n\n\u003cp\u003eCompany InformationDetailed analysis and profiling of additional market players (up to five).Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.  Single User license will be delivered in PDF format without printing rights\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 72 Pages \/ MCW16225231","offer_id":47639645290802,"sku":null,"price":4200.0,"currency_code":"USD","in_stock":true}]},{"product_id":"asia-pacific-nerve-repair-regeneration-market-forecast-to-2028-covid-19-impact-and-regional-analysis-by-product-neurostimulation-neuromodulation-devices-internal-neurostimulation-devices-spinal-cord-stimulation-deep-brain-stimulation-vagus-ne","title":"Asia Pacific Nerve Repair \u0026 Regeneration Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Neurostimulation \u0026 Neuromodulation Devices {Internal Neurostimulation Devices [Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Ne","description":"\u003cp\u003eAsia Pacific Nerve Repair \u0026amp; Regeneration Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Neurostimulation \u0026amp; Neuromodulation Devices {Internal Neurostimulation Devices [Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, and Gastric Electrical Stimulation] and External Neurostimulation Devices [Transcutaneous Electrical Nerve Stimulation Devices, Transcranial Magnetic Stimulation Devices, Respiratory Electrical Stimulation Devices]} and Biomaterials), and Application (Neurostimulation \u0026amp; Neuromodulation Applications {Internal neurostimulation \u0026amp; neuromodulation, and External neurostimulation \u0026amp; neuromodulation}, and Nerve Repair \u0026amp; Regeneration Applications {Direct Nerve Repair\/Neurorrhaphy [Epineural Repair, Perineural Repair, and Group Fascicular Repair], Nerve Grafting [Autografts, Allografts, and Xenografts], and Stem cell therapy})\u003c\/p\u003e\n\n\u003cp\u003eThe nerve repair \u0026amp; regeneration market in Asia Pacific is expected to grow from US$ 1,266.83 million in 2022 to US$ 2,263.79 million by 2028; it is estimated to grow at a CAGR of 10.2% from 2022 to 2028.\u003c\/p\u003e\n\n\u003cp\u003eProduct Launches and Approvals to Provide Opportunities to Asia Pacific Nerve Repair \u0026amp; Regeneration Market Players\u003c\/p\u003e\n\n\u003cp\u003eSeveral nerve repair and regeneration market players are launching various products such as internal neurostimulation devices, external neurostimulation devices, nerve conduits, nerve wraps, nerve connectors, and other biomaterials to enhance the treatment output for nerve repair and regeneration. They are also offering products such as neuromodulators, neurostimulation, and biomaterial devices. These devices are utilized for the treatment of neurodegenerative or traumatic disorders such as Parkinson's disease, Alzheimer's disease, sclerosis, multiple system atrophy, and amyotrophic lateral sclerosis. For instance, in July 2022, Checkpoint Surgical launched the Checkpoint Edge Nerve Cutting Kit, expanding the intraoperative nerve care portfolio of the company. The Checkpoint Edge Nerve Cutting Kit is the first offering in the planned portfolio of nerve-specific instruments by Checkpoint Surgical, with further expansion planned in the future. Further, in March 2022, Integra LifeSciences Holding Corporation launched the NeuraGen 3D Nerve Guide Matrix, which is a resorbable implant for the repair of peripheral nerve discontinuities. NeuraGen 3D is a nerve repair product specifically engineered to develop an optimized environment that enables a greater complete functional recovery following mid-gap nerve repair in comparison to hollow nerve conduits. In August 2021, Checkpoint Surgical, Inc. launched the NeuroShield Chitosan Nerve Wrap to expand its intraoperative nerve care product line. The NeuroShield Wrap marks the company's first product in a planned line of chitosan-based biological implants to support nerve healing. The product complements the existing product portfolio of Checkpoint Surgical, including the company’s flagship Checkpoint Nerve Stimulator\/Locator, the leading nerve stimulation device for intraoperative nerve protection and repair. Thus, the active participation of market players in product innovation and development and the increase in approvals of products are likely to fuel the market growth in the coming years.\u003c\/p\u003e\n\n\u003cp\u003eMarket Overview\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific is the fastest-growing regional market for nerve repair \u0026amp; regeneration. The Asia Pacific nerve repair \u0026amp; regeneration market is segmented into China, India, Japan, South Korea, Australia, and the Rest of APAC. Japan has accounted for a 30.8% share of the Asia Pacific nerve repair \u0026amp; regeneration market in 2021, owing to the growing incidence of nerve injuries, high prevalence of neurological disorders, rising medical tourism, and growing government support for research on neurological disorders in the country. These factors are expected to propel the Asia Pacific nerve repair \u0026amp; regeneration market in the coming years.\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific Nerve Repair \u0026amp; Regeneration Market Revenue and Forecast to 2028 (US$ Million)\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific Nerve Repair \u0026amp; Regeneration Market Segmentation\u003c\/p\u003e\n\n\u003cp\u003eThe Asia Pacific nerve repair \u0026amp; regeneration market is segmented into product and application.\u003c\/p\u003e\n\n\u003cp\u003eBased on simulator type, the market is segmented into neurostimulation and neuromodulation devices and biomaterials. The neurostimulation and neuromodulation devices segment registered the largest market share in 2022. Based on application, the market is categorized into neurostimulation \u0026amp; neuromodulation applications and nerve repair \u0026amp; regeneration applications. The nerve repair \u0026amp; regeneration applications segment held the largest market share in 2022. Based on country, the Asia Pacific nerve repair \u0026amp; regeneration market is segmented into Australia, China, India, Japan, South Korea, and the Rest of APAC. Japan dominated the market in 2022. Axogen Corporation, Boston Scientific Corporation, Integra LifeSciences, Medtronic, Abbott Laboratories, Stryker Corporation, Neuronetics, LivaNova PLC, Baxter, and Polyganics BV are the leading companies operating in the nerve repair \u0026amp; regeneration market in Asia Pacific.\u003c\/p\u003e \n\n\u003cp\u003eReasons to Buy\u003c\/p\u003e\n\n\u003cp\u003eSave and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe airway management devices market.\u003cbr\u003e\nHighlights key business priorities in order to assist companies to realign their business strategies\u003cbr\u003e\nThe key findings and recommendations highlight crucial progressive industry trends in the Europe airway management devices market, thereby allowing players across the value chain to develop effective long-term strategies\u003cbr\u003e\nDevelop\/modify business expansion plans by using substantial growth offering developed and emerging markets\u003cbr\u003e\nScrutinize in-depth Europe market trends and outlook coupled with the factors driving the airway management devices market, as well as those hindering it\u003cbr\u003e\nEnhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 204 Pages \/ MCW16225233","offer_id":47639645323570,"sku":null,"price":3600.0,"currency_code":"USD","in_stock":true}]},{"product_id":"meningitis-diagnostic-testing-market-share-size-trends-industry-analysis-report-by-test-type-latex-agglutination-test-lateral-flow-assay-pcr-assay-elisa-test-culture-test-by-end-use-by-region-segment-forecast-2023-2032","title":"Meningitis Diagnostic Testing Market Share, Size, Trends, Industry Analysis Report, By Test Type (Latex Agglutination Test, Lateral Flow Assay, PCR Assay, ELISA Test, Culture Test); By End Use; By Region; Segment Forecast, 2023 - 2032","description":"\u003cp\u003eMeningitis Diagnostic Testing Market Share, Size, Trends, Industry Analysis Report, By Test Type (Latex Agglutination Test, Lateral Flow Assay, PCR Assay, ELISA Test, Culture Test); By End Use; By Region; Segment Forecast, 2023 - 2032\u003c\/p\u003e\n\n\u003cp\u003eThe global meningitis diagnostic testing market size is expected to reach USD 162.62 million by 2032, according to a new study by Polaris Market Research. The report “Meningitis Diagnostic Testing Market Share, Size, Trends, Industry Analysis Report, By Test Type (Latex Agglutination Test, Lateral Flow Assay, PCR Assay, ELISA Test, Culture Test); By End-use; By Region; Segment Forecast, 2023 – 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.\u003c\/p\u003e\n\n\u003cp\u003eKey factors influencing the market growth rise in the cases of meningitis in developed economies, upsurge in diagnostic centers, and patient’s awareness regarding the severity of the disease. Moreover, emerging nations with viable options for treatment and a massive target population contribute to market growth. In line with this, in January 2021, Thermo Fisher Scientific signed a final agreement to buy Mesa Biotech, Inc., a privately held molecular diagnostic firm, for about $450 million to provide reliable testing solutions.\u003c\/p\u003e\n\n\u003cp\u003eAround 375 instances of meningococcal infection were recorded in the U.S. In June 2021, according to the Center for Disease Control and Prevention Updates (an incidence rate of 0.11 cases per 100,000 persons). All these factors cumulatively affect the industry growth of this region in the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific region is estimated to show the fastest growth rate in the forecast period for some key reasons, including the increasing prevalence of meningitis, continuous research initiatives, and developing economies. Additionally, continuing trials in the region, favorable regulatory efforts, and increased investments by regional market participants are expected to boost regional growth throughout the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eIn June 2022, the Florida Department of Health and the Centers for Disease Control and Prevention (CDC) worked together to discover one of the worst meningococcal disease outbreaks among homosexual and bisexual men in American history. There have been at least 24 cases and six fatalities among homosexual and bisexual males recorded till that time. These outbreaks boosted the market’s growth. The development of diagnostic tests which can detect meningitis in less time provides additional help in treating meningitis, leading to the growth of this industry.\u003c\/p\u003e\n\n\u003cp\u003eMeningitis Diagnostic Testing Market Report Highlights\u003c\/p\u003e\n\n\u003cp\u003ePCR Assay segment is anticipated to grow at the highest CAGR over the forecast period due to its rapid test findings that are highly exact and accurate; it has the most significant market revenue. This fast turnaround for results improved clinical outcomes for patient care.\u003c\/p\u003e\n\n\u003cp\u003eThe hospital sector is expected to hold a significant market share over the forecast period due to the availability of optimal care delivery and the severity of meningitis in patients.\u003c\/p\u003e\n\n\u003cp\u003eNorth America is expected to grow significantly over the projected period because of an increase in the number of patients suffering from the disease.\u003c\/p\u003e\n\n\u003cp\u003eKey players in the market include Thermo Fisher Scientific, Bio-Rad Laboratories, ELI TechGroup, Abbott Laboratories, Becton and Dickinson, Luminex Corporation, GlaxoSmithKline, Merck KGaA, Baxter Quest Diagnostics, Roche, Cepheid, Pfizer.\u003c\/p\u003e\n\n\u003cp\u003ePolaris Market Research has segmented the meningitis diagnostic testing market report based on test type, end-use, and region:\u003c\/p\u003e\n\n\u003cp\u003eMeningitis Diagnostic Testing, Test Types Outlook (Revenue – USD Million, 2019 – 2032)\u003c\/p\u003e\n\n\u003cp\u003eLatex Agglutination Test\u003c\/p\u003e\n\n\u003cp\u003eLateral Flow Assay\u003c\/p\u003e\n\n\u003cp\u003ePCR Assay\u003c\/p\u003e\n\n\u003cp\u003eELISA Test\u003c\/p\u003e\n\n\u003cp\u003eCulture Test\u003c\/p\u003e\n\n\u003cp\u003eMeningitis Diagnostic Testing, End-Use Outlook (Revenue – USD Million, 2019 – 2032)\u003c\/p\u003e\n\n\u003cp\u003eHospitals\u003c\/p\u003e\n\n\u003cp\u003eDiagnostic Centers\u003c\/p\u003e\n\n\u003cp\u003eOthers\u003c\/p\u003e\n\n\u003cp\u003eMeningitis Diagnostic Testing, Regional Outlook (Revenue – USD Million, 2019 – 2032)\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003c\/p\u003e\n\n\u003cp\u003eU.S\u003c\/p\u003e\n\n\u003cp\u003eCanada\u003c\/p\u003e\n\n\u003cp\u003eEurope\u003c\/p\u003e\n\n\u003cp\u003eGermany\u003c\/p\u003e\n\n\u003cp\u003eUK\u003c\/p\u003e\n\n\u003cp\u003eFrance\u003c\/p\u003e\n\n\u003cp\u003eItaly\u003c\/p\u003e\n\n\u003cp\u003eSpain\u003c\/p\u003e\n\n\u003cp\u003eRussia\u003c\/p\u003e\n\n\u003cp\u003eNetherlands\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific\u003c\/p\u003e\n\n\u003cp\u003eChina\u003c\/p\u003e\n\n\u003cp\u003eIndia\u003c\/p\u003e\n\n\u003cp\u003eJapan\u003c\/p\u003e\n\n\u003cp\u003eSouth Korea\u003c\/p\u003e\n\n\u003cp\u003eIndonesia\u003c\/p\u003e\n\n\u003cp\u003eMalaysia\u003c\/p\u003e\n\n\u003cp\u003eLatin America\u003c\/p\u003e\n\n\u003cp\u003eArgentina\u003c\/p\u003e\n\n\u003cp\u003eBrazil\u003c\/p\u003e\n\n\u003cp\u003eMexico\u003c\/p\u003e\n\n\u003cp\u003eMiddle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eUAE\u003c\/p\u003e\n\n\u003cp\u003eSaudi Arabia\u003c\/p\u003e\n\n\u003cp\u003eIsrael\u003c\/p\u003e\n\n\u003cp\u003eSouth Africa\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 117 Pages \/ MCW16225235","offer_id":47639645356338,"sku":null,"price":5100.0,"currency_code":"USD","in_stock":true}]},{"product_id":"active-pharmaceutical-ingredient-market-by-type-innovative-generic-manufacturer-captive-merchant-synthesis-synthetic-biotech-product-mab-hormones-cytokines-drug-otc-rx-application-diabetes-oncology-cvd-global-forecast-to-2027","title":"Active Pharmaceutical Ingredient Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormones, Cytokines), Drug (OTC,Rx) Application (Diabetes, Oncology, CVD) - Global Forecast to 2027","description":"\u003cp\u003eActive Pharmaceutical Ingredient Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormones, Cytokines), Drug (OTC,Rx) Application (Diabetes, Oncology, CVD) - Global Forecast to 2027\u003c\/p\u003e\n\n\u003cp\u003eThe global Active Pharmaceutical Ingredient (APIs) market is estimated to reach USD 145.9 billion by 2022 to USD 216.4 billion in 2027, at a CAGR of 8.2% during the forecast period. Factors such as the increasing uptake of biopharmaceuticals, the growing importance of generics, and the rising focus on precision medicine are some of the major factors driving the growth of the global APIs market.\u003c\/p\u003e\n\n\u003cp\u003e“The biotech APIs segment is expected to grow at the highest CAGR during the forecast period.”\u003c\/p\u003e\n\n\u003cp\u003eOn the basis of the type of synthesis, the APIs market is categorized into synthetic APIs and biotech APIs. In 2021, the synthetic APIs segment accounted for the largest share. However, the biotech APIs segment is expected to grow at a higher rate over the forecast period. Factors such as the growing demand for biotech drugs due to their specificity in action and advancements in biotechnology are driving market growth in the market.\u003c\/p\u003e\n\n\u003cp\u003e“The monoclonal antibodies segment is expected to account for the largest share of the global biotech APIs market.”\u003c\/p\u003e\n\n\u003cp\u003eBased on product, the biotech APIs market is segmented into monoclonal antibodies, hormones \u0026amp; growth factors, cytokines, fusion proteins, therapeutic enzymes, recombinant vaccines, and blood factors. In 2021, the monoclonal antibodies segment was estimated to account for the largest share of the biotech APIs market.\u003c\/p\u003e\n\n\u003cp\u003e“North America to dominate the market during the forecast period.”\u003c\/p\u003e\n\n\u003cp\u003eIn 2021, North America dominated the market, followed by Europe. The major factors driving the overall growth of the APIs market in this region include the presence of major pharmaceutical and biopharmaceutical manufacturing facilities, an increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs. This market segment is expected to grow at a modest rate due to a combination of economic and healthcare severity measures as well as the introduction of low-cost and generic versions of branded drugs.\u003c\/p\u003e\n\n\u003cp\u003eBreakdown of the profile of primary participants:\u003c\/p\u003e \n\n\u003cp\u003eBy Company Type: Tier 1 – 37%, Tier 2 – 22%, and Tier 3 – 41%\u003c\/p\u003e \n\n\u003cp\u003eBy Designation: C-level Executives – 25%, Directors – 20%, Others - 55%\u003c\/p\u003e\n\n\u003cp\u003eBy Region: North America – 40%, Europe – 27%,  Asia Pacific – 20%, and RoW – 13%\u003c\/p\u003e\n\n\u003cp\u003eList of companies profiled in the report\u003c\/p\u003e \n\n\u003cp\u003ePfizer, Inc. (US),\u003c\/p\u003e\n\n\u003cp\u003eNovartis AG (Switzerland),\u003c\/p\u003e \n\n\u003cp\u003eSanofi (France),\u003c\/p\u003e \n\n\u003cp\u003eBoehringer Ingelheim (Germany),\u003c\/p\u003e \n\n\u003cp\u003eBristol-Myers Squibb (US),\u003c\/p\u003e \n\n\u003cp\u003eTeva Pharmaceutical Industries Ltd. (Israel),\u003c\/p\u003e \n\n\u003cp\u003eEli Lilly and Company (US),\u003c\/p\u003e \n\n\u003cp\u003eGlaxoSmithKline plc (UK),\u003c\/p\u003e \n\n\u003cp\u003eMerck \u0026amp; Co., Inc. (US),\u003c\/p\u003e \n\n\u003cp\u003eAbbVie Inc. (US),\u003c\/p\u003e \n\n\u003cp\u003eF. Hoffmann-La Roche Ltd. (Switzerland),\u003c\/p\u003e \n\n\u003cp\u003eAstraZeneca (UK),\u003c\/p\u003e \n\n\u003cp\u003eCipla, Inc. (India),\u003c\/p\u003e \n\n\u003cp\u003eMylan N.V. (US),\u003c\/p\u003e \n\n\u003cp\u003eDr. Reddy’s Laboratories Ltd. (India),\u003c\/p\u003e \n\n\u003cp\u003eSun Pharmaceutical Industries Ltd. (India),\u003c\/p\u003e \n\n\u003cp\u003eAPI Pharma Tech (India),\u003c\/p\u003e \n\n\u003cp\u003eBDR Pharmaceuticals Internationals Pvt. Ltd. (India),\u003c\/p\u003e \n\n\u003cp\u003eSreepathi Pharmaceuticals Limited (India),\u003c\/p\u003e \n\n\u003cp\u003eShilpa Medicare Limited (India),\u003c\/p\u003e \n\n\u003cp\u003eEvonik Industries AG (Germany),\u003c\/p\u003e\n\n\u003cp\u003eAurobindo Pharma Limited (India).\u003c\/p\u003e\n\n\u003cp\u003eResearch Coverage:\u003c\/p\u003e\n\n\u003cp\u003eThis report provides a picture of the global APIs market. It aims at estimating the size and future growth potential of the market across different segments, such as type, potency, type of synthesis, type of drug, therapeutic application, and region. Furthermore, the report also includes an in-depth competitive analysis of key market players, along with their company profiles, recent developments, and key market strategies.\u003c\/p\u003e\n\n\u003cp\u003eKey Benefits of Buying the Report:\u003c\/p\u003e\n\n\u003cp\u003eThe report will help market leaders\/new entrants by providing them with the closest approximations of the revenue numbers for the overall APIs market and its subsegments. Also, this report will help stakeholders to better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on key market drivers, restraints, challenges, and opportunities.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 361 Pages \/ MCW16225237","offer_id":47639645389106,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}]},{"product_id":"ingredients-market-for-plant-based-food-beverages-size-by-product-probiotics-lactobacilli-bifidobacterium-streptococcus-bacillus-proteins-amino-acids-proteins-l-glutamate-lysine-methionine-threonine-tryptophan-phytochemicals-plant-extra","title":"Ingredients Market for Plant-Based Food \u0026 Beverages Size By Product (Probiotics [Lactobacilli, Bifidobacterium, Streptococcus, Bacillus] Proteins \u0026 Amino Acids [Proteins, L-Glutamate, Lysine, Methionine, Threonine, Tryptophan] Phytochemicals \u0026 plant extra","description":"\u003cp\u003eIngredients Market for Plant-Based Food \u0026amp; Beverages Size By Product (Probiotics [Lactobacilli, Bifidobacterium, Streptococcus, Bacillus] Proteins \u0026amp; Amino Acids [Proteins, L-Glutamate, Lysine, Methionine, Threonine, Tryptophan] Phytochemicals \u0026amp; plant extracts [Carotenoids, Flavonoids, Phytosterols] Prebiotics [FOS, Inulin, GOS, MOS] Specialty carbohydrates, Fatty acids [Omega 3, Omega 6, Omega 7, Omega 9] Vitamin [Vitamin A, Vitamin D, Vitamin K, Vitamin E, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B7, Vitamin B12, Vitamin C] Minerals [Zinc, Magnesium, Calcium, Iron] Enzymes [Proteases, Lipases, Carbohydrases {Amylases, Xylanases, Cellulases, Pectinases, Lactases} Polymerases \u0026amp; Nucleases, Phytases, Catalyses] Fibers [Soluble and Insoluble] Food texturants[ Hydrocolloids, Emulsifiers, Stabilizers), By Application (Plant-based Milk \u0026amp; Derivatives, Bakery \u0026amp; Confectionery, Sweet \u0026amp; Savory Snacks, Plant-based juices, RTD Tea \u0026amp; Coffee, RTE \u0026amp; RTC Meals), Industry Analysis Report, Regional Outlook, Application Potential, Price Trend, Competitive Landscape \u0026amp; Forecast, 2023 - 2032\u003c\/p\u003e\n\n\u003cp\u003eGlobal Ingredients Market for Plant Based Food and Beverages is slated to attain high gains through 2032 owing to the rising demand to improve nutritional content in food \u0026amp; beverages.\u003c\/p\u003e\n\n\u003cp\u003eThe market from the probiotic section will be driven by a rise in demand for bakery items because of factors like elasticity and stability. Customers have begun to favor higher-value products with wellness and health-related attributes. The production of foods that help consumers limit their calories and sugar intake without sacrificing flavor is being experimented with by several manufacturers.\u003c\/p\u003e \n\n\u003cp\u003eThis will help flourish the probiotics sector and the market on the whole. For instance, in June 2021, Cargill and Caldic announced a strategic alliance. Caldic Ingredients DACH will be Cargill's sole partner for the Swiss food business under the terms of the cooperation.\u003c\/p\u003e\n\n\u003cp\u003eThe ingredients market for plant based food and beverages has been divided in terms of product, application, and region.\u003c\/p\u003e\n\n\u003cp\u003eBased on product, the vitamin segment is expected to garner USD 50 million in revenues by 2032. Over the past few years, there has been a significant rise in demand for vitamins as an additive in plant-based food and beverages as a result of consumer demand for processed foods that are nutritionally enhanced and functional. Additionally, the prevalence of vitamin deficiencies among individuals worldwide has boosted the integration of vitamins as a key component in plant-based foods and beverages.\u003c\/p\u003e\n\n\u003cp\u003eWith respect to application, the sweet \u0026amp; savory snacks segment is poised to grow significantly over the review timeframe. The demand for snacks is rising across all age groups on the back of the increased adoption of fast-paced or busy lifestyles. While young people favor healthy snacks to replace hefty meals, the working population prefers to nibble in between meals. These elements are raising the market's desire for savory snacks.\u003c\/p\u003e\n\n\u003cp\u003eFrom the regional perspective, the Europe ingredients market for plant-based food and beverages is speculated to attain $2 billion in revenue by 2032. As globalization intensifies in European nations, the need for food and beverage ingredients also increases. Due to their substantial presence in the functional food and beverage industries, countries such as Germany, France, and the United Kingdom dominate the market for specialty carbohydrates.\u003c\/p\u003e\n\n\u003cp\u003eThe ingredients market for plant-based food and beverages is considerably competitive. Some of the major organizations operating in the market include BASF SE, Cargill Incorporated, DuPont Nutrition \u0026amp; Biosciences, Archer Daniels Midland Company, DSM NV, and more.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 805 Pages \/ MCW16225239","offer_id":47639645421874,"sku":null,"price":6180.0,"currency_code":"USD","in_stock":true}]},{"product_id":"extensive-stage-small-cell-lung-cancer-market-a-global-and-regional-analysis-focus-on-epidemiology-product-and-region-analysis-and-forecast-2022-2032","title":"Extensive Stage Small Cell Lung Cancer Market - A Global and Regional Analysis: Focus on Epidemiology, Product, and Region - Analysis and Forecast, 2022-2032","description":"\u003cp\u003eExtensive Stage Small Cell Lung Cancer Market - A Global and Regional Analysis: Focus on Epidemiology, Product, and Region - Analysis and Forecast, 2022-2032\u003c\/p\u003e\n\n\u003cp\u003eGlobal Extensive Stage Small Cell Lung Cancer Market Overview\u003c\/p\u003e\n\n\u003cp\u003eExtensive stage small cell lung cancer is extremely aggressive sub-type of small cell lung cancer. Small cell lung itself is a sub-type of lung cancer which accounts for less than 20% cases. The treatment of extensive stage small cell lung cancer has been extremely challenging owing to poor survival rate of the patients. The median overall survival reported among the extensive stage small cell lung cancer patients has been slightly above a year while the overall progression free survival is reported to be of six months. Before the emergence of immune checkpoint inhibitors, traditional chemotherapy which included etoposide in combination with platinum (cisplatin or carboplatin) were the treatment mainstay however since the approval of immune checkpoint inhibitors; these have been included in the standard treatment regimen along with chemotherapy.\u003c\/p\u003e\n\n\u003cp\u003eThe Growing Prevalence of Extensive Stage Small Cell Lung Cnacer\u003c\/p\u003e\n\n\u003cp\u003eThe prevalence of extensive stage small lung cancer is estimated to increase in five of the seven major markets included in the study. Geographically, the U.S. remains at the top with an estimated prevalence for 2021 of more than 47,000 patients followed by the U.K. with over 8,500 patients. The prevalence is forecasted to be growing at a CAGR of 2.61% and 1.61% respectively for the U.S. and the U.K for the period 2022-2032.\u003c\/p\u003e \n\n\u003cp\u003eCompetitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eThe current global extensive stage small cell lung cancer market has two approved immune checkpoint inhibitors namely Imfinzi (Durvalumab) from AstraZeneca PLC and Tecentriq (Atezolizumab) from F. Hoffmann La-Roche Ltd. Zepzelca (Lurbinectedine) from Jazz Pharmaceuticals Plc and Cosela (Trilaciclib) from G1 Therapeutics Inc. are other two products approved for the treatment of extensive stage small cell lung cancer patients.\u003c\/p\u003e\n\n\u003cp\u003eSince, the introduction of immune checkpoint inhibitors to the extensive stage small cell lung cancer treatment, the competition in the global extensive stage small cell lung cancer market has significantly increased. F. Hoffmann La-Roche Ltd. and AstraZeneca Plc are the leading players among the companies having immune checkpoint inhibitor portfolio in the global extensive stage small cell lung cancer market. The companies having immune checkpoint inhibitors under clinical development have also added extensive stage small cell lung cancer treatment to their portfolio.\u003c\/p\u003e\n\n\u003cp\u003eCurrently there are four products available in the market which are patented. The chemotherapeutic products which constituted the standard of care have all become generic. There is a rich clinical pipeline of extensive stage small cell lung cancer maket with dominance of immune checkpoint inhibitors along with bispecific antibodies.\u003c\/p\u003e\n\n\u003cp\u003eSegmentation:\u003c\/p\u003e\n\n\u003cp\u003eWithin the research report, the segmentation has made on the basis of:    Existing as well as Expected competition in the global extensive stage small cell lung cancer market. Commercial and Clinical products constitute “Products” segment., and    Region is the other segment which covers the seven major markets (the U.S., the U.K., Germany, France, Italy, Spain, and Japan).Demand – Drivers and Challenges\u003c\/p\u003e\n\n\u003cp\u003eSome of the potential drivers identified by BIS Research includes:    Potential therapeutic effects of immune checkpoint inhibitors in improving overall survival among cancer patients    Treatment directed toward decreasing the chemotherapy induced toxic effectsThere are some challenges identified for the global extensive stage small cell lung cancer market include; treatment related toxic effects, lack of effective diagnostic tools\/methods among others.\u003c\/p\u003e\n\n\u003cp\u003eHow can this report add value to an organization?\u003c\/p\u003e\n\n\u003cp\u003eProduct\/Innovation Strategy: The report provides an insight into estimated patient population eligible to receive treatment in the seven major market, with a view where the disease is on a decline and where it is showing an increasing trend. Additionally, the report provides an exhaustive list of pipeline products along with their developmental details which are currently in the development for extensive stage small cell lung cancer treatment. This can help organizations in assess the research activities, potential candidates to enter first into the market as well it can help the organization to assess where should they place themselves in order to get maximum benefit.\u003c\/p\u003e\n\n\u003cp\u003eGrowth\/Marketing Strategy: The several growth strategies identified in the report include increased focus toward development of immunotherapies, use of immunotherapies in combination with existing standard treatment options, expanding the market reach by entering into licensing agreement with potential players.\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Strategy: Key players in the global extensive stage small cell lung cancer market were analyzed and profiled in the study, who have commercially available treatment for extensive stage small cell lung cancer. Moreover, a detailed competitive benchmarking of the players operating in the global extensive stage small cell lung cancer market has been included to help the reader understand how players stand against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.\u003c\/p\u003e\n\n\u003cp\u003eKey Companies Profiled    F. Hoffmann-La Roche Ltd    AstraZeneca PLC    Jazz Pharmaceuticals Plc    G1 Therapeutics Inc.    Shanghai Henlius Biotech, Inc.    Lee's Pharmaceutical Limited    Jiangsu Hengrui Pharmaceuticals Co., Ltd.    Beigene Ltd.\u003c\/p\u003e\n\n\u003cp\u003e*PDF email from publisher allows for 1-3 users, with permission to print*\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 153 Pages \/ MCW16225241","offer_id":47639645454642,"sku":null,"price":6300.0,"currency_code":"USD","in_stock":true}]}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0792\/8053\/7906\/collections\/McKInsey_well_400_x_400_px_2000_x_2000_px_1000_x_1000_px_400_x_400_px_37.jpg?v=1709720991","url":"https:\/\/www.hardmanwell.com\/collections\/biotechnology.oembed?page=4","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}